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Summary 
 I 
Summary 
Dual specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) is encoded 
on human chromosome 21 and thus 1.5-fold overexpressed in Down syndrome (DS). 
Reports from animal models provide strong evidence that an altered DYRK1A gene 
dosage results in disturbed brain development. Neuronal differentiation is regulated by an 
accurate control of G1-G0 cell cycle exit, and a disturbed expression of DYRK1A is 
assumed to deregulate this process. Hence, normalization of elevated DYRK1A kinase 
activity is currently considered as a possible therapeutic option in DS. Nonetheless, the 
underlying mechanisms how DYRK1A affects cell cycle regulation and neuronal 
development remain largely unknown. 
Therefore, the main part of this study aimed to elucidate the hypothesis that DYRK1A 
overexpression alters neuronal cell cycle progression and differentiation, and to identify 
the underlying molecular mechanisms. To investigate effects of DYRK1A overexpression 
in neuronal cell cycle progression a human cell model with controllable overexpression of 
DYRK1A was developed. This study shows that DYRK1A overexpression arrested 
SH-SY5Y neuroblastoma cells in G1-phase dependent on its kinase activity and 
expression levels. Long-term overexpression of DYRK1A led to G0 cell cycle exit and 
premature neuronal differentiation. Moreover, DYRK1A affected protein stability of the cell 
cycle regulators p27Kip1 and Cyclin D1 in G1-phase by phosphorylation of their regulatory 
sites Ser10 and Thr286, respectively. Furthermore, DYRK1A contributed to p27Kip1 Ser10 
phosphorylation in differentiating primary mouse neurons and in developing embryonic 
mouse brain. In summary, the study provides new mechanistic evidence that DYRK1A 
mediates neuronal cell cycle progression by regulation of G1-S-phase transition and G0 
cell cycle exit. The reported findings support the assumption that DYRK1A overexpression 
contributes to the neurodevelopmental alterations that are present in DS. 
Septins are a family of GTP-binding and filament forming proteins that fulfill important 
cellular functions by formation of scaffolds or diffusion barriers. Septin4 was found in 
neurodegeneration related protein aggregates and is required for proper migration of 
cortical neurons. Nonetheless, the functional regulation of Septin4 remains unclear.  
Therefore, the second part of this thesis reports a novel mechanism to regulate Septin4 
function. It is shown that DYRK1A phosphorylated Septin4 at Ser107 and that Ser107 
phosphorylation affected Septin4 protein stability. These findings strongly indicated a 
functional relation of DYRK1A and Septin4. Therefore, Septin4 fusion proteins for future 
analysis of Ser107 phosphorylation in the regulation of protein stability and filament 
assembly were constructed. 
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Zusammenfassung 
Dual specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) ist auf dem 
humanen Chromosom 21 kodiert und daher beim Down Syndrom 1,5-fach überexprimiert. 
Tierexperimentelle Studien belegen, dass Änderungen der DYRK1A Genexpression zu 
einer veränderten Gehirnentwicklung führen. Die Entwicklung des Gehirns wird durch eine 
präzise Regulation der neuronalen Differenzierung durch Kontrolle des Zellzyklusaustritts 
gesteuert. Es wird angenommen, dass eine vermehrte Expression von DYRK1A diesen 
Prozess negativ beeinflusst. Eine Normalisierung der erhöhten Aktivität von DYRK1A wird 
daher als eine mögliche Therapieoption im Down Syndrom angesehen. Allerdings sind die 
grundlegenden zellulären Mechanismen, über die DYRK1A die neuronale Entwicklung 
und den neuronalen Zellzyklus beeinflusst, weitgehend ungeklärt. 
Im Hauptteil dieser Arbeit wurde daher untersucht, ob DYRK1A eine regulatorische 
Funktion im neuronalen Zellzyklus einnimmt. Hierzu wurden humane SH-SY5Y 
Neuroblastomzellen erzeugt, die DYRK1A kontrollierbar überexprimieren. Es konnte 
gezeigt werden, dass DYRK1A sowohl abhängig vom Grad der Überexpression als auch 
abhängig von der Kinaseaktivität zu einem G1-Phase Zellzyklusarrest von SH-SY5Y 
Zellen führte. Eine anhaltende Überexpression führte letztendlich zu einem G0 
Zellzyklusaustritt und einer vorzeitigen neuronalen Differenzierung. Darüber hinaus 
regulierte DYRK1A die Proteinstabilität der Zellzyklusregulatoren p27Kip1 und Cyclin D1 
durch Phosphorylierung an Ser10, beziehungsweise Thr286. Zudem wurde 
nachgewiesen, dass DYRK1A p27Kip1 sowohl in differenzierenden primären 
Mausneuronen, als auch im embryonalen Mausgehirn maßgeblich an Ser10 
phosphorylierte. Damit wurde in dieser Arbeit ein neuer Mechanismus identifiziert, über 
den DYRK1A den neuronalen Zellzyklus und die neuronale Differenzierung beeinflusst. 
Septine sind GTP-bindende und filamentbildende Proteine. Zu ihren zellulären Funktionen 
zählen der Aufbau von zytoskeletalen Gerüsten und Diffusionsbarrieren. Septin4 
akkumuliert in neurodegenerativen Proteinaggregaten und ist für die korrekte Migration 
kortikaler Neurone elementar. Die Regulation von Septin4 ist jedoch unbekannt.  
In dieser Arbeit wird ein neuer Mechanismus zur Regulation von Septin4 vorgestellt. Eine 
DYRK1A vermittelte Phosphorylierung an Ser107 bewirkte eine Änderung der Septin4 
Proteinstabilität, was einen funktionellen Zusammenhang von DYRK1A und Septin4 
vermuten lässt. Darüber hinaus wurden neue Fusionsproteine konstruiert, um zukünftig 
den Einfluss der Ser107 Phosphorylierung auf die Proteinstabilität, die subzelluläre 
Lokalisation und den Filamentaufbau von Septin4 genauer untersuchen zu können.
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1 Introduction 
1.1 Regulation of the cell cycle 
The cell cycle can be subdivided into four different phases, referred to as G1- 
(gap-1/growth), S- (DNA synthesis), G2- (gap-2) and M-phase (mitosis) (figure 1) (Bertoli 
et al., 2013). Altogether, G1-, S- and G2-phase represent the interphase, preparing the cell 
for division during mitosis. In G1-phase the cell integrates intra- and extracellular signals 
and decides to undergo replication or to pause cell cycle progression. When pausing, cells 
can either undergo apoptosis or enter a quiescent, nondividing state (G0) which still allows 
a re-entry into the cell cycle (figure 1). In quiescence, cellular gene expression and protein 
activity profiles differ remarkably from that of cycling cells, indicating that quiescence is 
not only an extended G1-phase (Coller et al., 2006; Spencer et al., 2013). Maintenance of 
quiescent conditions can be long lasting, but can also promote cells to undergo 
differentiation. However, the molecular mechanisms to enter and to maintain a quiescent 
G0-state differ between diverse cell types. Besides quiescence, cellular senescence is 
another nondividing and resting state in which cells are incapable to re-enter the cell 
cycle. Senescence is considered as a stress response, mainly induced by damaging 
environmental influences or by the onset of oncogenesis (Collado and Serrano, 2010). 
Figure 1: Overview of the cell cycle. 
The mammalian cell cycle is divided into four different 
phases. In G1-phase the cell can decide to enter a 
quiescent state (G0) or to prepare entering S-phase for 
DNA replication and subsequent cell division. In G2-
phase the cell prepares for cytokinesis (M-phase). 
Cells in a quiescent G0 state can reenter the cell cycle. 
Illustration according to Massagué (2004). 
A complex network of regulatory proteins controls 
the cell cycle. In many components, this network 
is conserved from lower eukaryotes to humans. 
An initial restriction point determines if a cell in 
G1-phase enters S-phase to pass through the cell 
cycle independently of further signals. Furthermore, other DNA structure checkpoints 
prevent the cell from cell cycle transition and cell division if DNA is damaged or 
imperfectly replicated. The importance of these checkpoint mechanisms becomes 
apparent by mutations of the required regulatory proteins in oncogenesis (Massagué, 
2004). Numerous proteins that regulate transcription of specific genes control the correct 
transition throughout the different cell cycle phases. For all cell types, the activation of 
cyclin-dependent kinases (CDKs) is an essential prerequisite for cell cycle transition 
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(Massagué, 2004). CDKs belong to the CMGC-group of protein kinases (section 1.3) and 
fulfill core functions in cell cycle regulation when activated by binding a cyclin subunit. 
Each cyclin interacts with one or two different CDKs and vice versa. The different stages 
of the cell cycle are associated with an oscillating appearance of different cyclins. D-type 
cyclins are active in G1-phase, E- and A-type cyclins in S-phase and B- and A-type cyclins 
in M-phase (figure 2) (Murray, 2004). 
 
Figure 2: Major components of cell cycle regulation. 
Different cyclin/CDK-complexes are assembled in different phases of the cell cycle and function as 
regulators of cell cycle progression by phosphorylation of various proteins (Murray, 2004). Upon 
differentiation or lacking growth signals in G1-phase, on the one hand the activity of cyclin/CDK-
complexes is inhibited by CKIs (cyclin-dependent kinase inhibitors) of the INK4 (p15, p16, p18, 
p19) or Cip/Kip (p21Cip1, p27Kip1, p57Kip2) family (Sherr and Roberts, 1999; Besson et al., 2008). On 
the other hand, cyclin/CDK-complexes are regulated by rapid degradation of the cyclin component 
via the ubiquitin proteasome pathway and being targeted by E3 ubiquitin ligases of the APC- 
(Anaphase promoting complex) or SCF-type (Skp1-cullin-F-box protein) (Vodermaier, 2004). 
Ubiquitination by the SCF-complex depends on phosphorylation (P) by upstream kinases like 
GSK3β (Glycogen synthase kinase-3 β). In G1-phase, the pocket proteins RB (retinoblastoma), 
RBL1 or RBL2 that bind and inhibit transcription factors of the E2F family control gene 
transcription. After Cyclin D/CDK4/6 dependent phosphorylation, pocket proteins release E2F 
transcription factors to initiate gene transcription for cell cycle progression to the S-phase 
(Massagué, 2004). 
Oscillation of cyclin levels is a major component of cell cycle control and thereby ensures 
correct progression to the next cell cycle stage and prevents a reverse progression. For a 
proper regulation of cyclin/CDK complexes in cell cycle progression, cyclins have to be 
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inactivated, what is assured by rapid protein degradation via the ubiquitin-proteasome 
system. Upon selective phosphorylation, cyclins are recognized by the SCF (Skp1-cullin-
F-box protein) E3 ubiquitin ligase and are subsequently ubiquitinated for 26S proteasomal 
degradation. Alternatively, without prior phosphorylation, cyclins can be recognized by 
another E3 ligase named APC (anaphase-promoting complex) (Vodermaier, 2004). Since 
the SCF complex is active throughout the whole cell cycle, and the APC is activated at the 
onset of the anaphase, both complexes function in different stages of the cell cycle. G1-
phase cyclins therefore are ubiquitinated by the SCF complex, whereas mitotic cyclins are 
targeted by the APC (Murray, 2004). 
Besides regulation of Cyclin D and E protein stability, cyclin/CDK activity is additionally 
controlled by CDK inhibitors (CKIs) at the transition from G1- to S-phase. Based on their 
structure and specificity, CKIs are divided into two families. The INK4 family (Inhibitors of 
CDK4) consists of p16INK4a, p15INK4b, p18INK4c and p19INK4d, which specifically bind to CDK4 
and CDK6 and disturb their interaction with the respective D-type cyclins (Sherr and 
Roberts, 1999). In contrast, CKIs of the Cip/Kip1 family, comprising p21Cip1/Waf1
 
(also called 
cyclin-dependent kinase inhibitor 1A, CDKN1A), p27Kip1 (CDKN1B) and p57Kip2 
(CDKN1C), are characterized by binding CDKs as well as cyclins. Cip/Kip1 CKIs regulate 
the activity of Cyclin D-, E-, A- and B-/CDK complexes (Sherr and Roberts, 1999; Besson 
et al., 2008). The importance of CKIs in G1-S-phase regulation was emphasized by 
studies of respective knockout mice. Heterozygous p27Kip1 knockout mice showed an 
increased body size and organ hyperplasia, whereas a p21Cip1/Waf1 knockout resulted in 
deregulation of DNA-damage dependent G1-phase cell cycle arrest (Deng et al., 1995; 
Fero et al., 1996). The knockout of p57Kip2 led to organ hyperplasia due to a defective cell 
cycle exit (Zhang et al., 1997). Cip/Kip proteins are intrinsically unstructured and only 
adopt specific conformations after binding to other proteins (Lacy et al., 2004), allowing for 
a broad range of binding partners. In addition to blocking G1-S-phase progression, CKIs of 
the Kip/Cip family fulfill additional functions in the regulation of gene transcription, 
apoptosis, cell motility, or differentiation (Besson et al., 2008). Posttranslational 
modifications, especially phosphorylation, are thought to modulate their functions by 
changing stability, affinity to binding partners or subcellular localization (Borriello et al., 
2007; Child and Mann, 2006; Vervoorts and Lüscher, 2008). 
Once a cell decided to replicate, one important function of the G1-phase is to prepare the 
cell for DNA replication and the subsequent cell division. Therefore, during G1-phase the 
transcription of genes encoding for proteins that are required for cell cycle progression is 
induced. One of the proteins regulating gene transcription in G1-S-phase is the tumor 
suppressor protein RB (Retinoblastoma) (Weinberg, 1995). The so-called pocket proteins 
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RB, p107 (also named RBL1, retinoblastoma-like protein 1) and p130 (RBL2) inhibit E2F 
transcription factors due to their binding. In all phases of the cell cycle including G0, E2F-
dependent gene transcription is inhibited, until the cell cycle reaches late G1-phase. 
Pocket proteins are then phosphorylated by phase specific D-type cyclin/CDK4/6 
complexes and release the E2F transcription factors to induce gene transcription (Bertoli 
et al., 2013). 
A complex network of many different proteins thus characterizes regulation of cell cycle 
progression. A functional disturbance of one or several of these proteins can therefore 
deregulate accurate cell cycle progression and potentially promote developmental 
alterations or severe diseases like cancer.  
1.1.1 Cell cycle exit and neuronal differentiation 
The balance between progenitor maintenance and differentiation of neurons is crucial for 
normal brain development. This balance is achieved through the precise coordination of 
sequential cellular steps, which include the proliferation of progenitor cells, their transition 
to neurogenic progenitors, the cell cycle exit of neuronal precursors, and finally their 
differentiation into neurons. Cell cycle regulation appears to be critical for keeping this 
balance, highlighting the importance of cell cycle regulatory proteins in neurodevelopment 
(Frank and Tsai, 2009; Hindley and Philpott, 2012; Salomoni and Calegari, 2010). For 
instance, a selective lengthening of G1-phase appears to be pivotal for the switch of 
proliferation to neurogenesis (Calegari et al., 2005). In particular, the antiproliferative CDK 
inhibitor p27Kip1 (CDKN1B) promotes cell cycle exit, whereas positive regulators such as 
Cyclin D1 (CCND1) promote proliferation (Doetsch et al., 2002; Ohnuma and Harris, 
2003; Nguyen et al., 2006a; Lange et al., 2009). 
Phosphorylation is a key mechanism in the regulation of p27Kip1 and Cyclin D1 by 
controlling their protein turnover during G1-phase (Diehl et al., 1997; Ishida et al., 2000). 
p27Kip1 is primarily modulated by phosphorylation at Ser10, which is increased in G1-G0 
phase of the cell cycle and enhances p27Kip1 stability (Ishida et al., 2000). Several kinases 
have been proposed to target Ser10, including KIS, AKT, ERK2, CDK5, HIPK2 and 
DYRK1B (Ishida et al., 2000; Boehm et al., 2002; Fujita et al., 2002; Deng et al., 2004; 
Kawauchi et al., 2006; Pierantoni et al., 2011). Proteasomal degradation of Cyclin D1 
during G1-phase is induced by phosphorylation at Thr286 via GSK3β (Diehl et al., 1997). 
However, also DYRK1A and DYRK1B were recently shown to phosphorylate this residue 
in non-neural cells (Ashford et al., 2014). Phosphorylation of p27Kip1 and Cyclin D1 has 
been mainly investigated in tumorigenic cell cycle progression, but the kinases regulating 
their phosphorylation in G1/G0 of neuronal progenitor cells remain uncharacterized. 
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1.2 Protein kinases and phosphorylation 
Protein kinases are a class of enzymes that posttranslationally modify their target proteins 
by phosphorylation. Specifically, protein kinases actively catalyze a transfer of the 
γ-phosphate from adenosine triphosphate (ATP) to the side chain hydroxyl group of serine 
(Ser), threonine (Thr) or tyrosine (Tyr) amino acid residues. 
The enzymatic process of protein phosphorylation was firstly described for casein by 
Burnett and Kennedy (1954). Later on, phosphorylation and dephosphorylation were 
described for phosphorylase b in muscle extracts by Fischer and Krebs (1955). The 
superfamily of protein kinases is classified by the catalytic kinase domain, consisting of 
250 – 300 amino acids (Hanks et al., 1988). Within this superfamily, the majority are 
Ser/Thr-kinases, which are distinguished from Tyr-kinases (Hanks, 1991). Approximately 
30% of all cellular proteins are phosphorylated by protein kinases on at least one amino 
acid, for which reason phosphorylation is the most common posttranslational modification 
(Ubersax and Ferrell Jr, 2007). Kinase mediated phosphorylation of amino acids can be 
reversed by phosphatases (Barford et al., 1998). Due to its high velocity and reversibility, 
phosphorylation is one of the major mechanisms of intracellular signal transduction. 
Phosphorylation mediates biological activity of proteins by changing their conformation, 
stability, mobility or interaction. The importance of this mechanism is emphasized by 
multiple site phosphorylation of a single protein by one or even several different kinases 
(Cohen, 2000). Furthermore, priming phosphorylation of a distinct site can be a 
prerequisite for another kinase to phosphorylate a nearby site, as known for GSK3β (Fiol 
et al., 1987). Therefore, a plenty of cellular functions like metabolism, transcription, 
cytoskeletal reorganization and cell cycle control are critically regulated by 
phosphorylation (Manning et al., 2002a). 
Approximately 2% of all human genes encode for protein kinases. In total, 518 protein 
kinases were identified, whereof 244 are associated to diseases (Manning et al., 2002a, 
2002b). As predicted by Cohen (2002), with actually more than 20 clinically approved 
kinase inhibitors and approximately 100 compounds in clinical development, protein 
kinases emerged as the second important class of molecular targets in drug development 
beside G-protein coupled receptors (Barouch-Bentov and Sauer, 2011). 
1.3 The family of DYRK protein kinases 
DYRK (Dual Specificity Tyrosine-(Y)-Phosphorylation-Regulated Kinase) protein kinases 
were first described in 1996 (Kentrup et al., 1996). Human DYRK kinases belong to the 
CMGC-group of protein kinases that comprises cyclin dependent kinases (CDK), mitogen 
activated protein kinases (MAPK), Glycogen synthase kinase-3 (GSK-3), CDC2-like 
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kinases (CLK), SR-protein kinases (SRPK) and homeodomain-interacting protein kinases 
(HIPK) (Manning et al., 2002a). 
Minibrain (MNB) and dDYRK2 (Drosophila DYRK2) were identified as DYRK homologues 
in Drosophila melanogaster, MBK-1 and MBK-2 as homologues in Caenorhabditis 
elegans (Tejedor et al., 1995; Lochhead et al., 2003; Raich et al., 2003). Additionally, 
Yak1p was described as DYRK related in Saccharomyces cerevisiae, Pom1p in 
Schizosaccharomyces pombe and YakA in Dictyostelium discoideum (Garrett and Broach, 
1989; Bähler and Pringle, 1998; Souza et al., 1998). With AtYAK1, the first DYRK family 
member in plants was identified in Arabidopsis thaliana (Wu, 2007), but its function 
remains unexplored. 
Due to conserved structural similarities in the kinase domain and the N-terminal DH-box 
(DYRK homology box), five members can be distinguished within the human family of 
DYRK kinases. Class I DYRKs, comprising DYRK1A and DYRK1B (also named Mirk), 
share a nuclear localization signal (NLS) closely N-terminal, and a PEST region (a proline, 
glutamic acid, serine and threonine rich motif) C-terminal to the kinase domain. The PEST 
region is assumed to play a role in rapid protein degradation (Rogers et al., 1986). In 
contrast, DYRK2, DYRK3, and DYRK4 as class II DYRKs, lack these sequence 
characteristics but contain an N-terminal autophosphorylation accessory region (NAPA-
region) which is assumed to provide a chaperone-like function during autophosphorylation 
(Becker and Joost, 1999; Kinstrie et al., 2010; Aranda et al., 2011). Additionally, an 
N-terminal NLS was identified in DYRK2 and DYRK4 (Aranda et al., 2011; Papadopoulos 
et al., 2011). 
A hallmark of DYRK kinases is their dual specificity. At first, an autophosphorylation of 
critical tyrosine residues in the activation loop (cis phosphorylation) enhances the 
subsequent substrate phosphorylation at serine or threonine residues (trans 
phosphorylation) (Himpel et al., 2001; Lochhead et al., 2003, 2005). In contrast to former 
assumptions, it was recently shown that autophosphorylation capacity of DYRK1A is not 
only restricted to a co-translational intermediate structure of the immature kinase, but 
persists in the mature and tyrosine autophosphorylated form (Walte et al., 2013). 
1.3.1 DYRK1A 
DYRK1A was the first described member of the DYRK family in mammals (Kentrup et al., 
1996) and to date is the best characterized isoform. In vertebrates, two alternatively 
spliced isoforms are present, differing by nine amino acids in the N-terminal domain. Both 
isoforms are equally expressed and show no apparent differences (Kentrup et al., 1996; 
Guimera et al., 1999). The structure of DYRK1A is illustrated in figure 3. 
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Figure 3: Structure of the protein kinase DYRK1A. 
DYRK1A contains different domains. ASR, alternatively spliced region, generating two different 
isoforms of 763 or 754 amino acids (AA); NLS, nuclear localization signal; DH, DYRK homology 
box; PEST, proline (P), glutamic acid (E), serine (S) and threonine (T) rich motif; His, histidine rich 
motif (13 AA); Ser/Thr, a motif enriched of serine and threonine residues. Illustration according to 
Kentrup et al. (1996) and Aranda et al.(2008). 
Besides the NLS and the PEST region as hallmarks of class I DYRKs, a second NLS 
motif was reported as localized in the rear of the kinase domain (Aranda et al., 2011). 
C-terminally, a motif of 13 histidine residues and a sequence mainly consisting of serine 
and threonine residues are located. The histidine rich region is assumed to target 
DYRK1A into nuclear splicing compartments (speckles) (Alvarez et al., 2003; Salichs et 
al., 2009). Due to its N-terminal NLS, heterologously expressed GFP-DYRK1A is mainly 
localized in the nucleus (Becker et al., 1998). Nonetheless, regarding its function in 
neuronal development, DYRK1A also has been detected in the cytosol of neurons or 
astrocytes, and is described to be asymmetrically distributed during differentiation of 
neurons (Hämmerle et al., 2002; Martí et al., 2003; Hämmerle et al., 2008; Ferron et al., 
2010). A recent study identified DYRK1A to be mainly associated to cytoskeletal 
structures in mouse and human brain (Kaczmarski et al., 2014). Since DYRK1A is 
constitutively active after translation and its autophosphorylation on Tyr321 (Himpel et al., 
2001), a changing subcellular localization may be a mechanism to control its function. 
Although other mechanisms including regulation of transcription and interaction with 
14-3-3 proteins, as well as upstream phosphorylation have been suggested, the functional 
regulation of DYRK1A is still poorly understood (Becker and Sippl, 2011; Tschöp et al., 
2011; Kaczmarski et al., 2014). 
DYRK1A phosphorylates target proteins at the following consensus motif (Himpel et al., 
2000; Campbell and Proud, 2002): 
Arg-Pro-X-Ser/Thr-Pro 
-3   -2   -1      0       +1 
Nonetheless, also atypical phosphorylation sites have been identified (Skurat and Dietrich, 
2004; de Graaf et al., 2006; Papadopoulos et al., 2011; Soundararajan et al., 2013; Jang 
et al., 2014). In the recent years, numerous targets have been reported to be 
phosphorylated by DYRK1A, implicating diverse cellular functions. Among those targets 
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are transcription factors and splicing factors, as well as components of chromatin 
remodeling, signal transduction, and cytoskeletal dynamics (Aranda et al., 2011). Given 
that many of the reported phosphorylation sites were identified in non-physiological 
overexpression models, it is of interest to define the physiological relevant DYRK1A 
targets. 
1.3.2 DYRKs and cell cycle regulation 
Several reports provide evidence that protein kinases of the DYRK family are involved in 
cell cycle control, especially due to their conserved function to regulate protein stability by 
phosphorylation (Becker, 2012). 
Overexpression of the Dictyostelium discoideum DYRK homologue YakA has been 
reported to cause a cell cycle arrest and to promote expression of genes required for 
development (Souza et al., 1998), implicating a regulatory function at the switch from 
growth to development. Furthermore, mutations of the yeast homologues Pom1p 
(Schizosaccharomyces pombe) and Yak1 (Saccharomyces cerevisiae) have been shown 
to interfere with cell division (Garrett and Broach, 1989; Bähler and Pringle, 1998). 
Caenorhabditis elegans mbk-2 is essential for cell viability and phosphorylates proteins 
that promote the oocyte-embryo-transition at the end of meiosis (Raich et al., 2003; 
Cheng et al., 2009), indicating an indispensable function in development. Another well 
investigated DYRK family member is the DYRK1A homologue minibrain in Drosophila 
melanogaster. Mnb mutant flies show an abnormal neuroblast proliferation during 
postembryonic neurogenesis, resulting in a reduced size of the optic lobes and central 
brain hemispheres (Tejedor et al., 1995). 
In vertebrates, DYRK1B is best characterized concerning cell cycle regulation. DYRK1B 
mediates growth arrest, differentiation and survival of muscle cells and is expressed in 
different solid tumors (Mercer and Friedman, 2006). Moreover, DYRK1B was shown to 
regulate exit of colon carcinoma cells from quiescence and therefore is closely linked to 
regulation of G1-S-phase transition (Jin et al., 2009; Gao et al., 2013). Besides that, 
DYRK1B phosphorylates p27Kip1, p21Cip and Cyclin D1 at phosphorylation sites known to 
regulate their protein turnover during cell cycle progression (Deng et al., 2004; Mercer et 
al., 2005; Ashford et al., 2014). 
In human cancer cells, also DYRK2 regulates G1-S-phase transition by priming 
phosphorylation of c-Jun and c-Myc, leading to additional phosphorylation by GSK3-β and 
subsequent ubiquitination-dependent degradation (Taira et al., 2012). 
In summary, kinases of the DYRK family fulfill evolutionary conserved anti-proliferative 
functions in cell cycle regulation from yeast, worm and fly to higher vertebrates. 
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1.3.3 DYRK1A in neurodevelopment and cell cycle control 
The gene encoding DYRK1A is located on human chromosome 21 and is thus 1.5-fold 
overexpressed in Down syndrome (DS) (Guimera et al., 1996, 1999; Dowjat et al., 2007). 
Transgenic mouse models overexpressing DYRK1A show some phenotypic hallmarks of 
DS like a neurodevelopmental delay, motor abnormalities, cognitive defects and an 
altered synaptic plasticity (Altafaj et al., 2001; Ahn et al., 2006). Moreover, a down 
regulation of DYRK1A by shRNA or an inhibition of DYRK1A kinase activity by EGCG 
(Epigallocatechin gallate) in DS mouse models reduced the hippocampal alterations and 
the cognitive defects (Altafaj et al., 2013; De la Torre et al., 2014). Evidence from mouse-, 
chicken- and Drosophila models revealed that the overexpression of DYRK1A causes 
neurodevelopmental alterations by a deregulation of neurogenesis during early brain 
development (Tejedor and Hämmerle, 2011). Remarkably, brain development in DS is 
associated with an arrest of neurogenesis and synaptogenesis, leading to a reduced 
number of neurons in the cortical plate (Wisniewski, 1990; Larsen et al., 2008). Moreover, 
DYRK1A regulates cytoskeletal components like Tau, actin and MAP1B, and thereby 
possibly alters neuronal plasticity in DS (Park and Chung, 2013). The lethality of a 
homozygous DYRK1A knockout, as well as the reduced number of cerebral neurons and 
the altered motor development in a heterozygous knockout, highlight the importance of 
the DYRK1A gene dose in neuronal development (Fotaki et al., 2002, 2004; Benavides-
Piccione et al., 2005; Arqué et al., 2008). Together, these findings hint for contribution of 
DYRK1A to the altered brain development in DS (Dierssen and de Lagrán, 2006; Park et 
al., 2009), what currently raises the interest in its potential pharmacological inhibition 
(Becker et al., 2014).  
Overexpression of DYRK1A induces premature differentiation of PC12 cells and of 
neuronal progenitors (Kelly and Rahmani, 2005; Yabut et al., 2010; Hämmerle et al., 
2011; Stefos et al., 2013), suggesting a possible role in cell cycle regulation. Consistent 
with the conserved functions of DYRK family kinases in cell cycle control (chapter 1.3.2), 
DYRK1A has been reported to phosphorylate proteins involved in cell cycle regulation, 
including the LIN52 component of the DREAM (DP, RB, E2F, and MuvB) complex (Park 
et al., 2010; Litovchick et al., 2011). Phosphorylation of LIN52 on Ser28 by DYRK1A 
promotes assembly of the DREAM complex, thereby inducing gene expression towards 
cellular quiescence. Moreover, DYRK1A overexpression dependent phosphorylation of 
p53 was reported to induce p21Cip1 (CDKN1A) gene expression and to inhibit proliferation 
of embryonic neuronal cells (Park et al., 2010). Moreover, a transient expression of 
DYRK1A was shown to couple cell cycle exit and differentiation of neuronal precursors 
(Hämmerle et al., 2011). The proposed functions of DYRK1A in G1-phase regulation are 
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summarized in figure 4. 
 
Figure 4: Proposed functions of DYRK1A in G1-phase cell cycle regulation. 
DYRK1A phosphorylates p53 at Ser15 and thereby induces p21Cip1 (CDKN1A) gene expression 
and proliferation arrest (Park et al., 2010). In neuronal precursors, transient expression of DYRK1A 
was reported to up regulate p27Kip1 (CDKN1B) gene expression and to promote cell cycle exit and 
differentiation (Hämmerle et al., 2011). Moreover, DYRK1A phosphorylates the LIN52 component 
of the DREAM complex, thereby promoting cellular quiescence (Litovchick et al., 2011). DYRK1A 
also regulates Cyclin D1 stability via Thr286 phosphorylation and subsequent SCF dependent 
ubiquitination (Chen et al., 2013; Ashford et al., 2014). 
Moreover, DYRK1A affects destabilization and nuclear export of overexpressed Cyclin D1 
in Neuro2a cells and in mouse brain (Yabut et al., 2010). So far, it was assumed that 
Cyclin D1 stability in G1-phase was controlled by ubiquitination via the Skp1-Cul1-F box 
(SCF) ubiquitin ligase after Thr286 phosphorylation by GSK-3β (Diehl et al., 1997, 1998; 
Lin et al., 2006). Novel results provide evidence that DYRK1A and DYRK1B 
phosphorylate Cyclin D1 at Thr286 (Ashford et al., 2014). Recently, Chen et al. (2013) 
reported that DYRK1A plays a role in regulation of G1-phase by control of Cyclin D1 
signaling in DS-derived fibroblasts.  
In summary, these findings strongly support the hypothesis that DYRK1A has a functional 
role in regulating G1-S-phase transition of the cell cycle. Nonetheless, the detailed 
mechanistic network by which DYRK1A contributes to the regulation of cell cycle 
withdrawal and differentiation of neuronal precursors is still poorly understood. 
Introduction 
 11
1.4 The SH-SY5Y cell line 
SH-SY5Y cells are a subline of SK-N-SH cells that were isolated from bone marrow of a 
four year old child with a malignant neuroblastoma in 1970 (Biedler et al., 1973). SK-N-SH 
cells consist of two morphologically and biochemically different subtypes, the neuroblastic 
type (N-type) and the epithelial like substrate type (S-type) (Biedler et al., 1973; Ross et 
al., 1983). Although SH-SY5Y cells have been three times subcloned from the N-type of 
SK-N-SH cells (SK-N-SH → SH-SY → SH-SY5 → SH-SY5Y), they retain a low proportion 
of S-type cells (Biedler et al., 1978). N-type SH-SY5Y cells can be differentiated to 
neuronal cells by sequential treatment with all-trans-retinoic acid (RA) and BDNF (brain-
derived neurotrophic factor) (Påhlman et al., 1995; Encinas et al., 2000) as shown in 
figure 5. 
 
Figure 5: Undifferentiated and differentiated SH-SY5Y cells. 
SH-SY5Y cells were left untreated (A), or were differentiated for 7 days with 10µM RA (B) or for 5 
days with RA followed by 2 days with 50 ng/ml BDNF (C). Scale bar = 100 µm. 
Treatment of N-type SH-SY5Y cells with RA leads to development of morphological 
neuronal characteristics and increases the surface expression of the BDNF receptor TrkB 
by up regulation of the NTRK2 gene (Kaplan et al., 1993; Lucarelli et al., 1995). BDNF 
signaling then induces full neuronal differentiation (Encinas et al., 2000). Differentiated 
SH-SY5Y cells arrest in G1/0-phase of the cell cycle and develop a distinct morphological 
neuronal phenotype with increased neurite formation and expression of cytoskeletal 
neuronal markers including Tau and MAP2 (microtubule associated protein 2) 
(Constantinescu et al., 2007). Moreover, differentiated cells acquire further neuron like 
characteristics as the expression of ion channels, synaptic markers, and the capacity to 
release neurotransmitters (Biedler et al., 1978; Abemayor and Sidell, 1989; Encinas et al., 
2000; Constantinescu et al., 2007; Agholme et al., 2010; Korecka et al., 2013). Due to 
their neuronal properties, their human origin and infinite quantities for biochemical 
analyses, SH-SY5Y neuroblastoma cells are a widely used cell model for the investigation 
of neurobiological questions (Jämsä et al., 2004; Cheung et al., 2009; Agholme et al., 
2010; Korecka et al., 2013). 
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1.5 Septins 
Cell division cycle (cdc) genes were first described in cytokinesis deficient 
Saccharomyces cerevisiae mutants (Hartwell, 1971). Later, those genes and their 
respective gene products were collectively named septins due to their observed ring like 
localization in the bud neck of yeast and their assumed crucial functions in cell separation 
and division (Byers and Goetsch, 1976; Kim et al., 1991; Sanders and Field, 1995; 
Longtine et al., 1996). Further studies identified functionally similar proteins (named 
peanut) in Drosophila melanogaster. Septins were characterized as Ras-like small p-loop 
GTPases that are able to assemble to filaments (Neufeld and Rubin, 1994; Field et al., 
1996; Leipe et al., 2002). Septins are phylogenetically conserved from fungi and algae to 
animals but are absent in terrestrial plants (Cao et al., 2007; Pan et al., 2007; Nishihama 
et al., 2011). The diversity of septins varies between different organisms. For instance, in 
Saccharomyces cerevisiae seven genes encode for septins, Caenorhabditis elegans 
expresses two different septins and Drosophila melanogaster five, whereas the human 
genome encodes for thirteen different septins and additionally contains eleven 
pseudogenes (Hall and Russell, 2004; Nishihama et al., 2011; Russell and Hall, 2011). 
Moreover, translation of different isoforms gives rise to a plethora of possible septin 
complexes and functions. As known for human Septin9, expression of 18 different 
transcript variants results in 15 protein isoforms (McDade et al., 2007). Mammalian 
septins are expressed throughout different tissues, but specific functions of particular 
septins in a tissue- or cell type are not yet clear (Hall and Russell, 2012). 
1.5.1 Septin classification, sequence characteristics and filament assembly 
By sequence similarity, human septins can be categorized into four different classes, 
which show clear parallels to septins in yeast or other organisms (table 1) (Kinoshita, 
2003; Hall and Russell, 2004). 
All septins contain a central GTP-binding domain and an adjacent N-terminal polybasic 
domain which allows binding to the plasma membrane. GTP hydrolysis reduces the 
binding capacity of the polybasic region to phosphatidylinositol polyphosphates (PIP2 and 
PIP3), indicating a function to regulate septin membrane association (Zhang et al., 1999). 
In all septins the central GTP-binding domain is C-terminally flanked by a structurally 
conserved septin unique element of so far unknown function (Mostowy and Cossart, 
2012). Additionally, all septins possess variable N- and C-terminal domains. For instance, 
one single member of each septin group (septins 4, 8 and 9) contains a proline rich 
domain as an N-terminal extension, which is spatially unstructured. Although it is 
predicted from sequence analyses that these extensions might contain src homology 
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(SH-2 or SH-3) phosphotyrosine binding domains, any cellular functions of these 
N-terminal domains are still unknown (Hall and Russell, 2004; Sirajuddin et al., 2007). 
Except for class I septins, all septins contain C-terminal coiled coil domains of variable 
length, originally thought to be involved in septin filament formation. As an overview, the 
fundamental structure of all septin classes is illustrated in figure 6A. 
Table 1: Classification of human septins according to Kinoshita (2003), Hall and Russell 
(2004), and Sirajuddin et al. (2007). 
 
Figure 6: Sequence characteristics of mammalian septin classes and principles of septin 
complex formation. 
(A) Mammalian septins are subdivided into four different classes, whereof each class comprises a 
group of different septins due to sequence homologies. All septins share a central GTP-binding 
domain but remarkably differ in the flanking N- and C-terminal extensions. Off note, Septin6 lacks 
the GTPase function due to an amino acid exchange of Thr78. PR = proline rich domain; 
PB = polybasic domain; GTP = GTP binding domain; SUE = septin unique element; CC = coiled 
coil domain. (B) Scheme of a mammalian Septin9/7/6/2 complex. Septins form heterooligomers by 
interaction of their GTP-binding domains (G-interface) or at their N- and C-terminal domains 
(NC-interface). Illustrations according to Mostowy and Cossart (2012) and Kim et al. (2012). 
Septin 
class 
Septin group/ 
family Septin members Structural features 
I septin3-group 3, 9, 12 no coiled coil domain 
II septin6-group 6, 8, 10, 11, 14 two coiled coil domains; no 
GTPase function 
III septin2-group 1, 2, 4, 5 one coiled coil domain 
IV septin7-group 7 two coiled coil domains. 
unusual features 
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Septins from all species assemble into filaments and thereby form distinct structures and 
scaffolds (Field and Kellogg, 1999; Sirajuddin et al., 2007; McMurray and Thorner, 2008). 
Evolutionary conserved, filament assembly clearly follows the septin classification. For 
instance, Drosophila as well as mammalian septin complexes contain three different 
septins from each septin group. Although conservation of filament composition is still not 
understood, it is assumed that an exchange of septin isoforms alters filament properties. 
Besides, the role of class I septins that lack the coiled coil domain in filament formation is 
still unclear (Field et al., 1996; Kinoshita, 2003, 2006; Barral and Kinoshita, 2008). For 
instance, in fibroblasts Septin7 forms ordered structures with Septin2 and Septin6, 
whereas in neurons it forms structures with Septin5 and Septin11, or Septin5 and Septin3 
(Joberty et al., 2001; Fujishima et al., 2007; Xie et al., 2007). 
Regarding their assembly in higher ordered structures, analysis of the molecular structure 
revealed that septins form dimers by an alternating interaction either via their GTP-binding 
domains (G-interface) or via their C- and N-terminal domains (NC-interface) (figure 6B). 
Interestingly, G-interfaces are built up prior to NC-interfaces. Analysis of a crystallized 
Septin2/6/7 complex showed no involvement of the coiled coil domain in septin assembly 
(Sirajuddin et al., 2007; Sellin et al., 2011; Kim et al., 2011, 2012). Septin-septin interfaces 
are uniform, therefore allowing multiple interactions in vitro. Nonetheless, the significance 
and consequence of different septin complex compositions in vivo is still not understood 
(Barral and Kinoshita, 2008). 
In contrast to microtubules or actin microfilaments, septin filaments are not of polar 
structure. Furthermore, the coiled-coil domains are arranged in an orthogonal orientation 
to the axis of septin oligomers. Coiled-coild domains laterally protruding from the filament 
implicate functions as protein docking sites or for membrane association of whole septin 
filaments. Although the coiled coil domains are not directly involved in septin complex 
formation, they seem to facilitate the assembly of parallel septin filaments (Rodal et al., 
2005; DeMay et al., 2011). Like typically observed at the bud neck of yeast, septin 
filaments predominantly form ring like structures, what relies on bending of single 
filaments. Anyway, ring-like assembled septin filaments at the yeast bud neck show no 
rotational flexibility but maintain a strait and fixed orientation (Vrabioiu and Mitchison, 
2006; Sirajuddin et al., 2007). 
1.5.2 Septin functions 
During cytokinesis, septin filaments are often found to be associated with cell membranes 
and signaling molecules, but also attached to microtubules and actin filaments 
(Casamayor and Snyder, 2003; Kremer et al., 2005, 2007; Spiliotis, 2010; Nakahira et al., 
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2010; Bowen et al., 2011). Dependent on their subcellular localization, septin filaments 
fulfill numerous cellular functions. 
In cytokinesis, septins form structures of higher orders. These structures function as 
diffusion barriers, reorganize the cellular cytoskeleton, or define cellular asymmetry, 
polarization and movement (Barral et al., 1999, 2000; Hu et al., 2010; Kim et al., 2010). In 
yeast, septins form a ring like structure during cytokinesis at the bud neck (Longtine et al., 
1996; Dobbelaere and Barral, 2004; Spiliotis et al., 2005). Besides that, in neurons, 
photoreceptors and epithelial cells, septins form diffusion barriers at cytoplasmatic 
interfaces to axons, dendritic spines, cilia or other cell type specific compartments 
(Caudron and Barral, 2009). A septin knockout in Xenopus laevis caused aberrant cell 
movement. In Caenorhabditis elegans and in mouse embryos with different septin 
depletions, neurons fail to guide their axons properly, show an altered dendritic spine 
morphology and do not correctly migrate to the cortical plate (Finger et al., 2003; Tada et 
al., 2007; Xie et al., 2007; Kim et al., 2010; Shinoda et al., 2010; Cho et al., 2011). 
Furthermore, septins are required for the function of immune cells. In particular, after a 
Septin7 knockdown, T-lymphocytes exhibit abnormally elongated protrusions and an 
altered cellular motility in vitro (Tooley et al., 2009). Furthermore, macrophages show a 
deregulated phagocytosis after Septin2 and Septin11 silencing (Huang et al., 2008). In 
summary, septins fulfill fundamental functions in regulation of morphology and motility of 
different cell types. 
Due to their functions, a disturbed cellular septin regulation is associated with different 
diseases. For instance, Septin4 was found in neurodegenerative protein aggregates and 
to be essential for spermatogenesis (Ihara et al., 2005, 2007). Beyond that, Septin9 was 
identified as a tumor suppressor and p53 response gene in breast cancer. The expression 
of other septins was reported as altered in tumorigenesis and neoplasia (Russell and Hall, 
2005; McDade et al., 2007).  
1.5.3 Posttranslational modifications of septins 
Although septins raised attention as important components of the cellular cytoskeleton, 
regulation of polymerization and filament assembly is poorly understood. However, 
posttranslational modifications are thought to control spatial and temporal organization of 
septin filaments (Hernández-Rodríguez and Momany, 2012). 
As an analogous process to ubiquitination, covalent addition of SUMO proteins (Small 
Ubiquitin-like Modifier) to septins was observed in yeast. Mutations of SUMOylation sites 
prevented septin ring degradation after cell division (Johnson and Blobel, 1999; Takahashi 
et al., 1999). Additionally, in Saccharomyces cerevisiae, acetyltransferase depletion as 
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well as lysine mutations of septins led to defects in ring transition and formation (Mitchell 
et al., 2011). Further studies revealed that lysine acetylation is spread over all septin 
domains in several lower eukaryotes. Interestingly, in fungal septins, an acetylated lysine 
is located in the region involved in formation of the G-interface, indicating that acetylation 
might be an additional mechanism to regulate septin function and assembly (Hernández-
Rodríguez and Momany, 2012). 
Phosphorylation is the best characterized posttranslational modification of septins. To 
date, 59 potential phosphorylation sites are identified in fungal septins, predominantly 
localized in the N- and C-terminal extensions (Hernández-Rodríguez and Momany, 2012). 
Remarkably, only one phosphorylation site was determined within the GTP-binding 
domain, nearby the region building up the G-interface. In yeast, phosphorylation of septins 
alters during cell cycle progression and thereby regulates septin dynamics. In 
S. cerevisiae, the CDK Cdc28 (Cdk1) regulates septin (Cdc3) ring disassembly at the end 
of G1-phase. Moreover, Cla4 and Gin4 dependent phosphorylation mediates 
immobilization of septins in S-, G2- and M-phase. In contrast, septin mobility is increased 
in telophase of cytokinesis due to reduced phosphorylation (Dobbelaere et al., 2003). 
Additionally, phosphomimetic amino acid mutations revealed pivotal phosphorylation sites 
for proper gauze and ring formation in S. cerevisiae. Remarkably, phosphorylation of the 
yeast septins Cdc10 and Cdc12 by Cla4, combined with GTP-binding, is required for 
adequate ring formation (Versele and Thorner, 2004). In addition, CDKs regulate septin 
organization during cell cycle in Candida albicans (Sinha et al., 2007; Li et al., 2012). 
Interestingly, none of the regulative phosphorylation sites identified in yeast is evolutionary 
conserved in higher eukaryotes. Anyhow, phosphorylation is supposed to affect formation 
of septin structures in higher organisms (Hernández-Rodríguez and Momany, 2012).  
1.5.4 Septin4 
Human Septin4 belongs to the class III of septin GTPases (section 1.5.1, table 1 and 
figure 6) and was formerly termed septin H5, PNUTL2 (peanut-like protein 2), 
hCDCREL-2 (human cell division control-related protein 2) or Bradeion beta. 
Characteristics are an unstructured N-terminus and a catalytic active GTP-binding site. 
Septin4 is expressed in six different isoforms, whereof isoforms 1-5 show variations in the 
N-terminal sequence. In contrast, isoform 6 shows more evident sequence alterations, 
and lacks 184 C-terminal amino acids. Because of its fundamental differences in 
sequence and function, the protein isoform 6 was named ARTS (apoptosis-related protein 
in the TGF-beta signaling pathway). In contrast to all other septins, ARTS shows a 
mitochondrial localization and is a mediator of apoptosis and tumor suppression (Larisch 
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et al., 2000; Gottfried et al., 2004; García-Fernández et al., 2010; Fuchs et al., 2013). 
Septin4 forms stable homodimers in vitro and its polybasic domain associates to 
phosphatidylinositol (3,4,5)-trisphosphate upon GTP-binding (Zhang et al., 1999; Garcia et 
al., 2006). Mammalian Septin4 is expressed in different tissues, but a predominant 
physiological expression is detected in brain (Xie et al., 1999; Zieger et al., 2000; Tanaka 
et al., 2001). 
In human brains Septin4 was found to accumulate with Septin1 and Septin3 in tau based 
neurofibrillary tangles (NFTs) and dystrophic plaques which represent hallmarks of 
Alzheimer’s disease  and cerebral neurodegeneration (Kinoshita et al., 1998). 
Interestingly, the GTPase domain of human Septin4 forms amyloid like filaments in vitro 
(Garcia et al., 2007). Moreover, Septin4 was identified as a component of α-synuclein-
positive cytoplasmatic inclusions, also known as Lewy bodies (LBs). LBs occur in 
Parkinson’s disease (PD), dementia with Lewy bodies, and multiple-system atrophy 
(MSA) (Ihara et al., 2003). Remarkably, in mouse dopaminergic neurons Septin4 not only 
associates with α-synuclein, but also with presynaptic proteins like the dopamine 
transporter. Interestingly, Septin4 knockout mice exhibit reduced dopaminergic 
neurotransmission and Septin4 depletion enhances neuropathological characteristics in a 
PD mouse model (Ihara et al., 2007). Beyond that, Septin4 binding prevents α-synuclein 
from self aggregation in vitro (Ihara et al., 2007). In contrast, Septin4 transgenic mice 
show an abnormal behavior but no neurodegeneration (Ageta-Ishihara et al., 2013). 
Furthermore, selective silencing of Septin4 in mouse embryo cortex neurons resulted in a 
inaccurate migration to the cortical plate (Shinoda et al., 2010).  
In addition, Septin4 was identified as a mediator of store operated Ca2+-channels in HeLa 
cells and to be elementary for functional spermatogenesis in mice (Ihara et al., 2005; 
Kissel et al., 2005; Sharma et al., 2013).  
Furthermore, Septin4 silencing led to a G2-cell cycle arrest of human cancer cell lines and 
Septin4 is abnormally expressed in bladder and colorectal cancer, as well as in malignant 
melanoma (Tanaka et al., 2002; Bongiovanni et al., 2012). 
Although Septin4 transcription is supposed to be regulated by p53 and notch signaling 
(Kostic and Shaw, 2000; Liu, 2012), posttranslational modifications for fast regulation of its 
cellular functions and dynamics are almost disregarded. A yeast two hybrid screen 
identified Septin4 as a target of the SUMO conjugating enzyme UBC9 (UBE2I), indicating 
regulated protein degradation (Nakahira et al., 2010). Large scale phosphoproteomic 
screens identified Septin4 as specifically phosphorylated in mouse brain homogenates 
and in mouse postsynaptic density preparations but not in other tissues (Trinidad et al., 
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2006; Huttlin et al., 2010). Nonetheless, the respective kinases and the functional 
consequences of these phosphorylation events are still unknown. 
Interestingly, Septin4 interacts with the DYRK1A kinase domain and was identified as a 
DYRK1A substrate (Sitz et al., 2008). In mouse brain neurons, DYRK1A is co-expressed 
and co-localizes with Septin4. However, the respective phosphorylation site as well as 
potential functional consequences of DYRK1A mediated Septin4 phosphorylation remain 
univestigated. 
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2 Working hypothesis and objective 
DYRK1A and neuronal cell cycle regulation 
DYRK1A is a candidate gene for the neurodevelopmental alterations in Down syndrome. 
Nonetheless, how DYRK1A is involved in neuronal development is still poorly understood. 
Proper brain development requires a correct number of differentiating neuronal progenitor 
cells, achieved by a precise control of their G1-G0 cell cycle exit. The fact that DYRK1A is 
overexpressed in Down syndrome led to the hypothesis that DYRK1A overexpression 
may deregulate neuronal cell cycle progression. 
Therefore, the major aim of the study was to address the question if DYRK1A 
overexpression alters neuronal cell cycle progression and differentiation. 
To pursue this objective, the study aimed to construct SH-SY5Y neuroblastoma cells with 
a doxycycline inducible DYRK1A overexpression as a neuronal cell model. It should be 
analyzed if DYRK1A overexpression affects proliferation, cell cycle progression, and 
neuronal differentiation in SH-SY5Y cells. Finally, target proteins that are phosphorylated 
by DYRK1A in neuronal cell cycle regulation should be identified to elucidate the 
underlying molecular mechanisms. 
 
DYRK1A and Septin4 
Septin4 is essential for the development of neurons and accumulates in 
neurodegenerative protein aggregates. Anyway, details of cellular Septin4 functions and 
regulative mechanisms are completely unknown. Recently, Septin4 was identified as a 
DYRK1A substrate, leading to the hypothesis that DYRK1A might regulate Septin4 
functions by phosphorylation. 
Thus, the second aim of the study was to characterize the DYRK1A phosphorylation site 
in Septin4 and to elucidate the potential functional consequences of this phosphorylation. 
To pursue this objective, the DYRK1A phosphorylation site should be determined by 
Septin4 mutagenesis and overexpression studies. Moreover, the study aimed to generate 
a phosphospecific antibody against the DYRK1A phosphorylation site. Furthermore, 
potential functional consequences of DYRK1A mediated Septin4 phosphorylation should 
be identified. Finally, an experimental strategy for future characterization of these 
consequences should be developed. 
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3 Materials and Methods 
3.1 Chemicals 
If not stated otherwise, all chemicals were obtained from Sigma Aldrich (Munich, 
Germany), Merck Eurolab (Darmstadt, Germany) or AppliChem (Darmstadt, Germany). 
3.2 Technical equipment 
All frequently used technical equipment is listed below. Extraordinary used equipment is 
stated in the manuscript. 
Cell culture 
TC75 culture flask, red lid (75 cm2), Sarsted (Nümbrecht, Germany) 
6-well culture dish, Sarsted (Nümbrecht, Germany) 
24-well culture dish, Sarsted (Nümbrecht, Germany) 
10 cm culture dish, Sarsted (Nümbrecht, Germany) 
6 cm culture dish, Thermo Scientific Nunc (Langenselbold, Germany) 
12 mm microscope coverslips, Marienfeld (Lauda-Königshofen, Germany) 
PCR 
Primus 96+, MWG Biotech (Ebersberg, Germany) 
LightCycler®480, Roche (Basel, Switzerland) 
RNA isolation 
QIAcube, Quiagen (Hilden, Germany) 
Nucleic acid analytics 
Agagel Mini, Biometra (Göttingen, Germany) 
NanoDrop ND-1000 UV-Vis spectrophotometer, NanoDrop Technologies (Wilmington, DE, 
USA) 
Molecular Imager® Gel DocTM XR+ with Image LabTM software, Bio-Rad Laboratories 
(Munich, Germany) 
Protein biochemistry 
Minigel Twin G42, Biometra (Göttingen, Germany) 
TE22 Mini Transfer Tank, Hoefer (Holliston, MA, USA) 
LAS-3000 chemiluminescence imager, Fujifilm (Düsseldorf, Germany) 
Lambda E multiwell plate reader, MWG Biotech (Ebersberg, Germany) 
Real-time-cell-analysis 
xCELLigence, Roche Diagnostics (Mannheim, Germany) 
96-well E-Plate Roche Diagnostics (Mannheim, Germany) 
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Fluorescence microscopy 
DM IRB, Leica (Solms, Germany) 
Axiovert 200M, Zeiss Microimaging (Göttingen, Germany) 
Olympus spectral FV1200 confocal microscope (Tokyo, Japan) 
IncuCyteTM, Live Content Microscope, (Welwyn Garden City, UK) 
Centrifugation 
Sigma 112 table top centrifuge, Sigma (Osterode, Germany)  
Centrifuge 5417R, Eppendorf (Hamburg, Germany)  
Heraeus Multifuge 3SR+, Thermo Fisher Scientific (Langenselbold, Germany)  
AvantiTMJ25 Ultracentrifuge, Beckman Coulter (Fullerton, CA, USA) 
3.3 Antibodies 
All used primary and secondary antibodies are listed in table 2 and table 3 respectively, 
according to their application. 
Table 2: List of primary antibodies used for western blotting (WB), immunofluorescence (IF) 
or immunoprecipitation (IP) 
Target Application Species Amount/ 
Dilution 
Isotype 
(Clone/ID) Supplier 
FLAG WB mouse 2 µg/ml IgG1 (M2) 
Sigma Aldrich 
(Munich, Germany) 
GFP WB goat 1:1000 polyclonal Rockland (Gilbertsville, PA, 
GFP-trapM IP alpaca 15 µl/ml VHH Chromotek (Munich, Germany) 
RFP WB rabbit 1:5000 polyclonal Evrogen (Moscow, Russia) 
DYRK1A WB mouse WB 1:1000 IgG2b Kappa (7D10) 
Abnova 
(Taipei, Taiwan) 
Cyclin D1 WB mouse 1:1000 IgG2a (DCS6) 
Cell Signaling/NEB 
(Frankfurt a.M, 
Germany) 
Cyclin D1 
pThr286 WB rabbit 1:1000 
IgG 
(D29B3) 
Cell Signaling/NEB 
(Frankfurt a.M, 
Germany) 
p27Kip1 WB IF mouse 
1:1000 
1:200 
IgG1 
(57/Kip1/p27) 
BD Bioscience 
(Heidelberg, 
Germany) 
p27Kip1 
pSer10 WB rabbit 1:2500 
IgG 
(EP233(2)Y) Abcam (Heidelberg, 
Germany) 
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Continuation of table 2 
Target Application Species Amount/ 
Dilution 
Isotype 
(Clone/ID) Supplier 
p27Kip1 
pSer10 
WB 
IF rabbit 
1:1000 
1:200 
IgG 
(sc-12939-R) 
Santa Cruz 
(Heidelberg, 
Germany) 
WDR68 WB rabbit 1:1000 IgG (EPR8712) 
Abcam 
(Heidelberg, 
Germany) 
Histone H3 
pSer10 WB rabbit 1:1000 
IgG 
(D2C8) 
Cell Signaling/NEB 
(Frankfurt a.M, 
Germany) 
Septin4 WB goat 1µg/ml polyclonal (EB10428) 
Everest Biotech 
(Oxfordshire, UK) 
Septin4 
pSer107 WB rabbit 1µg/ml polyclonal Custom made 
MAP2 WB mouse 1:1000 IgG1 (HM2) 
Sigma Aldrich 
(Munich, Germany) 
Tau WB mouse 1:1000 IgG1 (Tau-13) 
Santa Cruz 
(Heidelberg, 
Germany) 
PARP WB rabbit 1:1000 polyclonal Cell Signaling/NEB (Frankfurt a.M, 
Germany) 
Beta Catenin WB mouse 1:1000 IgG1 (14/Beta-
Catenin) 
BD Bioscience 
(Heidelberg, 
Germany) 
Tub. β-III WB chicken 1:1000 IgY (Tuj1) 
Neuromics 
(Edina, MN, USA) 
Tub. β-III IF mouse 1:500 IgG2a (Tuj1) 
Covance 
(Princeton, NJ, 
USA) 
GAPDH WB rabbit 1:1000 IgG (14C10) 
Cell Signaling/NEB 
(Frankfurt a.M, 
Germany) 
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Table 3: List of secondary antibodies and conjugates used for western blotting (WB) or 
immunofluorescence (IF) 
Target 
(Isotype) Application 
Species 
(Isotype) Dilution Conjugation Supplier 
Mouse 
(IgG) WB 
donkey 
(IgG) 1:5000 HRP 
Rockland 
(Gilbertsville, 
PA,USA) 
Rabbit 
(IgG) WB 
donkey 
(IgG) 1:5000 HRP 
Rockland 
(Gilbertsville, PA, 
USA) 
Goat (IgG) WB donkey (IgG) 1:5000 HRP 
Rockland 
(Gilbertsville, PA, 
USA) 
Chicken 
(IgY) WB 
rabbit 
(IgG) 1:5000 HRP 
Promega 
(Mannheim, 
Germany) 
Biotin WB goat (IgG) 1:2000 HRP 
Cell Signaling/NEB 
(Frankfurt a.M, 
Germany) 
Mouse 
(IgG) IF 
Donkey 
(IgG) 1:600 Biotin 
Jackson 
Immunochemicals 
(Newmarket, UK) 
Rabbit 
(IgG) IF 
Donkey 
(IgG) 1:600 Biotin 
Jackson 
Immunochemicals 
(Newmarket, UK) 
Target Application Conjugate Dilution Conjugation Supplier 
Biotin WB (HaloTag) Streptavidin 1:500 HRP 
R&D Systems 
(Minneapolis, MN, 
USA) 
Biotin IF Streptavidin 1:500 Cy2TM 
Rockland 
(Gilbertsville, PA, 
USA) 
F-actin IF Phalloidin 1:40 Alexa®-546 
Invitrogen 
(Carlsbad, CA, 
USA) 
F-actin IF Phalloidin 1:100 Rhodamine 
GE Healthcare 
(Freiburg, 
Germany) 
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3.4 Microbiological methods 
3.4.1 Transformation of competent Escherichia coli 
For transformation, chemical competent E coli DH5α F‟Iq (High efficiency, NEB) were 
used. 
Genotype E. coli DH5α  F‟Iq: F´ proA+B+ lacIq ∆(lacZ)M15 zzf::Tn10 (TetR) / 
fhuA2∆(argF-lacZ)U169 phoA glnV44 80∆(lacZ)M15 gyrA96 recA1 endA1 thi-1 hsdR17 
Transformation of 100 µl E. coli was performed according to the following protocol: 
• Thaw up bacteria on ice 
• Add 1 µL plasmid (for recombination cloning see section 3.5.5) 
• Vortex and incubate 30 min on ice 
• Incubate for 90 sec at 42°C 
• Add 900 µl fresh LB-medium (see section 3.5.7) 
• Shake for 45 min (ampicillin) or 75 min (kanamycin) at 37°C 
• Pellet bacteria 
• Discard 700 µl LB supernatant 
• Resuspend bacteria 
• Spread on LB-agar-plates with tantibiotic 
• Incubate plate at 37°C over night 
For selection of positively transformed E. coli, the indicated antibiotics were used: 
Ampicillin [100 µg/ml] 
Kanamycin [30 µg/ml] 
3.5 Nucleic acid analytics and cloning techniques 
3.5.1 Agarose gel electrophoresis 
For analytical purposes or subsequent usage in cloning, DNA or RNA was separated by 
agarose gel electrophoresis. Depending on the size of nucleic acids to be analyzed, the 
concentration of agarose (Seakem® LE Agarose, BioWhittaker, Verviers, Belgium) was 
varied between 0.7% and 2.0% (w/v), dissolved in 1x TAE-buffer (table 4). Nucleic acids 
were stained for UV light detection via intercalation of GelRed® [1000x] (Biotium, 
Hayward, CA, USA). Depending on the agarose concentration and the size of the nucleic 
acids, appropriate DNA ladders were used (Fermentas). All samples were mixed with 
DNA Loading Dye (Fermentas) before gel loading. 
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Table 4: 50x TAE buffer 
50x TAE-buffer 
2 M Tris 
1 M Acetic acid 
50 mM EDTA pH 8.0 
in ddH2O 
 
3.5.2 Polymerase chain reaction (PCR) 
For subcloning into expression vectors, the cDNA of interest was amplified by PCR using 
the Advantage HD Polymerase from Clontech (Mountain View, CA, USA). Standard PCR 
conditions are listed in table 5 and table 6. 
Table 5: Standard PCR-mix for cloning approaches 
PCR-mix composition Final amount 
Template vector 100 ng 
dNTP mix 200 µM 
Forward primer 0.2 µM 
Reverse primer 0.2 µM 
Advantage HD polymerase  0.625 U 
5x Advantage HD buffer 1x 
ddH2O ad 25 µl 
 
Table 6: Standard PCR conditions for cloning approaches 
Time Temperature Step 
2 min 95°C Initial denaturation 
10 sec 95°C Denaturation 
5 sec 55°C Annealing 
1 min per 1 kb 72°C Elongation 
2 min 72°C Final elongation 
 
Additionally to control digestion with restriction enzymes, screening of cloned expression 
vectors was performed by PCR amplification of the integrated insert, using the cloning 
primers. PCR was performed with the GoTaq® Green polymerase from Promega 
25 cycles 
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(Mannheim, Germany). The used PCR conditions were set up according to the 
manufacturers’ protocol. Large-scale screenings of cloned expression vectors were 
performed by colony PCR. To this aim, positive selected bacterial colonies were slightly 
picked with a 10 µl pipette tip, and the tip rubbed at the bottom of a PCR tube. Afterwards 
the PCR mix was added and the PCR was performed at the same conditions as standard 
PCR. All PCR primers used for cloning are listed in the supplemental material (chapter 
7.2, table 18). 
3.5.3 Restriction and ligation of DNA 
For cloning of DNA fragments into mammalian expression vectors, 2 µg of the appropriate 
plasmid were digested. Restriction enzymes (NEB, Frankfurt a.M. or 
Fermentas/Thermo Scientific Molecular Biology, Schwerte, Germany) were used 
according to the manufacturers’ recommendations. For analytical test digestions 150 ng of 
plasmids were used. Successful digestion was analyzed by agarose gel electrophoresis. 
For extraction of DNA from agarose gels, the QIAquick Gel Extraction Kit (Quiagen, 
Hilden, Germany) was used. 
For ligation, 100 ng linearized vector and DNA fragments in a molar ratio of 1:1, 1:2 and 
1:3 (vector : insert) were used. Ligation of DNA fragments into digested and linearized 
expression plasmids was performed with 1 U of T4-ligase (Fermentas) for 1 h at 22°C. 
Subsequently, the ligase was heat inactivated for 10 min at 65°C.  
3.5.4 Site-directed mutagenesis 
For site-directed mutagenesis of expression plasmids, the QuikChange® Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA, USA) was used according to the 
manufacturers’ instructions. 
3.5.5 Recombination cloning 
If conventional cloning by blunt- or sticky end ligation was not practicable because of 
unfeasible restriction sites, insertion of PCR amplified DNA fragments was performed by 
recombination cloning (Zhang et al., 1998). 
In this study, lentiviral expression vectors with a tetON inducible expression of GFP-
DYRK1A were generated, based on the lentiviral backbone vector FUW-tetON-hMyc 
(Addgene: 20723) which provides two EcoRI sites for replacing the hMyc insert by GFP-
DYRK1A cDNA. Therefore, GFP-DYRK1A was amplified by PCR using primers with a 26-
nucleotide overhang flanking the opened FUW-tetON backbone vector at the 5´ sticky 
ends after removing the hMyc insert via the EcoRI sites. The primers also include a usual 
overhang of approximately 20 nucleotides to amplify the GFP-DYRK1A ORF, and an 
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additionally engineered EcoRI site in between the backbone und the ORF overhangs, 
allowing in-frame integration into the linearized FUW-tetON vector. 
The exemplary protocol for recombination cloning of GFP-DYRK1A into FUW-tetON-hMyc 
is stated here: 
• Digest FUW-tetON-hMyc with EcoRI for 1.5 h at 37°C 
• Inactivate EcoRI for 20 min at 65°C 
• Dephosphorylate 5´-sticky ends with 5 U CIP (NEB) for 1 h at 37°C 
• Verify digestion by agarose gel electrophoresis 
• Perform gel extraction of the linearized vector 
• Amplify GFP-DYRK1A ORF with recombination cloning primers by PCR 
• Perform gel extraction of the PCR product 
(not required if the target backbone vector and the template vector for PCR amplification 
have different selection markers) 
• Transform competent RecE and RecT positive E.coli with a 1:1, 1:2 or 1:3 ratio of vector : 
insert (see paragraph 3.4.1) 
• Incubate 2.5 h on a shaker at 37°C (Recombination and expression of selection resistance) 
• Plate bacteria on an pre-warmed selection plate and incubate at 37°C over night 
• Screen colonies after boiling prep as stated in 3.5.7 and 3.5.3 
By the same procedure, using BamHI and PstI for linearization of the target vector, the 
HaloTag from the pHT2 vector (Promega) was integrated into pCMV-Flag-Septin4 (Sitz et 
al., 2008), resulting in pCMV-Flag-HaloTag-Septin4. Flag-Septin4 was also integrated in 
pTag-RFP-N (Evrogen), resulting in pTag-Flag-Septin4-RFP. The used primers are listed 
in the supplemental material (chapter 7.2, table 18). 
3.5.6 Concentrating nucleic acids 
If necessary, DNA or RNA was concentrated by ethanol (EtOH) precipitation as follows: 
• Add 2.5-fold total sample volume of absolute EtOH 
• Add 10% total sample volume of sodium acetate (NaAc) pH 5.2 
• Incubate 1 h at -80°C 
• Centrifuge 15 min at max g in a table top centrifuge, discard supernatant 
• Air dry DNA pellet 
• Resuspend pellet in an appropriate amount of ddH2O 
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3.5.7 Isolation of plasmid DNA 
Isolation of plasmids from E. coli (boiling preparation) 
For large scale screening of new cloned expression vectors, after transformation of E. coli 
and subsequent selection by antibiotic resistance (see chapter 3.4.1), the plasmid was 
purified from the bacteria by the following protocol: 
• Pick a single bacterial clone and inoculate 3 ml of LB medium + antibiotic 
• Incubate at 37°C over night on a shaker 
• Pellet 1 ml of the over night culture 
• Resuspend pellet in 235 µl STET-buffer + 15 µl lysozyme [10 mg/ml] 
• Incubate 50 sec at 100°C, vortex 
• Pellet bacterial debris at 4°C and max g in a table top centrifuge 
• Remove pellet 
• Add 250 µL isopropanol to the supernatant 
• Pellet plasmid DNA for 15 min at 4°C and max g in a table top centrifuge 
• Discard supernatant 
• Air dry DNA pellet and resuspend in 30 µl TE-buffer pH 8.0 
Correct insertion of DNA fragments into expression vectors was verified by control 
digestion or PCR amplification (3.5.3). Compositions of used buffers and LB-medium are 
stated in table 7. 
Table 7: Buffers and LB-medium for plasmid isolation from E. coli 
STET-buffer pH 8.0  TE-buffer pH 8.0 LB-medium (agar plates) 
50 mM Tris 10 mM Tris Yeast extract [5 g/l] 
0.4 M Glucose 1 mM EDTA Trypton [10 g/l] 
50 mM EDTA in ddH2O NaCl [5 g/l] 
5% (v/v)Triton X-100  (+1.5% (w/v) agar) 
in ddH2O  in ddH2O 
 
Isolation of plasmids from E. coli (Kit preparation) 
For small scale screening or sequencing of cloned expression vectors the GeneJET 
Plasmid Miniprep Kit (Fermentas/Thermo Fisher Scientific) was used and correct cloning 
was verified by control digestion or PCR amplification (3.5.3), followed by DNA 
sequencing service (Eurofins MWG operon, Ebersberg, Germany). 
Correct expression vectors were retransformed into E. coli, amplified and purified for 
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further use by maxi preparation using the Qiagen Plasmid Maxi Kit (Qiagen). Precipitated 
plasmids were dissolved in ddH2O and stored at -20°C. Both kits were used following the 
manufacturers’ recommendations. 
3.5.8 Isolation of total RNA, cDNA synthesis and quantitative real-time PCR 
Total RNA from cultured cells was isolated with the NucleoSpin® RNA II kit from 
Macherey-Nagel (Düren, Germany) using a QIAcube (Qiagen). 2.0x106 SH-SY5Y-tetON-
GFP-DYRK1A or SH-SY5Y-tetON-GFP-DYRK1A-K188R cells were seeded into 6-cm 
culture dishes for RNA isolation after 24 h of treatment with doxycycline or RA. For RNA 
isolation after 72 h of treatment, differences in cellular proliferation were compensated by 
plating 1.0x106 control or DYRK1A-KR overexpressing cells and 2.0x106 cells 
overexpressing DYRK1A or undergoing RA differentiation. For cell lysis, cells were 
carefully washed once with 4°C PBS. Subsequently the cells were rinsed from the culture 
dish surface with 1 ml 4°C PBS, transferred to a 2.0 ml RNase free microcentrifugation 
tube (Qiagen) and pelleted at 500 g for 5 min. The PBS was discarded and the pellet 
resuspended in 500 µl RA lysis buffer containing 3% tris(2-carboxyethyl)phosphine 
(TCEP). The tubes were transferred to the QIAcube and RNA isolation was conducted 
automated using the standard program. Subsequently, an additional DNase treatment 
was performed with rDNase like recommended by the manufacturer (Macherey-Nagel) 
and RNA was concentrated as stated in 3.5.6. Afterwards RNA concentration and integrity 
was verified with a NanoDrop (Thermo Scientific) and the samples stored at -80°C until 
further usage. All steps were performed on ice.  
cDNA synthesis 
From total isolated RNA, mRNA was transcribed to cDNA using the Moloney Murine 
Leukemia Virus Reverse Transcriptase (M-MLV RT) obtained from Promega. All protocol 
steps are stated in table 8. 
Quantitative real-time PCR (qRT-PCR) 
Quantitative real-time PCR was used to analyze gene expression in cultured cells. 
Primers for qRT-PCR were designed intron-exon spanning or intron-exon flanking and 
ordered RP-HPLC purified (Eurogentec, Köln, Germany). Primer sequences and the 
respective qRT-PCR conditions are listed in the supplemental material (chapter 7.1, table 
16 and table 17). The qRT-PCR was established for each primer pair, optimizing 
annealing temperature and the number of cycles by analyzing the melting curves, the Cp 
and the qRT-PCR efficiency in known samples. Furthermore, PCR products were 
analyzed for correct amplification size, efficiency and unspecific products by agarose gel 
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electrophoresis. The LightCycler® 480 DNA SYBR Green I Master (Roche) was used as 
stated in table 9. As gold standard, all samples were mixed and a dilution series was 
generated (1:1, 1:2, 1:8, 1:32 and 1:128). Negative controls were performed with ddH2O 
instead of template and with samples lacking reverse transcription. Expression data were 
correlated to the expression of a housekeeping gene, using the advanced relative 
quantification provided by the LightCycler® software 1.5 (Roche). All samples were 
analyzed in triplicates. 
Table 8: Protocol of cDNA synthesis 
1 µg Total RNA 
+ 1 µl Oligo(dT)-primer [0.5 µg/µl] 
ad 12 µl Nuclease free H2O 
• Incubate 10 min at 65°C 
• Store on ice  
+ 4 µl M-MLV RT reaction buffer [5x] 
+ 2 µl dNTP-mix [10 mM] 
+ 1 µl RNasin® [40 U/µl] 
+ 1 µl M-MLV RT [2000 U/µl] 
• Incubate 90 min at 40°C 
• Incubate 2 min at 95°C  
+ 20 µl Nuclease free H2O 
Store cDNA at -80°C 
 
Table 9: Master mix for qRT-PCR (per sample) 
Composition Stock concentration Final concentration 
SYBR Green I Master  5.5 µl 
Forward primer 6.25 µM 0.625 µM (= 1 µl) 
Reverse primer 6.25 µM 0.625 µM (= 1 µl) 
ddH2O  ad 10 µl 
Template (cDNA)  1 µl 
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3.6 Cultivation of cell lines, primary cells and mouse embryos 
3.6.1 Cell lines 
All cell culture work was performed in sterile conditions using one way material (3.2). 
Testing for mycoplasma contamination was performed using the Venor®GeM-OneStep 
PCR kit (Minerva Biolabs, Berlin, Germany). The following cell lines were used: 
Human SH-SY5Y neuroblastoma cells (Biedler et al., 1973) (ATCC® Number: CRL-
2266™) were kindly provided by Dr. Gary Brooks (Institute of Neuropathology, RWTH 
Aachen University, Aachen, Germany). 
The human cervix carcinoma cell line HeLa (Gey et al., 1952; Scherer et al., 1953) 
(ATCC® Number: CCL-2™) were obtained from the American type culture collection 
(ATCC). 
Lenti-X 293T lentiviral packaging cells derived from HEK 293T human kidney cells were 
obtained from Clontech (Mountain View, CA, USA). 
3.6.2 Cultivation, treatment, differentiation and transfection of cell lines 
For treatment of cultured SH-SY5Y cells, the following substances were used: 
Doxycycline (Sigma), all-trans retinoic acid (Sigma), brain derived neurotrophic factor 
(BDNF) (Peprotech), harmine (Fluka), leucettine L41 (kindly provided by Laurent Meijer, 
ManRos Therapeutics, Roscoff, France, Tahtouh et al., 2012), LiCl (Sigma), CHIR99021 
(Cayman Chemical), staurosporine (Enzo Life Sciences). 
SH-SY5Y-tetON-GFP-DYRK1A/K188R cells were cultured in Dulbecco's modified Eagle 
medium (DMEM) high glucose (PAA) supplemented with 10% FCS (PAA) at 37°C, 5% 
CO2 and constant humidity. At 75% confluence, cells were washed twice with PBS, 
trypsinized and resuspended in fresh medium. Cells were centrifuged for 5 min at 500 g, 
resuspended in fresh medium and then plated into multiwell plates or dishes according to 
the experimental requirements. DYRK1A overexpression was induced by treatment with 
2 µg/ml doxycycline or as indicated. Neuronal differentiation was induced with 10 µM 
retinoic acid dissolved in 100% EtOH. For terminal differentiation, the RA containing 
medium was removed after 3 days and replaced by serum free DMEM high glucose 
containing 50 ng/ml BDNF for 2 additional days. For long-term differentiation with BDNF, 
culture dishes were pre-coated with 0.05 mg/ml collagen from rat-tail. 
Transfection of 2.0x106 SH-SY5Y cells with 2 µg plasmid DNA was performed using the 
AMAXA Nucleofector II and the Cell Line Nucleofector Kit V (Lonza) according to the 
manual. After nucleofection, 400,000 cells were plated per well into 6-well plates. 
HeLa cells were cultured in Quantum medium for HeLa cells (PAA) at 37°C, 5% CO2 and 
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constant humidity. For transfection, 100,000 cells were seeded into 6-well plates and 
transfected with 0.5 µg of a single expression vector using FuGene HD transfection 
reagent as recommended (Promega). In the case of co-transfection 0.5 µg of each 
expression vector was transfected. All expression vectors used for transfection are listed 
in the supplemental material (chapter 7.3, table 19). 
Pulse labeling of heterologously expressed HaloTag-Septin4 was performed using the 
HaloTag Biotin Ligand (Promega) according to the manufacturer’s instructions. 
3.6.3 Lentivirus production 
4×106 Lenti-X 293T cells were plated in 10 cm culture dishes pre-coated with 0.05 mg/ml 
collagen. The next day cells were transfected for lentivirus production with a 2nd 
generation packaging system (Zufferey et al., 1997) as stated in table 10. 
Table 10: Vector composition for lentivirus production in Lenti-X 293T cells 
Vector Amount 
FUW-tetON plasmid with gene of interest 
or FUW-M2rtTA (see chapter 3.6.4) 3.75 µg 
pMD2.G VSV G envelope plasmid (Addgene 
12259) 1.32 µg 
psPAX2 packaging plasmid 
(Addgene 12260) 2.43 µg 
 
7.50 µg 
 
For transfection, JetPEI transfection reagent (Polyplus, Illkirch, France) was used as 
recommended by the manufacturer. The virus containing medium was collected 24 h, 48 h 
and 72 h after transfection and stored at 4°C. After 72 h, all collected virus containing 
samples were combined, cleared by centrifugation (5 min, 500 g) and the supernatant 
filtered using a 0.20 µm syringe filter. Afterwards, the viruses were pelleted for 2 h at 
50,000 g. Virus pellets were dissolved in sterile PBS (1 µl PBS/500 µl supernatant), and 
used for cell transduction. Aliquots were frozen in PCR tubes at -80°C until further usage. 
3.6.4 Generation of tet-ON-GFP-DYRK1A SH-SY5Y cells 
A second generation lentiviral packaging system was used (3.6.3) to generate SH-SY5Y 
sublines with controllable overexpression of GFP-DYRK1A (wild type) or GFP-DYRK1A-
K188R (KR), which is a DYRK1A point mutant with minimal catalytic activity due to 
abolished ATP binding (Kentrup et al., 1996). In brief, rat DYRK1A and DYRK1A-K188R 
cDNA were amplified from pEGFP-DYRK1A (Becker et al., 1998) and integrated into the 
lentiviral FUW-tetON backbone (Hockemeyer et al., 2008) (after removing the hMYC 
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insert from Addgene plasmid 20723 with EcoRI) by homologous recombination in E. coli 
(Zhang et al., 1998) resulting in FUW-tetON-GFP-DYRK1A and FUW-tetON-GFP-
DYRK1A-K188R (see section 3.5.5). Co-transduction of the FUW-tetON vector with FUW-
M2rtTA (Addgene 20342), which encodes the tetracycline-dependent transactivator, 
allows for tetracycline-regulated expression of the transgene (Urlinger et al., 2000; 
Hockemeyer et al., 2008). Co-transduction of SH-SY5Y cells was titrated with different 
amounts of FUW-tetON-GFP-DYRK1A/KR and FUW-M2rtTA containing lentivirus to 
achieve maximal transduction efficiency as controlled by doxycycline-induced GFP 
fluorescence (paragraph 4.1.1). Due to the absence of an antibiotic selection marker in 
the lentiviral expression vector, cell populations with a GFP-positive ratio >90% were 
considered as stably transduced. Cells of a parallel transduced well, not treated with 
doxycycline were expanded, frozen, and used for further experiments. All experiments 
were performed with cells derived from the same transduction. 
3.6.5 Preparation and cultivation of mouse hippocampal neurons 
ICR mice were housed, bred, treated and used in experiments according to the 
corresponding Spanish laws (particularly, 32/2007, Nov 7 and 1201/2005, Oct 10). The 
Commission of Ethics in Animal Experimentation of the Instituto de Neurociencias and the 
Bioethics Commission of the CSIC (Spanish Upper Research Council) approved specific 
experimental procedures. 
Hippocampal neurons were isolated from E17.5 mouse embryos and cultured according 
to Kaech and Banker (2006). In detail, before neuron preparation, 12 mm coverslips 
(Thermo, Menzel Gläser, Germany) were incubated in 69% HNO3 for at least 48 h on a 
shaker. Coverslips were washed 4x for 30 min in ddH2O, dried and sterilized for 4 h at 
225°C. Afterwards, coverslips were transferred into 24-well plates and coated with poly-L-
lysine (1 mg/ml in borate buffer) over night. The next day, poly-L-lysine was removed and 
cover slips were washed once with ddH2O. Wells were filled with 250 µl ddH2O until cells 
were prepared for plating. E17.5 mouse embryos were removed from the uterus after 
cervical dislocation of the pregnant dam and transferred to 10 cm dishes on ice containing 
sterile PBS. The skulls were subsequently separated, washed again in PBS and finally 
transferred to a new 10 cm dish with fresh PBS on ice. Immediately, the cranium was 
opened and brains dissected using a binocular loupe, working under a cell culture hood. 
Brains were collected in sterile PBS on ice. Preparation of hippocampi was started by 
removing the meninges from single brains and dissecting the telencephalon hemispheres 
from the brain stem. Hippocampi were removed from the telencephalon, taking care to 
avoid glia contamination by eliminating all fimbria. Afterwards, hippocampi were cut into 
small pieces, transferred to cold HBSS and washed twice. Finally, hippocampi were 
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resuspended in 2 ml HBSS, supplemented with 20 µl DNAse (10 mg/ml) and 200 µl 
trypsin (2.5%), and incubated at 37°C for 10 min. Meanwhile, water was removed from the 
coverslips and wells prefilled with 500 µl plating medium. After incubation, the 
trypsin/DNase solution was removed and hippocampi were washed in 5 ml dissociation 
medium. Immediately, a second wash was performed by incubating the hippocampi in 
dissociation medium for 3 min and afterwards adding fresh dissociation medium to a final 
volume of 1.5 ml, supplemented with 15 µl DNase. Hippocampi were dissociated using a 
wide Pasteur pipette first and secondly using a narrow Pasteur pipette. After 3 min 
incubation, the cell containing supernatant was collected and cell viability was determined 
using trypan blue. If viability was higher than 75%, hippocampal neurons were pelleted for 
5 min at 120 g and the cells resuspended in dissociation medium to plate 50,000 
cells/well. After 2.5 h, when the neurons attached to the coverslips, plating medium was 
carefully removed and 500 µl neuronal medium per well were added. The composition of 
all used media is stated in table 11.  
Table 11: Media for preparation and culture of mouse hippocampal neurons 
Glial and plating medium Final concentration 50 ml 
FCS (Gibco) 10% 5 ml 
Pen/Strep (100x) 1% 0.5 ml 
DMEM (+Glutamax) (Gibco) 89% 44.5 ml 
Neurobasal medium Final concentration 25 ml 
Neurobasal medium (Invitrogen) 96% 24 ml 
Pen/Strep (100x) (Invitrogen) 1% 0.25 ml 
B27 supplement (50x) (Invitrogen) 2% 0.5 ml 
Glutamax (100x) (Invitrogen) 1% 0.25 ml 
Dissociation medium Final concentration 15 ml 
FCS 10% 1.5 ml 
DMEM (+Glutamax) 90% 13.5 ml 
HBSS/HEPES buffer Final concentration 50 ml 
HBSS (Hank´s balanced salt solution) (Invitrogen) 99% 49.5 ml 
HEPES [1 M] 0.01 M 0.5 ml 
Borate buffer [0.1M] in ddH2O, pH 8.5 MW 400 ml 
Boric acid 61.83 g/mol 1.24 g 
Sodium-tetraborate 381.37 g/mol 1.9 g 
 
The DYRK1A inhibitors harmine (2 µM) and epigallocatechin gallate (EGCG) (5 µM) were 
Materials and Methods 
 35
added when changing the plating medium to neuronal medium. This time point is 
considered as t0 since no signs of neuronal differentiation were observed before. After 
20 h of inhibitor treatment, neurons were fixed with 4% paraformaldehyde. Preparation 
and culture of mouse hippocampal neurons was planned and performed at the Instituto de 
Neurociencias (Alicante, Spain) in cooperation with the division of developmental 
neurogenetics (Dr. F.J. Tejedor). 
3.6.6 Mouse embryo culture 
Dissection and culture of mouse embryos was carried out comparably as described by 
(Takahashi et al., 2008). E12 embryos were cultured in the presence or absence of the 
DYRK1A inhibitors harmine (4 µM), epigallocatechin gallate (EGCG) (10 µM), leucettine 
L41 (8 µM) (kindly provided by Laurent Meijer, ManRos Therapeutics, Roscoff, France) or 
without inhibitor for 6 h. EdU (5-ethynyl-2’-deoxyuridine) (Invitrogen/Life Technologies) 
was added to the culture medium at a final concentration of 20 µM 1 h prior to the end of 
culture. Brains of the embryos were immediately dissected in cold PBS and fixed in 4% 
paraformaldehyde. After washing out the fixative, brains were embedded in 4% low gelling 
temperature agarose and sectioned in frontal orientation with a vibratome. Preparation 
and culture of mouse embryos was planned and performed at the Instituto de 
Neurociencias (Alicante, Spain) in cooperation with the division of developmental 
neurogenetics (Dr. F.J. Tejedor). 
3.7 Cell proliferation analysis, flow cytometry and imaging 
3.7.1 Real-time cell analysis (RTCA) 
The xCELLigence RTCA system with a 96-well E-plate (Roche) was used for continuous 
impedance-based monitoring of cell proliferation. The functional principle of the used 
RTCA system is illustrated in figure 7. Before plating cells, a blank measurement was 
performed to determine the baseline impedance of 200 µl medium/well. After removing 
100 µl of medium, 7500 SH-SY5Y cells/well were added in a volume of 100 µl. Impedance 
measurements were taken at intervals of 15 min for a total experimental time of 7 days. 
After cell adhesion over night, 100 µl medium per well were carefully replaced by 100 µl 
fresh medium containing doxycycline to reach the intended final concentrations. Harmine 
was added 24 h after doxycycline induction. All handling outside the incubator was 
performed using a 37°C pre-warmed hot plate to minimize impedance artifacts. 
Impedance values were averaged over triplicate wells and automatically converted to a 
dimensionless value called cell index (CI) by the xCELLigence software (RTCA 1.2.1, 
Roche), representing the density of cells per well. Data was exported to GraphPad Prism 
(5.0, GaphPad software, La Jolla, CA, USA) for determination of the area under the curve. 
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Figure 7: Impedance measurement with the xCELLigence RTCA system. 
Each well of a 96-well E-plate is covered with gold electrodes (orange). The impedance (Z, arrows) 
between the electrodes and the cell culture medium is measured for each single well. After plating, 
cells settle down and attach to the electrode covered well surface, what results in increased 
impedance. After reaching final adherence, changes in cell number or cell morphology result in 
altered measured impedance 
3.7.2 Cell cycle analysis and flow cytometry 
One-dimensional DNA content measurements of cells were performed with propidium 
iodide (PI). In brief, 750,000 SH-SY5Y-GFP-DYRK1A or GFP-DYRK1A-K188R cells/well 
were seeded into 6-well plates for measurements after 24 h of treatment with doxycycline 
or RA. For 72 h analysis, reduced proliferation of DYRK1A overexpressing and RA 
differentiating cells was compensated. Therefore, 350,000 control cells and cells 
overexpressing DYRK1A-KR were plated. In contrast, cells differentiating or 
overexpressing DYRK1A were plated in a number of 500,000 cells. The day after plating, 
cells were treated with 2 µg/ml doxycycline to induce DYRK1A overexpression or with 
10 µM RA to induce differentiation. After 24 h or 72 h of incubation, cells were carefully 
collected in cold PBS. After 24 or 72 h of incubation, cells were harvested in cold PBS and 
fixed in 75% EtOH at -20°C over night. The next day, cells were transferred to FACS 
tubes and pelleted for 5 min at 500 g, resuspended in 1 ml cold PBS and rehydrated for 
10 min. After additional centrifugation, the pellet was resuspended in 400 µl of PI staining 
solution (50 µg/ml PI (Sigma), 20 µg/ml RNase A in PBS) and stained for 30 min on ice. 
Two-dimensional (multiparameter) DNA and RNA content analysis (Shapiro, 1981) was 
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performed after plating 300,000 control or DYRK1A-KR overexpressing cells and 500,000 
cells overexpressing wild type DYRK1A or undergoing RA/BDNF-induced differentiation 
for 5 d. After fixation, cell pellets were resuspended in 400 µl PBS containing 2 µg/ml 
Hoechst 33342 (Sigma) and incubated for 30 min at room temperature. Afterwards 
4 µg/ml Pyronin Y (Sigma) was added to stain RNA and tubes were kept on ice for 20 min. 
Dyes were washed out by spinning the samples for 5 min at 500 g, washing the pellet with 
1 ml cold PBS, spinning again, and finally resuspending the pellet in 400 µl PBS. 
Nucleic acid contents were analyzed using an LSR Fortessa flow cytometer (BD 
Bioscience) and data were evaluated with FlowJo 7.6.5 software (Tree Star). For one-
dimensional DNA measurements the Dean-Jett-Fox algorithm was used to evaluate cell 
cycle phase distribution (constraints: G2 width = G1). In the case of two-dimensional DNA 
and RNA measurements, gates were applied and cell cycle phases determined according 
to Darzynkiewicz et al. (1980) and Shapiro (1981). 
3.7.3 Fluorescence and live cell imaging 
Analysis of GFP-DYRK1A expression in stably transduced SH-SY5Y cells 
To analyze transduction efficiency of GFP-DYRK1A or GFP-DYRK1A-K188R containing 
lentivirus in multiwell plates, DYRK1A expression was induced with 2 µg/ml doxycycline 
one day after transduction and GFP expression was analyzed by fluorescence imaging 
after further 24 h. 
To analyze expression kinetics of GFP-DYRK1A and GFP-DYRK1A-K188R, 400,000 
stably transduced SH-SY5Y cells were seeded into 6-well plates. Induction of expression 
was induced with 2 µg/ml doxycycline. Immediately, the 6-well plate was transferred into 
an IncuCyteTM Live Content Microscope (Essen Biosciences, Welwyn Garden City, UK) 
inside the incubator. DYRK1A expression was analyzed by following GFP signals via real 
time fluorescence microscopy. For 3 days in total, bright field images and images of GFP-
fluorescence at defined positions of each well were recorded every hour. Time-laps 
movies or single images were generated using the IncuCyte2011A (Rev 2) software. 
Analysis of SH-SY5Y cell proliferation by automated live cell imaging 
Continuous live cell imaging was performed using an IncuCyteTM Zoom kinetic imaging 
system (Essen Biosciences, Welwyn Garden City, UK). For analysis of proliferation and 
differentiation, 90,000 SH-SY5Y-tetON-GFP-DYRK1A or tet-ON-GFP-DYRK1A-K188R 
cells were seeded into 24-well plates and DYRK1A or DYRK1A-K188R overexpression 
induced the next day with 2 µg/ml doxycycline. Subsequently, cell proliferation was 
followed by automated continuous life cell imaging. The whole well was imaged by 
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recording 9 phase-contrast and GFP images per well in intervals of 1 h at defined 
positions (10x objective) for 96 h in total. For analysis of proliferation, the well confluence 
[percentage] was automatically calculated at 24 h and 96 h with the Basic Analyzer 
segmentation mask of the IncuCyte ZoomTM software (v2013B, Essen Biosciences). To 
analyze a potential loss of cells due to cell death induced by GFP-DYRK1A 
overexpression, the total number of GFP positive cells was assessed using the Basic 
Analyzer segmentation mask [nuclear count/mm2 image area]. 
Analysis of SH-SY5Y neurite length by automated live cell imaging 
After 96 h of cultivation, changes in neurite outgrowth by DYRK1A or DYRK1A-K188R 
overexpression were analyzed using the recorded images with the automated 
NeuroTrackTM image acquisition module of the IncuCyte ZoomTM software. The 
NeuroTrack algorithm automatically defines cell bodies and neurite extensions (as 
illustrated in figure 18) to calculate and quantify the total neurite length [mm/mm2 image 
area]. To compensate for different total cell numbers due to reduced proliferation of 
DYRK1A wild type overexpressing SH-SY5Y cells, total neurite length was standardized 
to the total count of GFP positive nuclei [nuclear count/mm2] resulting in the total neurite 
length per counted nuclei [mm/nuclear count]. 
Phalloidin staining of SH-SY5Y cells 
Prior to cell plating, coverslips were treated with 69% HNO3 for 48 h on a shaker, washed 
4 times for 30 min with ddH2O and finally stored in ddH2O. Before usage, cover slips were 
transferred to a filter paper under a hood, dried, and afterwards sterilized at 225°C for 4 . 
SH-SY5Y cells were seeded on collagen coated 12 mm glass coverslips (Marienfeld, 
Germany) in 24-well plates as follows: 30,000 control or DYRK1A-KR overexpressing 
cells and 60,000 cells overexpressing DYRK1A or undergoing RA or RA/BDNF 
differentiation. After 5 days of treatment, cells were fixed in 4% paraformaldehyde (Sigma) 
for 20 min at 4°C. Cells were permeabilized for 30 min at room temperature (5% BSA, 
0.1% Triton X-100, in PBS) and stained with Alexa®-546 coupled phalloidin (Invitrogen; 
1:40 in 5% BSA, 0.1% Triton X-100, in PBS). Cells were washed twice with PBS and 
mounted on object slides using DAPI containing Vectashield (Vectorlabs, Burlingame, CA, 
USA). Fluorescence imaging was performed with an Axiovert 200 M inverted microscope 
(Zeiss) and images were edited using the AxioVision 4.7 software (Zeiss). The neurite 
lengths of clearly definable neurites were measured using the AxioVision software. 
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Staining of mouse hippocampal neurons and embryonic mouse brain 
After fixation and permeabilization as described for SH-SY5Y cells, mouse hippocampal 
neurons were incubated with an anti-pSer10 p27Kip1 antibody (rabbit, Santa Cruz) over 
night as recommended by the manufacturer. ICC fluorescence labeling then was carried 
out using a secondary anti-rabbit biotin labeled antibody (Jackson ImmunoResearch) and 
Cy2-coupled Streptavidin (GE Healthcare). The cell structure was visualized by staining 
actin cytoskeleton with phalloidin-Rhodamine (1:100, Sigma). Images were collected by 
confocal microscopy with an Olympus spectral FV1200 microscope. 
After sectioning the telencephalon of cultured mouse embryos, EdU incorporation and IHC 
staining (rabbit anti-pSer10 p27Kip1, Santa Cruz; mouse anti-p27Kip1, BD Biosciences; 
rabbit anti-Caspase 3, CST and mouse anti-TUJ1, Covance) of floating sections was 
carried out as previously described in Hämmerle et al. (2011). Images were collected with 
an Olympus spectral FV1200 microscope. 
Antibodies and conjugates were used as listed in table 2 and table 3. 
3.8 Protein biochemistry 
3.8.1 Isolation of total protein, SDS-PAGE and western blotting 
Isolation of total protein from transfected HeLa cells or cultured SH-SY5Y cells was 
performed by SDS-lysis. 
750,000 SH-SY5Y-GFP-DYRK1A or DYRK1A-KR cells per well were seeded into 6-well 
plates for protein isolation after 24 h of treatment with doxycycline or RA. For protein 
isolation after 72 h of treatment, 300,000 control or DYRK1A-KR overexpressing cells and 
500,000 cells overexpressing DYRK1A or undergoing RA differentiation were plated. 
SH-SY5Y cells were carefully washed once with cold PBS on ice, collected in 1 ml cold 
PBS, and centrifuged for 5 min at 500 g. After discarding the supernatant, the cell pellet 
was lysed in 75 µl hot SDS-lysis buffer (20 mM Tris-HCl pH 7.4, 1% SDS in ddH20). After 
boiling for 5 min at 98°C, samples were sonicated on ice for 3 min and subsequently 
centrifuged for 5 min at 20,000 g. The supernatant was collected, and samples for SDS-
PAGE were adjusted to equal protein amounts using the bicinchoninic acid protein assay 
(Pierce).  
Accordingly, protein extraction of transfected HeLa cells was performed, except for 
using150 µl instead of 75 µl SDS-lysis buffer. 
Before loading on SDS-gels, all samples were adjusted to a final volume of 20 µl with 
SDS-lysis buffer, supplemented with 5 µl 4x Laemmli sample buffer (4x LSB, table 12) and 
boiled for 5 min at 98°C. As protein standard for SDS-PAGE the Biotinylated Protein 
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Ladder Kit (CST) was used. For electrophoretic separation of proteins, separation gels 
containing 0.1% SDS and 7% - 15% polyacrylamide were used. Stacking gels contained 
0.1% SDS and 4% polyacrylamide. Composition PAGE buffer is stated in table 13 
Transfer of PAGE separated proteins to nitrocellulose membranes (Protran®, 0.45 µm 
pore diameter, Whatman) was performed by tank blotting for 2 h at 200 mA. Composition 
of blotting buffer is stated in table 13. Afterwards, membranes were blocked for 1 h at 
room temperature in 5% BSA in TBST (table 12) and incubation of primary antibodies 
followed over night at 4°C in 5% BSA/TBST + 0.02% NaN3 on a shaker. After washing 
with TBST, incubation with HRP-coupled secondary antibodies in non-fat dry milk (3% in 
TBST) followed for 1 h at room temperature. After repeated washing with TBST, 
chemiluminescence detection (table 14) was performed with a LAS 3000 CCD imaging 
system (Fujifilm) and densitometric signals were quantified with the AIDA imager software 
(Raytest). For Immunodetection, primary and secondary antibodies were used as 
indicated in table 2 and table 3. 
 
Table 12: Composition of LSB and TBST for SDS-PAGE and immunodetection 
Laemmli sample buffer (4x LSB ±SDS) TBST pH 7.6  
200 mM Tris-HCl pH 8.6 20 mM Tris 
40% (v/v) Glycerol 150 mM NaCl 
0.08% (v/v) Bromphenol blue 0.1% (v/v) Tween-20 
400 mM Dithiothreitol (DTT) in ddH20 
(8% SDS)  
in ddH20  
 
Table 13: Composition of buffers for SDS-PAGE and tank blot transfer 
1x SDS-PAGE electrode buffer pH 8.4 1x tank blot transfer buffer 
25 mM Tris 25 mM Tris 
250 mM Glycine for electrophoreses 192 mM Glycine 
0.1% SDS 20% Methanol 
in ddH20 0.1% SDS 
 in ddH20 
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Table 14: Composition of chemiluminescence detection solution 
Solution A Solution B 
1000 µl Tris-HCl pH 8.5 [1 M] 1000 µl Tris-HCl pH 8.5 [1 M] 
40 µl H2O2 (30%) 100 µl Luminol [250 mM] 
9 ml ddH2O 44 µl p-coumaric acid [90 mM] 
 10 ml ddH2O 
 
3.8.2 Immunoprecipitation 
For immunoprecipitation (IP) of GFP-DYRK1A or GFP-DYRK1A K188R, 2.5x106 control or 
DYRK1A-KR overexpressing cells and 4.0x106 cells overexpressing DYRK1A or 
undergoing RA differentiation were plated into 10 cm culture dishes. RA was added 24 h 
and doxycycline 48 h after plating. Cells were lysed 72 h after plating under non-
denaturating conditions by addition of 1 ml lysis buffer supplemented with protease and 
phosphatase inhibitors (table 15). 
Table 15: Composition of buffers for immunoprecipitation 
Native lysis buffer Washing buffer 
50 mM Tris-HCl pH 7.5 50 mM Tris-HCl pH 7.5 
150 mM NaCl 150 mM NaCl 
2 mM EDTA 2 mM EDTA 
0.5% Igepal CA-630 0.1% Igepal CA-630 
1 mM Na3VO4 in ddH20 
1 mM Phenylmethylsulfonylfluoride (PMSF)  
10 µg/ml Aprotinin  
10 µg/ml Pepstatin  
10 µg/ml Leupeptin  
in ddH2O  
 
Culture dishes were then incubated for 20 min on ice on a shaker. Afterwards, cells were 
collected with a rubber policeman, the lysate sonicated for 2x 30 sec on ice, subsequently 
centrifuged for 5 min at 20,000 g and the supernatant collected. Prior to the IP, 20 µl 
supernatant were aliquoted as input control, supplemented with 5 µl 4x LSB + SDS (table 
12 ) and stored at -20°C until running SDS-PAGE. For IP, 15 µl of GFP trap® magnetic 
beads (ChromoTek, Martinsried, Germany) per sample were washed twice with 500 µl 
lysis buffer using a magnetic rack and finally redissolved in 15 µl lysis buffer. After 
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supplementing GFP trap magnetic beads to the lysate, the IP mix was incubated for 1 h 
on an overhead shaker at 4°C. Thereafter, beads were pelleted by brief centrifugation 
(30 sec at 20,000 g) and the final pull down of immunocomplexes was performed using a 
magnetic rack. The beads then were washed 3 times with 500 µl washing buffer (table 15) 
to remove unspecific bound proteins. To dissociate trapped GFP-DYRK1A, the beads 
were dissolved in 10 µl 1x LSB + SDS, boiled at 98°C for 5 min and stored at -20°C until 
further usage. Before loading on SDS gels, the dissociated beads were immobilized with a 
magnetic rack. The precipitate containing supernatant was subjected to SDS-PAGE and 
western blotting stated in 3.8.1. 
3.8.3 In vitro kinase assays 
HeLa cells were plated onto 10 cm culture dishes and transfected with GFP-DYRK1A and 
GFP-DYRK1B expression vectors using FuGene HD (see paragraph 3.6.2). GFP fusion 
proteins were immunoprecipitated 48 h after transfection using the GFP trap® M beads as 
described in paragraph 3.8.2. A fusion protein of human p27Kip1 and glutathione S-
transferase (GST-p27) was produced in E. coli using the PURExpress® in vitro protein 
synthesis kit (NEB) and purified by affinity adsorption to glutathione-sepharose (GST-p27 
was kindly provided by Simone Bamberg-Lemper, the pGEX-5x-3-p27Kip1 plasmid was 
kindly provided by J. Vervoorts-Weber, Institute of Biochemistry, RWTH Aachen 
University, Aachen, Germany). The immobilized kinases were incubated with 400 ng 
GST-p27 for 1 h at 30°C in 30 µl kinase buffer (25 mM Hepes pH 7.4, 0.5 mM DTT, 5 mM 
MgCl2) in the presence or absence of 500 µM ATP and phosphorylation of p27Kip1 Ser10 
was detected by SDS-PAGE and subsequent western blot analysis (see chapter 3.8.1). 
Kinase assays with bacterially translated DYRK1A or DYRK1A-K188R GST fusion 
proteins and GST-p27Kip1 were performed in 100 µl kinase buffer in the presence or 
absence of 100 mM ATP at room temperature. Aliquots of the kinase reaction were taken 
at the indicated time points and Ser10 phosphorylation analyzed by western blotting. 
3.9 Statistics 
Statistical analyses were performed with JMP 10.0.0 (SAS Institute, Cary, NC, USA) and 
GraphPad Prism 5.0 (GaphPad software, La Jolla, CA, USA). All data were tested for 
homoscedasticity. Equality of variances was analyzed by Bartlett´s test and normality of 
residues by Shapiro-Wilk test. In case of heteroscedasticity, data were transformed by 
Box-Cox transformation to achieve homoscedasticity. Parametric data were compared by 
either One-sample t-test (comparison to normalized control values), Student’s t-test 
(comparison of two groups), or One-way ANOVA followed by Bonferroni’s multiple 
comparison post-test (multiple comparisons of selected pairs of columns). If 
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homoscedasticity was not achieved after Box-Cox transformation, non-parametric 
Kruskal-Wallis test followed by Dunn’s post-test (multiple comparisons of selected pairs of 
columns) was performed. The used statistical tests are also indicated in the respective 
figure legends. 
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4 Results 
4.1 DYRK1A in neuronal cell cycle regulation 
4.1.1 Generation and validation of DYRK1A overexpressing SH-SY5Y cells 
To investigate the effects of DYRK1A overexpression on neuronal cells, SH-SY5Y cells 
with a stable and tet-ON inducible overexpression of either GFP-tagged DYRK1A or the 
kinase deficient point mutant DYRK1A-K188R (DYRK1A-KR) were constructed. 
Transfection of SH-SY5Y cells with different commercial transfection reagents and 
systems showed a remarkable low efficiency (data not shown). Moreover, SH-SY5Y are 
slowly dividing cells and low cell densities result in poor proliferation and viability, which 
hampers antibiotic selection to expand a single cell clone with stably integrated cDNA 
constructs after transfection. Therefore, lentiviral transduction was used to generate 
SH-SY5Y cells with a stable integration of GFP fused DYRK1A or the kinase deficient 
mutant DYRK1A-K188R (chapter 3.6.4). Transduction of SH-SY5Y cells resulted in GFP 
expression after stimulation with doxycycline (dox), indicating a stable integration of tet-
ON-GFP-DYRK1A or GFP-DYRK1A-KR (figure 8). 
 
Figure 8: Lentiviral transduction efficiency in stably transduced SH-SY5Y cells. 
SH-SY5Y cells were stably transduced with lentiviruses containing FUW-tetON-GFP-DYRK1A 
(GFP-D1A) or FUW-tetON-GFP-DYRK1A-K188R (GFP-D1A-KR) (section 3.6.4). To analyze 
transduction efficiency, cells were seeded into 6-well plates and treated with 2 µg/ml dox for 48 h. 
GFP-DYRK1A expression was verified by fluorescence microscopy. The upper panel shows 
SH-SY5Y cells overexpressing GFP-DYRK1A (A, bright field; B, GFP fluorescence; C, overlay). 
The lower panel shows SH-SY5Y cells overexpressing GFP-DYRK1A-K188R (D - F). Scale bar = 
100µm. 
By an overlay of GFP and bright field images, lentiviral transduction efficiency was verified 
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and considered as >90%. Analysis of the stably integrated vector system for leakiness 
and dox responsiveness revealed that doxycycline treatment for 24 h led to significantly 
elevated levels of DYRK1A mRNA if compared to untreated control cells or cells that were 
treated with retinoic acid (RA) to induce differentiation (figure 9A). After 72 h of 
doxycycline treatment, DYRK1A mRNA levels remained elevated (figure 9B). The results 
indicate a stable integration of the lentiviral constructs into the cellular genome. 
Furthermore, RA treatment did not significantly affect endogenous DYRK1A mRNA.  
 
Figure 9: DYRK1A mRNA levels in SH-SY5Y cells after dox-induced overexpression. 
SH-SY5Y cells were treated with 2 µg/ml doxycycline or RA for 24 (A) or 72 h (B) and DYRK1A 
mRNA levels were quantified by qRT-PCR. DYRK1A mRNA levels are shown relative to GAPDH 
mRNA levels as internal standard. Data are shown as means + SD; n = 3, ***, p ≤ 0.001, analyzed 
by One-way ANOVA + Bonferroni post test. 
To verify correct translation of GFP-DYRK1A and GFP-DYRK1A-KR, overexpression was 
induced with increasing dox concentrations and analyzed by western blotting and 
immunodetection with a C-terminal anti-DYRK1A antibody (figure 10). 24 h and 72 h after 
dox addition, GFP-DYRK1A and GFP-DYRK1A-KR overexpression was detected in whole 
cell lysates at the expected molecular weight of approximately 130 kDa. Moreover, GFP-
DYRK1A and GFP-DYRK1A-KR signals increased in parallel to increasing dox 
concentrations. Notably, untreated control cells showed slight bands at the expected 
molecular weight of GFP-DYRK1A after immunodetection with a mouse anti-DYRK1A 
antibody (figure 10). Reciprocal control with a goat GFP-antibody revealed no signals 
(data not shown). In general, weak bands at approximately 130 kDa were observed with 
secondary HRP-coupled anti-mouse or anti-rabbit antibodies, but not with secondary anti-
goat or anti-chicken antibodies (table 3). Therefore, it can be concluded that the band in 
untreated control cells is due to unspecific signals generated by the secondary anti-mouse 
or anti-rabbit antibodies. 
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Figure 10: Gradual induction of GFP-DYRK1A overexpression in SH-SY5Y cells. 
Overexpression of GFP-DYRK1A (GFP-D1A) or GFP-DYRK1A-K188R (GFP-D1A-K188R) was 
induced in lentiviral transduced SH-SY5Y cells with increasing dox concentrations as indicated. 
Cells were lysed 24 h (A) or 72 h (B) after induction of overexpression. Whole cell lysates were 
subjected to western blot analysis. GAPDH was analyzed as loading control. Representative blots 
from three independent experiments are shown. 
Furthermore, expression kinetics of GFP-DYRK1A and GFP-DYRK1A-KR after dox 
additions was verified by live cell imaging (figure 11). 
 
Figure 11: Expression kinetics of GFP-DYRK1A in stably transduced SH-SY5Y cells. 
Images show expression kinetics of GFP-DYRK1A and GFP-DYRK1A-K188R. Stably transduced 
SH-SY5Y cells were seeded into 6-well plates and treated with 2 µg/ml dox. GFP-DYRK1A 
expression was followed by real time fluorescence imaging (paragraph 3.7.3). Representative 
images from time laps videos are shown. 0 h indicates the point in time of dox addition. Panels on 
the left side of the dashed line show SH-SY5Y cells stably transduced with GFP-DYRK1A (GFP-
D1A) and panels on the right side of the dashed line show cells stably transduced with GFP-
DYRK1A-K188R (GFP-D1A-KR). Scale bar = 400 µm. 
GFP fluorescence was detectable 4 h after induction of overexpression in cells transduced 
with GFP-DYRK1A as well as with GFP-DYRK1A-KR. After 8 h of dox treatment, nearly 
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all cells showed distinct GFP fluorescence, reaching maximal intensity after 12 h. The 
data indicates that the used tetON-expression system allows overexpression of DYRK1A 
or DYRK1A-KR within a few hours after dox induction. 
In line with the respective mRNA levels (figure 9), GFP-DYRK1A showed a higher 
expression response than GFP-DYRK1A-KR at similar dox concentrations although 
identical expression constructs were used. This effect was also observed in other studies 
of DYRK1A and DYRK1A-KR overexpression (Litovchick et al., 2011; Chen et al., 2013) 
and still remains unclear. Nevertheless, gradual overexpression with different doxycycline 
concentrations allows comparison of DYRK1A and DYRK1A-KR at similar expression 
levels. 
4.1.2 DYRK1A overexpression reduces proliferation of SH-SY5Y cells 
To investigate the effects of DYRK1A overexpression on neuronal cell proliferation and 
cell cycle progression, proliferation of SH-SY5Y cells was followed for 7 days by 
continuous RTCA measurements (figure 12). Gradual induction of DYRK1A 
overexpression resulted in a dose-dependent suppression of cell proliferation after a lag 
time of 24 h (figure 12A), leading to a total arrest of proliferation at high levels of DYRK1A 
overexpression. In contrast, overexpression of kinase deficient DYRK1A-KR caused no 
significant alteration of cell growth (figure 12B), indicating that the observed effect 
depended on DYRK1A kinase activity and was not caused by protein overexpression or 
doxycycline treatment. Consistently, treatment with the DYRK1A inhibitor harmine 
attenuated the effect of DYRK1A overexpression (figure 12C), although the cells did not 
recover to proliferation rates of untreated control cells within the observation time. Taken 
together, these results show that an elevated kinase activity due to overexpression of 
DYRK1A leads to a dose dependent reduction of SH-SY5Y cell proliferation. 
Moreover, to analyze the influence of harmine treatment, proliferation of wild type HeLa 
and SH-SY5Y cells was followed for 7 days after treatment with different harmine 
concentrations. When treated with 1 µM or 3.3 µM harmine, HeLa cells showed normal 
proliferation, whereas treatment with 10 µM harmine resulted in decreased proliferation 
(data not shown, published in Göckler et al., 2009). In contrast, SH-SY5Y cells showed a 
more sensitive response to harmine treatment. Addition of 1 µM harmine only slightly 
reduced SH-SY5Y proliferation but concentrations of 3.3 µM or 10 µM harmine caused an 
immediate stop of proliferation (data not shown). Finally, treatment with 10 µM harmine 
led to cell index values lower than the initial measurement. This data revealed a high 
sensitivity of SH-SY5Y cells to harmine concentrations higher than 1 µM. 
To ensure that the effects of DYRK1A overexpression observed by impedance 
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measurements were not caused by a loss of cells due to induced cell death, cell 
proliferation was additionally followed by continuous live cell imaging using an IncuCyte 
ZoomTM kinetic imaging system (Essen Biosciences, chapter 3.7.3) (figure 13).  
 
Figure 12: DYRK1A overexpression induces proliferation arrest of SH-SY5Y cells. 
The curves show representative real-time impedance measurements of proliferating SH-SY5Y cells 
after induced overexpression of wild type DYRK1A (A, GFP-D1A) or the kinase deficient mutant 
DYRK1A-K188R (B, GFP-D1A KR). Panel C shows the proliferation of SH-SY5Y cells treated with 
harmine 24 h after induction of GFP-DYRK1A overexpression. DYRK1A overexpression was 
induced 24 h after plating with doxycycline as indicated (arrow). Column diagrams illustrate the 
quantitative evaluation (means + SD) of 3 independent experiments (AUC, area under the curve 
from 24-168 h, normalized to the untreated control cells). In panel C, the AUCs were normalized to 
the untreated control cells (as shown panel A). Statistical significance was tested with One-sample 
t-test if comparing columns to normalized control (A-C) or One-way ANOVA and Bonferroni post 
test if comparing multiple not-normalized columns (C). *, p ≤ 0.05; **, p ≤ 0.01; n.s, not significant. 
Automated image acquisition to evaluate and compare well confluences at 96 h and 24 h 
after induction of DYRK1A overexpression revealed that DYRK1A overexpression 
resulted in a 96 h/24 h confluence ratio of 1.07 (± 0.06) (figure 13A), indicating a constant 
cell number. In comparison, cells not overexpressing DYRK1A showed a nearly doubled 
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confluence ratio of 1.92 (± 0.31). As expected, overexpression of DYRK1A-KR generated 
no significant change of confluence if compared to control cells. Moreover, cellular GFP-
DYRK1A or GFP-DYRK1A-KR fluorescence was used to determine the count of GFP 
positive cells per well (figure 13B). Comparison of the GFP positive cell count showed that 
overexpression of DYRK1A resulted in a 96 h/24 h GFP positive cell ratio of 1.13 (± 0.07) 
and overexpression of DYRK1A-KR in a ratio of 2.11(± 0.43). The results strongly indicate 
that DYRK1A overexpression suppresses cell proliferation but does not cause a loss of 
cells. Nonetheless, it was investigated if DYRK1A overexpression or harmine treatment as 
shown in the real-time impedance measurements induces apoptosis in SH-SY5Y cells. 
Analysis of PARP (Poly ADP ribose polymerase) activation after 72 h of DYRK1A 
overexpression or harmine treatment revealed no pro-apoptotic PARP cleavage (figure 
13C). In contrast, PARP activation could be observed in SH-SY5Y cells treated with 
different concentrations of staurosporine as positive control for induced apoptosis (figure 
13C and D) (Prince and Oreland, 1997; López and Ferrer, 2000). Taken together, the data 
show that DYRK1A overactivity leads to a dose dependent reduction of SH-SY5Y cell 
proliferation and not to a loss of cells by induced cell death. 
 
Figure 13: DYRK1A overexpression does not cause apoptotic loss of cells. 
(A, B) Analysis of SH-SY5Y cell proliferation by continuous live cell imaging with the IncuCyteTM 
kinetic imaging system. Relative confluence of cells expressing wild type DYRK1A or kinase 
deficient DYRK1A-K188R and the number of GFP positive cells were automatically evaluated using 
the IncuCyteTM software at 24 h and 96 h of doxycycline treatment. Untreated cells served as 
control. Confluence (A) and cell counts (B) after 96 h were standardized to the 24 h-values 
(means + SD, n = 4 independent experiments). (C) Analysis of apoptosis in SH-SY5Y cells that 
were treated with doxycycline and harmine under the same conditions as shown in figure 12. Total 
protein was extracted after 72 h of treatment and analyzed for PARP activation by western blotting. 
Cells treated with staurosporine for 24 h served as positive control (C, D). An asterisk indicates 
cleaved and activated PARP. GAPDH served as loading control. Statistical significance was tested 
with Kruskal-Wallis-test + Dunn’s multiple comparison post-test (A) or Student’s t-test (B). *, 
p ≤ 0.05; **, p ≤ 0.01; n.s, not significant. 
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4.1.3 DYRK1A regulates G1-phase transition in SH-SY5Y cells 
To address the question if the observed effects of DYRK1A overexpression on cell 
proliferation were due to alterations in cell cycle progression, the cell cycle phase 
distribution of SH-SY5Y cells was analyzed by DNA staining with propidium iodide (PI) 
and subsequent measurement of DNA contents by flow cytometry (figure 14). After 24 h of 
DYRK1A overexpression, the number of cells in S- or G2/M-phase was significantly 
reduced (12% compared to 30% in untreated control cells) and more cells were found to 
be in G1/0-phase (88% vs. 70%) (figure 15A), an effect that persisted after 72 h of 
DYRK1A overexpression (figure 15B). 
 
Figure 14: Cell cycle analysis of SH-SY5Y cells. 
Analysis of cell cycle phase distribution by flow cytometry after DNA staining with propidium iodide 
(PI). Overexpression of DYRK1A (upper panel) or DYRK1A-K188R (lower panel) was induced with 
2 µg/ml doxycycline (Dox). For comparison, neuronal differentiation was induced with 10 µM 
retinoic acid (RA). Control cells were left untreated. The different cell cycle phases are indicated in 
green (G1/0), orange (S) and blue (G2/M). 
In contrast, overexpression of DYRK1A-KR resulted in a small and transient increase of 
cells in G1/0 after 24 h, but this effect was not persistent after 72 h of overexpression. For 
comparison, cells were treated with retinoic acid (RA) to induce cell cycle arrest and 
neuronal differentiation of SH-SY5Y cells (Cuende et al., 2008). RA induced only a weak, 
non-significant increase of G1/0 cells after 72 h, possibly because its action has a slower 
onset or does not affect all cells (Encinas et al., 2000). In conclusion, these results provide 
evidence that overexpression of DYRK1A but not DYRK1A-KR immediately arrests 
SH-SY5Y cells in G1/0-phase of the cell cycle.  
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Figure 15: DYRK1A overexpression induces G1/0 cell cycle arrest of SH-SY5Y cells. 
Column diagrams show the cell cycle phase distribution 24 h (A) or 72 h (B) after induction of 
DYRK1A overexpression or RA induced differentiation. Left panels show the quantitative evaluation 
of representative experiments. The right panels summarize the results of three independent 
experiments (means + SD). *, p ≤ 0.05; **, p ≤ 0.01; ***; p ≤ 0.001; analyzed by One-way ANOVA + 
Bonferroni post test comparing DYRK1A or DYRK1A-K188R data to the respective untreated 
controls. 
4.1.4 DYRK1A induces G0 cell cycle exit of SH-SY5Y cells 
A prolonged retention of neuronal precursors in G1-phase is known to increase the 
probability of cell cycle exit and differentiation (Nguyen et al., 2006b). Cells that have 
exited the cell cycle can be identified by their reduced RNA content (Darzynkiewicz et al., 
1980; Shapiro, 1981).  
To test the hypothesis that DYRK1A overexpression induced G1-phase cell cycle arrest 
leads to cell cycle exit of SH-SY5Y cells, DYRK1A and DYRK1A-KR were overexpressed 
for 5 days and cellular RNA and DNA contents were analyzed by two dimensional flow 
cytometry (figure 16A). As a positive control for differentiation and cell cycle exit, 
SH-SY5Y cells were treated for 5 days with RA to induce differentiation or for 3 days with 
RA followed by 2 days BDNF to achieve full differentiation (Encinas et al., 2000). 
Overexpression of DYRK1A, but not of DYRK1A-KR, resulted in a large increase of cells 
staining low for pyronin Y (figure 16B and C), which identifies them as quiescent cell 
populations with low RNA content, that have exited the cell cycle (Darzynkiewicz et al., 
1980). The percentage of cells in G0-phase was significantly increased after DYRK1A 
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overexpression (45% compared to 16% of control cells, figure 16C). Differentiation with 
either RA alone or RA and BDNF altered the rate of cells in G0-phase to 45% or 75%, 
respectively.  
 
Figure 16: Long-term DYRK1A overexpression induces cell cycle exit of SH-SY5Y cells. 
To distinguish cells in G1- and G0-phase, two-dimensional analyses of cellular DNA and RNA 
contents were performed after staining SH-SY5Y cells with Hoechst 33342 and pyronin Y (PY). 
Nucleic acid contents were analyzed by flow cytometry after 5 days of treatment with doxycycline 
(Dox), 10 µM RA only or treatment with 10 µM RA followed by 50 ng/ml BDNF. Representative 
plots of one experiment (A). The different cell cycle phases are indicated in the upper left panel. 
(B) Quantification of cells in G1/0- and G2-phase in the experiment shown in A. (C) Evaluation of 
average cell counts in G0-phase of three independent experiments. Here, the cell population with 
4n DNA content and low RNA staining is referred to as sub-G2-phase (Sub G2). Means + SD; 
*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001, analyzed by One-way ANOVA + Bonferroni post test 
comparing DYRK1A or DYRK1A-K188R data to the respective untreated controls. 
Two-dimensional staining also revealed a subpopulation of SH-SY5Y cells in S- and G2 
phase with reduced RNA content. These populations have also been observed in other 
cell types and indicate a quiescent state (SQ- and G2Q) besides G0 (Darzynkiewicz et al., 
1980). Here, these cells may represent the intermediate and substrate type (I- and S-type) 
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of SH-SY5Y cells that exit cell cycle but do not develop characteristics of the neuroblastic 
cell type (N-type) (Melino et al., 1997). These results provide evidence that long-term 
overexpression of DYRK1A not only prevents S-phase entry of SH-SY5Y neuroblastoma 
cells but also results in subsequent cell cycle exit into G0-phase.  
4.1.5 DYRK1A couples G0 exit with neuronal differentiation in SH-SY5Y cells 
Because a G0 cell cycle exit of neuronal cells is linked to differentiation, the next question 
was if DYRK1A overexpression induces neuronal differentiation of SH-SY5Y cells. 
Therefore, the differentiation-related morphological changes of SH-SY5Y cells were 
visualized by staining the F-actin cytoskeleton with fluorescently labeled phalloidin, and 
the average neurite length was manually quantified (figure 17).  
 
Figure 17: DYRK1A overexpression induces neurite outgrowth of SH-SY5Y cells. 
Actin cytoskeleton staining of SH-SY5Y cells. DYRK1A (A) or DYRK1A-K188R (B) overexpression 
was induced with dox (b). As positive control, cells were differentiated with 10 µM RA (c) or with RA 
followed by 50 ng/ml BDNF (d). Control cells were left untreated (a). After 5 days, F-actin was 
labeled with phalloidin-Alexa®-546 and nuclei were stained with DAPI. Scale bar = 20 µm. a´-d´ 
show magnified cutouts of the respective images a-d. To exclude effects on neuritogenesis 
resulting from different cell densities, proliferation differences were compensated as described in 
chapter 3.7.3. Column diagrams illustrate the quantification of average neurite lengths of SH-SY5Y 
cells after 5 days. Means + SEM; analyzed by One-way ANOVA + Bonferroni post test comparing 
DYRK1A or DYRK1A-K188R data to untreated controls. The number of analyzed neurites is 
indicated in each column. 
As a reference, cells were treated for 5 days with RA or RA and BDNF to induce the 
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differentiating phenotype of SH-SY5Y cells with proliferation arrest accompanied by 
formation of an extensive neurite network (figure 17A, images c, d and bar chart) 
(Constantinescu et al., 2007; Encinas et al., 2000). In contrast, after 5 days, 
undifferentiated cells showed only few and shorter neurite-like extensions and a higher 
cell density. DYRK1A overexpression did not only stop cell proliferation but also induced 
obvious changes in the cytoskeletal organization of SH-SY5Y cells with an increased 
neurite formation and neurite length (figure 17A, image b and bar chart). Moreover, 
DYRK1A-induced differentiation, as reflected by increased neurite formation and length, 
occurred earlier than neuritogenesis triggered by RA treatment (data not shown). In spite 
of comparable neurite lengths, DYRK1A overexpressing cells did not seem to attain 
complete neuronal network morphology like induced by BDNF. Cells overexpressing 
DYRK1A-KR continued to proliferate and showed no evident morphological changes and 
no altered neurite length (figure 17B, image b and bar chart). 
Furthermore, live cell imaging with an automated acquisition and evaluation of total 
neurite length per cell was performed for additional quantification. Analysis revealed that 
96 h of DYRK1A overexpression in SH-SY5Y cells significantly increased the total neurite 
length per cell in comparison to cells overexpressing DYRK1A-KR (figure 18). The shown 
result confirms the effects on average neurite length determined by manual quantification, 
indicating that DYRK1A overexpression induces neurite elongation of SH-SY5Y cells.  
 
Figure 18: Automated evaluation of neurite length per cell 
Computational analysis of neuritogenesis in SH-SY5Y cells using automated live cell microscopy. 
Overexpression of DYRK1A or DYRK1A-KR was induced with dox. After 96 h, total neurite length 
was quantified using an IncuCyteTM kinetic imaging system with automated NeuroTrackTM image 
acquisition. Images a and b show representative bright field images after 96 h with an overlay of 
the NeuroTrack analysis (red) and the automatically assessed count of GFP positive nuclei 
(yellow). Images a´ and b´ provide GFP fluorescence of nuclear localized GFP-DYRK1A or GFP-
DYRK1A, respectively. Scale bar = 300 µm. The column diagram illustrates evaluation of total 
neurite length standardized to the total count of GFP positive nuclei to compensate for different cell 
proliferation. Data shown as means + SEM of four independent experiments and was analyzed 
with student’s t-test. ***, p ≤ 0.001. 
Next, to validate DYRK1A induced morphological differentiation of SH-SY5Y cells, the 
effects of DYRK1A on mRNA and protein abundance of the neuronal markers MAP2 and 
Tau (MAPT) were analyzed. The expression of both proteins is known to be upregulated 
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after long-term RA-induced differentiation (Constantinescu et al., 2007; Cuende et al., 
2008). Transcript levels of both markers were significantly upregulated after 24 h of 
DYRK1A overexpression, whereas DYRK1A-KR overexpression had no effect (figure 
19A).  
 
Figure 19: DYRK1A transiently increases mRNA levels of neuronal markers in SH-SY5Y 
cells. 
DYRK1A or DYRK1A-K188R overexpression was induced in SH-SY5Y cells with 2 µg/ml dox. 
Control cells were left untreated or were differentiated with 10 µM RA. After 24 h (A) or 72 h (B), 
total RNA was extracted and analyzed by qRT-PCR. mRNA levels of MAP2 (left panel) and Tau 
(right panel) were quantified relative to GAPDH mRNA. n = 3, means + SD; *, p ≤ 0.05; analyzed 
by One-way ANOVA + Bonferroni post test comparing DYRK1A or DYRK1A-K188R data to 
untreated controls. 
Remarkably, after 72 h of DYRK1A overexpression, no differences in MAP2 or MAPT 
mRNA levels could be observed (figure 19B). In contrast to the mRNA levels, MAP2c and 
Tau protein levels showed no detectable changes after 24 h but were significantly 
increased 72 h after induction of DYRK1A overexpression (figure 20). DYRK1A 
overexpression also resulted in an increased phosphorylation of Tau at Thr212, what is 
consistent with previous findings by Ryoo et al. (2007). Overexpression of DYRK1A-KR 
did not affect MAP2 or Tau protein levels and did not cause Tau hyperphosphorylation. 
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The results suggest that expression of the neuronal proteins is transiently induced by 
DYRK1A overexpression and returns to steady state levels in differentiated cells although 
DYRK1A remains overexpressed. 
 
Figure 20:DYRK1A increases protein levels of neuronal markers in SH-SY5Y cells. 
DYRK1A or DYRK1A-K188R overexpression was induced in SH-SY5Y cells with 2 µg/ml dox. 
Control cells were left untreated (-) or were differentiated with 10 µM RA. After 24 h or 72 h, total 
protein was extracted, subjected to SDS-PAGE and analyzed by western blotting with the indicated 
antibodies. (A) Representative western blot. (B, C) Densitometric evaluation of MAP2c and Tau 
immunoreactivity relative to GAPDH is shown in. n = 3, means + SD; *, p ≤ 0.05; analyzed by One-
sample t-test to compare columns to normalized control. Migration of mass standards is indicated 
in kDa (left). 
Unexpectedly, treatment of SH-SY5Y cells with RA as differentiation control did not 
increase MAP2 or Tau mRNA and protein levels within 72 h. To exclude that RA induced 
differentiation failed, the expression of the neurotrophin receptor NTRK2 (TrkB) was 
analyzed that is strongly upregulated in RA-treated SH-SY5Y cells (Kaplan et al., 1993). 
As shown in figure 21, RA treatment for 72 h elevated TrkB mRNA levels, indicating a 
successfully induced neuronal differentiation, whereas undifferentiated control cells did 
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not express the receptor. Interestingly, also overexpression of DYRK1A but not of 
DYRK1A-KR induced a weak increase of TrkB mRNA levels. Notably, endogenous 
DYRK1A mRNA levels were unchanged during RA-induced differentiation (see figure 9). 
Taken together, these results provide evidence that the overexpression of DYRK1A 
triggers G0-cell cycle exit and neuronal differentiation of SH-SY5Y cells. 
 
Figure 21: Analysis of DYRK1A and TrkB mRNA 
levels by qRT-PCR. 
SH-SY5Y cells were treated with dox or RA for 72 h 
and TrkB mRNA levels were quantified by qRT-PCR. 
mRNA levels are shown as relative quantification to 
GAPDH mRNA levels, which were used as internal 
standard. n = 3, means + SD; ***, p ≤ 0.001, analyzed 
by One-way ANOVA + Bonferroni post test comparing 
DYRK1A or DYRK1A-K188R data to untreated 
controls. 
 
4.1.6 DYRK1A phosphorylates p27Kip1 at Ser10 in living cells and in vitro 
Since DYRK1A overexpression links cell cycle exit and neuronal differentiation, the 
underlying molecular mechanisms were addressed. The G1-phase cell cycle regulator 
p27Kip1 is functionally regulated by phosphorylation and moreover mediates cell cycle exit 
and neuronal differentiation (Nguyen et al., 2006a). It was previously reported that 
DYRK1B phosphorylates and stabilizes p27Kip1 by Ser10 phosphorylation in tumor cells 
(Deng et al., 2004). Similar consensus phosphorylation sequences of DYRK1A and 
DYRK1B led to the hypothesis that DYRK1A might regulate neuronal cell cycle 
progression by phosphorylation of p27Kip1.  
First, to analyze if DYRK1A phosphorylates p27Kip at Ser10 in a cellular environment, 
HeLa cells were transiently transfected with p27Kip1 and endogenous DYRK1A was 
pharmacologically inhibited with the newly synthesized inhibitor AnnH31 (Rüben et al., 
unpublished data). Compared to untreated control cells, inhibition of endogenous 
DYRK1A for 5 h reduced p27Kip1 Ser10 phosphorylation about 26% (figure 22). To 
elucidate the effect of DYRK1A overexpression on Ser10 phosphorylation, p27Kip1 was 
cotransfected with GFP-DYRK1A or GFP-DYRK1A-KR. As positive control, HeLa cells 
were also cotransfected with p27Kip1 and HIPK2, that was previously described to 
phosphorylate p27Kip1 at Ser10 (Pierantoni et al., 2011). Compared to non-DYRK1A 
overexpressing control cells, cotransfection of DYRK1A increased Ser10 phosphorylation 
about 2.5-fold, whereas cotransfection of DYRK1A-KR did not induce obvious changes. In 
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comparison, cotransfection of HIPK2 increased Ser10 phosphorylation about 2-fold. To 
verify a direct effect of overexpressed DYRK1A on p27Kip1 Ser10 phosphorylation, 
cotransfected cells were treated for 5 h with three different DYRK1A inhibitors. Treatment 
with either harmine or AnnH31 reduced the increased Ser10 phosphorylation due to 
DYRK1A overexpression about 30%, Iodotubercidin about 50%. These results strongly 
indicate that DYRK1A phosphorylates heterologously expressed p27Kip1 at Ser10 in living 
cells.  
 
Figure 22: DYRK1A increases Ser10 phosphorylation of overexpressed p27Kip1 in HeLa cells. 
HeLa cells were transiently transfected with expression plasmids for p27Kip1 and co-transfected with 
GFP-DYRK1A, GFP-DYRK1A-K188R or GFP-HIPK2 as indicated. Control cells were left 
untransfected (-). To analyze p27Kip1 phosphorylation by endogenous DYRK1A, cells were treated 
with 1 µM of the DYRK1A inhibitor AnnH31 (AH31) for 5 h before cell lysis. To inhibit 
overexpressed DYRK1A, cells were treated with 1 µM of the DYRK1A inhibitors harmine (Har), 
AH31 or Iodotubercidin (Iodo) for 5 h prior to cell lysis. Total protein extracts were analyzed for 
p27Kip1 phosphorylation by western blotting with the indicated antibodies. Phosphorylation of Ser10 
relative to total p27Kip1 protein is indicated below. The value of untreated control cells was 
normalized to 1. GFP-HIPK2 was not resolved on this gel due to its high MW. One representative 
blot from n = 3.  
Because HeLa cells are fast proliferating and non-neuronal cervix carcinoma cells, 
DYRK1A dependent phosphorylation of p27Kip1 was additionally verified in slowly 
proliferating SH-SY5Y neuroblastoma cells to exclude cell type specific effects. Therefore, 
SH-SY5Y cells with an inducible overexpression of GFP-DYRK1A or GFP-DYRK1A-KR 
were nucleofected with p27Kip1. To analyze Ser10 phosphorylation of heterologously 
expressed p27Kip1 by endogenous DYRK1A, cells without induced overexpression of the 
kinase were treated with harmine. Consistent with the results in HeLa cells, 5 h of harmine 
treatment reduced Ser10 phosphorylation by about 25% (figure 23) in SH-SY5Y cells. 
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Additionally, DYRK1A or DYRK1A-KR overexpression was induced for 24 h with dox, 
whereupon DYRK1A overexpression resulted in a slight p27Kip1 band shift and a 2-fold 
increased Ser10 phosphorylation. In contrast, DYRK1A-KR overexpression induced no 
changes. Inhibition of overexpressed DYRK1A with harmine for 5 h reduced p27Kip1 Ser10 
phosphorylation also about 25%. In conclusion, these results indicate that DYRK1A also 
phosphorylates p27Kip1 at Ser10 in slowly dividing neuronal cells. 
 
Figure 23: DYRK1A increases Ser10 phosphorylation of overexpressed p27Kip1 in SH-SY5Y 
cells. 
SH-SY5Y cells with an inducible overexpression of GFP-DYRK1A or GFP-DYRK1A-K188R were 
transiently transfected with plasmids encoding for p27Kip1 by nucleofection. To analyze p27Kip1 
phosphorylation by DYRK1A, cells were treated with 1 µM harmine for 5 h prior to cell lysis. 
Additionally, DYRK1A or DYRK1A-KR overexpression was induced with dox for 24 h as indicated. 
Total protein extracts then were analyzed for p27Kip1 phosphorylation by western blotting with the 
indicated antibodies. Densitometric evaluation of Ser10 phosphorylation relative to total p27Kip1 is 
indicated below. The respective values of untreated control cells were normalized to 1. 
Furthermore, to address the question whether DYRK1A directly phosphorylates p27Kip1 at 
Ser10, DYRK1A was overexpressed in HeLa cells, immunoprecipitated and subjected to 
an in vitro kinase assay with recombinant GST-fused p27Kip1. Immunoprecipitated 
DYRK1B was used as positive control (Deng et al., 2004). The assay showed that 
DYRK1A phosphorylates Ser10 directly and with an efficiency comparable to DYRK1B 
(figure 24A). Additionally, to exclude p27Kip1 phosphorylation by possible co-precipitated 
other cellular kinases, a kinase assay was performed with recombinant p27Kip1 and 
recombinant DYRK1A or DYRK1A-KR, respectively (figure 24B). As expected, DYRK1A 
but not DYRK1A-KR phosphorylated p27Kip1 at Ser10. These results provide evidence, 
that DYRK1A phosphorylates p27Kip directly at Ser10 and not by activating another 
downstream kinase. 
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Figure 24: DYRK1A directly phosphorylates p27Kip1 at Ser10 in vitro. 
Representative in vitro kinase assays. (A) GFP-DYRK1A and GFP-DYRK1B were 
immunoprecipitated from HeLa cells and subjected to a kinase assay with recombinant GST-
p27Kip1. The phosphorylation reaction was started by ATP addition (+ ATP). No ATP addition 
served as negative control. Phosphorylation of p27Kip1 was detected by immunoblotting with a 
specific antibody. The presence of GFP-DYRK1A, GFP-DYRK1B as well as total p27Kip1, were 
verified by using the indicated antibodies. (B) In vitro kinase assay with bacterial GST fusion 
proteins of DYRK1A or kinase deficient DYRK1A-K188R and p27Kip1. Aliquots of the kinase 
reaction were taken at the indicated time points. Ser10 phosphorylation of p27Kip1 was detected by 
immunoblotting. Control lanes were loaded with GST-p27 only. The majority of GST-DYRK1A is 
isolated as a catalytically active C-terminally truncated mutant (indicated with an asterisk) (Himpel 
et al., 2001). Florian Glenewinkel and Simone Bamberg-Lemper carried out the presented 
experiments. 
4.1.7 DYRK1A regulates p27Kip1 and Cyclin D1 protein levels by phosphorylation 
Next, it was investigated if DYRK1A overexpression affected proteins that regulate 
neuronal G1/0-phase transition. Besides p27Kip1, also Cyclin D1 promotes neuronal cell 
cycle exit and differentiation (Lange et al., 2009).  
Analysis of the sequence motifs flanking Thr286 as an important stability regulating 
phosphorylation site revealed that also DYRK1A might phosphorylate Cyclin D1. 
Therefore, total protein extracts from SH-SY5Y cells were analyzed for Cyclin D1 Thr286 
phosphorylation after DYRK1A overexpression. DYRK1A overexpression led to 
remarkably reduced total Cyclin D1 protein levels, concomitant with increased 
phosphorylation at Thr286 (figure 25). Independently of the present study, Ashford et al. 
(2014) reported that DYRK1B, and also DYRK1A directly phosphorylate Cyclin D1 at 
Thr286, thereby regulating Cyclin D1 protein turnover. Hence, in this study a detailed 
validation of the DYRK1A phosphorylation site in Cyclin D1 was obsolete and therefore 
not pursued. 
To verify, if DYRK1A-induced G1-phase cell cycle arrest is accompanied by changes in 
endogenous p27Kip1 and Cyclin D1 levels due to altered phosphorylation, both proteins 
were analyzed in detail after DYRK1A and DYRK1A-KR overexpression in SH-SY5Y cells. 
Western blot analysis of total protein extracts from SH-SY5Y cells overexpressing 
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DYRK1A revealed changes of phosphorylation and protein levels of Cyclin D1 and p27Kip1 
(figure 25).  
 
Figure 25: DYRK1A overexpression increases phosphorylation of endogenous p27Kip1 and 
Cyclin D1 in SH-SY5Y cells and alters their protein levels. 
(A) Representative western blot analysis of total protein extracts from SH-SY5Y cells. Cells were 
treated with 2 µg/ml doxycycline to induce overexpression of DYRK1A or DYRK1A-K188R. Control 
cells were differentiated with 10 µM RA or left untreated (-). Whole cell lysates were prepared 24 h 
or 72 h after induction of DYRK1A overexpression or differentiation and analyzed by 
immunoblotting with the indicated antibodies. Migration of mass standards is indicated in kDa (left). 
Densitometric evaluation of three independent experiments is shown in panels B (Cyclin D1) and C 
(p27Kip1). pSer10 or Thr286 phosphorylation is shown as relative quantification to p27Kip or 
Cyclin D1 total protein, respectively. Total p27Kip or Cyclin D1 levels are shown as relative 
quantification to loading control (GAPDH). One-sample t-test was used to compare columns to 
normalized controls. Means + SD; *, p ≤ 0.05. 
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Statistical analysis of independent experiments revealed that overexpression of DYRK1A 
resulted in significantly decreased levels of Cyclin D1 after 24 h and 72 h, which were 
paralleled by increased phosphorylation of Thr286 (figure 25B). As a positive control for 
differentiation induced G1-phase cell cycle arrest, SH-SY5Y cells were treated with RA. 
RA induced differentiation finally resulted in increased Thr286 phosphorylation levels, but 
not in significant changes of total Cyclin D1 protein. Overexpression of DYRK1A-KR 
neither influenced Cyclin D1 phosphorylation nor total protein levels. 
To verify the overexpression dependent G1-phase cell cycle arrest, Ser10 phosphorylation 
of HistoneH3 was analyzed, which is increased during chromatin condensation in mitosis 
(Hendzel et al., 1997). Phosphorylation levels of HistoneH3 were remarkably reduced 
after DYRK1A overexpression, but not after overexpression of DYRK1A-KR or treatment 
with RA (figure 25A). Consistent with the results shown above (figure 15), this finding 
assures that DYRK1A overexpression reduced the number of cells in mitosis. 
Furthermore, DYRK1A overexpression for 24 h strongly enhanced Ser10 phosphorylation 
of p27Kip1 and additionally increased p27Kip1 total protein levels (figure 25C). After 72 h, 
DYRK1A overexpression significantly resulted in 3-fold higher Ser10 phosphorylation 
levels and in 1.8-fold elevated total p27Kip1 protein levels. In contrast, treatment with RA 
increased p27Kip1 protein levels 1.8-fold but only slightly increased Ser10 phosphorylation. 
Kinase deficient DYRK1A-KR did not alter p27Kip1 phosphorylation or protein levels. 
The neurodevelopmental function of DYRK1A is considered to be particularly sensitive to 
its expression levels (Dierssen and de Lagrán, 2006). Therefore, the effects on p27Kip1 
and Cyclin D1 phosphorylation and protein levels after gradually induced overexpression 
of DYRK1A were investigated in SH-SY5Y cells (figure 26). Western blot analysis 
revealed that after 24 h of dox treatment, phosphorylation levels of p27Kip1 and Cyclin D1 
closely correlated with the increasing amounts of overexpressed DYRK1A, and reached 
statistical significance after induction of DYRK1A overexpression with 0.25 µg/ml 
doxycycline (figure 26A and C). As expected, p27Kip stabilization as well as Cyclin D1 
destabilization followed the level of DYRK1A overexpression, and Cyclin D1 depletion 
reached statistical significance after 24 h with the lowest doxycycline concentration. After 
72 h, phosphorylation levels of p27Kip1 and Cyclin D1 significantly increased concomitant 
to DYRK1A expression (figure 26B and D). Total p27Kip1 protein levels were stepwise 
increased and Cyclin D1 levels reciprocally decreased with increasing DYRK1A 
expression. DYRK1A overexpression finally depleted Cyclin D1 to approximately 40% of 
primary levels. p27Kip1 was stabilized after 72 h according to Ser10 phosphorylation that 
was already present after 24 h of DYRK1A overexpression. In general, gradual 
overexpression of DYRK1A-KR generated no overall changes.  
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Figure 26: Phosphorylation and protein levels of p27Kip1 and Cyclin D1 correlate with 
DYRK1A expression levels. 
Overexpression of DYRK1A or DYRK1A-K188R was gradually induced using increasing dox 
concentrations as indicated. Cells were lysed 24 h (A) or 72 h (B) after induction of DYRK1A 
overexpression and whole cell lysates were subjected to western blot analysis (representative blots 
are shown). Migration of mass standards is indicated in kDa (left). Densitometric evaluations of 
three independent experiments are summarized in panels C (24 h) and D (72 h). pSer10 and 
Thr286 phosphorylation are shown as relative quantification to p27Kip or Cyclin D1 total protein, 
respectively. Total p27Kip or Cyclin D1 levels are shown as relative quantification to loading control 
(GAPDH). One-way ANOVA + Bonferroni post test was used to analyze effects of increasing dox 
concentrations. Significances are indicated for comparison of GFP-D1A with GFP-D1A-KR (C, D). 
p27Kip1/GAPDH data (panel D) was tested using Kruskal-Wallis test and Dunn´s multiple 
comparison post test; *, p ≤ 0.05.; **, p ≤ 0.01***, p ≤ 0.001.  
Hence, in SH-SY5Y cells the effects on Cyclin D1 and p27Kip1 protein stability are parallel 
to DYRK1A expression levels and expression time. Moreover, the effects strictly depend 
on the catalytic activity of the kinase. Furthermore, the data suggest that DYRK1A 
phosphorylation-dependent Cyclin D1 depletion occurs prior to DYRK1A mediated p27Kip1 
stabilization. Additionally, DYRK1A overexpression does not lead to complete cellular 
Cyclin D1 depletion, as indicated by residual detectable protein levels. Thus, other cellular 
mechanisms might counteract Thr286 dependent protein destabilization. 
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Since DYRK1A was reported to induce p27Kip1 mRNA levels during neurogenesis 
(Hämmerle et al., 2011), it was analyzed if DYRK1A affects CDKN1B (cyclin-dependent 
kinase inhibitor 1B, encoding p27Kip1) mRNA levels in SH-SY5Y cells (figure 27). 
Quantitative real-time PCR analysis revealed no statistically significant effect of DYRK1A 
or DYRK1A-KR overexpression on p27Kip1 mRNA levels after 24 h or 72 h. In contrast, 
24 h treatment of SH-SY5Y cells with RA significantly upregulated p27Kip1 mRNA levels. 
Thus, DYRK1A modulates p27Kip1 abundance primarily by posttranslational mechanisms 
in SH-SY5Y cells. 
 
Figure 27: DYRK1A overexpression does not affect p27Kip1 mRNA level in SH-SY5Y cells. 
SH-SY5Y cells were treated with dox or RA for 24 h (A) or 72 h (B) before p27Kip1 mRNA levels 
were analyzed by quantitative real-time PCR (qRT-PCR). Control cells were left untreated. p27Kip1 
mRNA levels are shown as relative quantification to GAPDH mRNA levels. n = 3, means + SD; **, 
p ≤ 0.01; ***, p ≤ 0.001, analyzed by One-way ANOVA + Bonferroni post test to compare DYRK1A 
or DYRK1A-K188R data with the respective untreated controls. 
DYRK1B and DYRK1A were recently reported to phosphorylate Cyclin D1 at Thr286 
independently of GSK3β (Ashford et al., 2014). Nonetheless, it should be excluded that 
DYRK1A overexpression causes Cyclin D1 Thr286 phosphorylation in SH-SY5Y cells by 
activation of GSK3β. Therefore, SH-SY5Y cells overexpressing DYRK1A were treated 
with the GSK3β inhibitor CHIR99021 or the DYRK1A inhibitor leucettine L41 (figure 28). 
Consistent with the findings of Ashford et al. (2014), GSK3β inhibition did not reduce 
DYRK1A mediated Cyclin D1 Thr286 phosphorylation (figure 28A and B). In contrast, 
inhibition of overexpressed DYRK1A reduced Cyclin D1 phosphorylation. The results 
indicate that DYRK1A phosphorylates Cyclin D1 independently of GSK3β in SH-SY5Y 
cells. As control, the efficacy of GSK3β inhibition was verified by detection of beta-Catenin 
(figure 28A and C), that is stabilized due to reduced GSK3β dependent phosphorylation 
(Yost et al., 1996). 
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Figure 28: DYRK1A does not trigger GSK3β dependent Cyclin D1 Thr286 phosphorylation in 
SH-SY5Y cells. 
(A) SH-SY5Y cells were treated with 0.5 µg/ml dox to induce DYRK1A overexpression. After 5 h, 
cells were additionally treated with the DYRK1A inhibitor leucettine L41 (1 µM) or the GSK3β 
inhibitor CHIR99021 (3 µM) for further 24 h. DMSO was used as solvent control. Afterwards, total 
cellular protein was isolated, and analyzed by western blotting with the indicated antibodies. Beta-
Catenin stabilization due to reduced GSK3β mediated phosphorylation was used to validate 
GSK3β inhibition (Yost et al., 1996). The vertical line indicates where an irrelevant lane was 
deleted from the final image. Column diagrams show densitometric quantifications of CyclinD1 
Thr286 phosphorylation (B) and total beta-Catenin protein levels (C) from three independent 
experiments. GAPDH served as loading control. 
The observation that p27Kip1 and Cyclin D1 are phosphorylated by DYRK1A led to the 
question if DYRK1A forms stable cellular complexes with both proteins. To reveal 
potential protein-protein interactions, GFP-DYRK1A or GFP-DYRK1A-KR was 
immunoprecipitated from SH-SY5Y cells 24 h after induction of overexpression (figure 29). 
 
Figure 29: DYRK1A does not form stable complexes with endogenous p27Kip1 or Cyclin D1 in 
SH-SY5Y cells. 
Immunoprecipitation (IP) of GFP-DYRK1A or GFP-DYRK1A-KR from SH-SY5Y cells. To increase 
endogenous p27Kip1 protein levels, cells were treated with RA for 72 h. DYRK1A overexpression 
was induced after 48 h of RA treatment for further 24 h. Potential protein-protein interactions were 
analyzed by western blotting and immunodetection, using the indicated antibodies. WDR68 is 
known to form stable complexes with DYRK1A and was therefore used as positive control (Miyata 
and Nishida, 2011). The input lanes show aliquots of the total cell lysates. Migration of mass 
standards is indicated in kDa (left). 
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To elevate endogenous p27Kip protein levels cells were additionally treated with RA. As 
shown in figure 29, neither p27Kip1 nor Cyclin D1 was co-immunoprecipitated with 
DYRK1A, although input controls revealed that all proteins were present. As positive 
control, binding of the known DYRK1A interaction partner WDR68 (Miyata and Nishida, 
2011) was well detectable. Conclusively, overexpressed DYRK1A phosphorylates p27Kip1 
and Cyclin D1 in SH-SY5Y cells without forming a stable complex. 
4.1.8 DYRK1A phosphorylates p27Kip1 in primary neurons and in vivo 
That DYRK1A phosphorylates Cyclin D1 at Thr286 and thereby regulates its protein 
turnover, was independently discovered by Ashford et al. (2014). Additionally, a second 
study introduced DYRK1A mediated Cyclin D1 regulation as a crucial mechanism for cell 
cycle exit of DS-derived fibroblasts (Chen et al., 2013). However, this study is the first 
report providing evidence that DYRK1A regulates p27Kip1 protein stability via Ser10 
phosphorylation. Therefore, the question was addressed if p27Kip1 phosphorylation by 
endogenous DYRK1A plays a physiological role in neuron and brain development. 
Hence, DYRK1A dependent p27Kip1 phosphorylation was analyzed in early differentiating 
mouse hippocampal neurons (figure 30). 
 
Figure 30: Inhibition of DYRK1A decreases Ser10 phosphorylation of p27Kip1 in 
differentiating mouse hippocampal neurons. 
Cells were cultured on coverslips in the presence of the DYRK1A inhibitors harmine (2 µM) or 
EGCG (5 µM), or without inhibitor (control) for 20 h before cells were fixed. Immunostaining of 
pSer10 p27Kip1 (P-p27) and phalloidin-rhodamine labeled F-actin was analyzed by confocal 
microscopy. The upper panels show overlays of pSer10 p27Kip1 and phalloidin signals. The lower 
panels show pSer10 p27Kip1 staining only. Scale bar = 25 µm. One representative experiment is 
shown from n = 3. The shown experiment was planned and designed in collaboration with Dr. 
Francisco J. Tejedor at the Instituto de Neurociencias, Alicante, Spain. Victoria Florencio Ortiz 
carried out the presented experiment. 
Hippocampal neurons from E17 mouse embryos were isolated and cultured to initiate 
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differentiation. Differentiating neurons were treated with the DYRK1A inhibitors harmine or 
EGCG for 20 h, and p27Kip1 Ser10 phosphorylation was analyzed with ICC and confocal 
microscopy. Inhibition of endogenous DYRK1A resulted in a strong reduction of 
pSer10 p27Kip1 immunostaining, predominantly localized in the nucleus (figure 30). 
Harmine treatment seemed to decrease Ser10 phosphorylation with a higher potency than 
EGCG, probably due to different pharmacological properties (Becker et al., 2014). 
Consistent with previous findings (Göckler et al., 2009), staining of F-actin revealed that 
inhibition of DYRK1A suppressed neurite formation, indicating that inhibition of DYRK1A 
kinase activity was effective. 
Since DYRK1A is involved in different processes of brain development (Tejedor and 
Hämmerle, 2011), it was analyzed whether DYRK1A contributes to p27Kip1 Ser10 
phosphorylation in brain development. Therefore, whole mouse embryos (E12) were 
cultured for 6 h in absence or presence of the different and chemically unrelated DYRK1A 
inhibitors harmine, EGCG and leucettine L41 (figure 31A). This time period is substantially 
shorter than the duration of a cell cycle, which at this stage has been determined to 20-
24 h (Takahashi et al., 1995; Calegari et al., 2005). Moreover, at this embryonic age, all 
relevant neurodevelopmental stages are coexisting and DYRK1A was shown to be highly 
expressed in the telencephalon (Finlay and Darlington, 1995; Hämmerle et al., 2008). All 
three DYRK1A inhibitors have been profiled against large panels of protein kinases 
(Becker et al., 2014) and do not inhibit other kinases known to phosphorylate p27Kip1 at 
Ser10 (KIS, AKT, CDK5, and HIPK2) (Boehm et al., 2002; Fujita et al., 2002; Kawauchi et 
al., 2006; Pierantoni et al., 2011; Zheng et al., 2010). The only exception is DYRK1B, 
which is not associated to neurodevelopment but reported as a regulator of p27Kip1 in 
cancer (Deng et al., 2004; Jin et al., 2009). After cultivation, embryo brains were sectioned 
and p27Kip1 phosphorylation detected by IHC. As shown in figure 31A, all three DYRK1A 
inhibitors remarkably reduced pSer10 p27Kip1 immunostaining in developing E12 
embryonic mouse telencephalon. Moreover, most of pSer10 p27Kip1 immunostaining was 
overlapping with β-III-tubulin (TUJ1) signals, a well known marker of early differentiating 
neurons (Lee et al., 1990). At the same time, the ventricular zone, where neuronal 
progenitors and newborn neuronal precursors localize, was nearly devoid of pSer10 
p27Kip1 immunostaining. This result strongly suggests that Ser10 phosphorylated p27Kip1 is 
mainly present in differentiating neurons, what is consistent with the results in early 
differentiating neurons shown above in figure 30. 
To exclude that the reduction of Ser10 phosphorylation reflected an indirect effect of the 
inhibitors on total p27Kip1 protein levels or cell cycle progression in general, 
immunostaining of p27Kip1 was performed (figure 31B). Additional staining of caspase 3 
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and EdU labeling were performed to identify apoptosis and altered proliferation patterns. 
As illustrated in figure 31B, neither remarkable changes of p27Kip1 protein levels, nor an 
increase of proliferation or cell death were observed. 
In summary, the data from primary mouse hippocampal neurons and mouse embryo 
telencephalon strongly indicate that DYRK1A accounts for a large part of p27Kip1 
phosphorylation at Ser10 in differentiating brain neurons. 
 
Figure 31: Inhibition of DYRK1A decreases p27Kip1 Ser10 phosphorylation but not total 
p27Kip1 protein levels or cell proliferation in embryonic mouse brain. 
Confocal images of the mouse telencephalon showing one hemisphere. E12 mouse embryos were 
cultured for 6 h in the presence of the DYRK1A inhibitors harmine (4 µM), EGCG (10 µM), 
leucettine L41 (8 µM) or without inhibitor (control). (A) Brain slices were stained for pSer10 p27Kip1 
(P-p27, green) and the neuronal differentiation marker β-III-tubulin (TUJ1, red). (B) EdU (red) was 
added to the culture medium 1 h before the end of cultivation. Brain slices were then stained for 
p27Kip1 (green, upper panel) and activated caspase 3 (Casp3, green, lower panel). The dorso-
ventral (D - V) and medial-lateral (M-L) orientations are indicated. Scale bar = 200µm. In each case 
one representative experiment is shown from n = 3. The shown experiments were planned and 
designed in collaboration with Dr. Francisco J. Tejedor at the Instituto de Neurociencias, Alicante, 
Spain. Sofia Jimenez Garcia carried out the presented experiments. 
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4.2 DYRK1A and Septin4 
4.2.1 DYRK1A phosphorylates Septin4 at Ser107 
Septin4 was previously identified as a substrate of DYRK1A (Sitz et al., 2008). 
Nonetheless, the respective phosphorylation site and functional consequences of this 
phosphorylation have remained unknown. Therefore, the Septin4 amino acid sequence 
(based on Septin4_v1, see chapter 7.3, table 19) was analyzed for putative DYRK1A 
consensus phosphorylation motifs, revealing three potential matching proline directed 
sites as illustrated in figure 32A. Although Ser68 reflects an optimal DYRK1A consensus 
motif, this residue is not conserved in human Septin4. By site directed mutagenesis, 
single or combined phosphorylation resistant alanine point mutants of Flag-tagged mouse 
Septin4 (hereafter named Septin4) at Ser68, Ser100 and Ser107 were constructed. Co-
transfection of GFP-DYRK1A with Septin4-wt or the serine to alanine point mutants into 
HeLa cells revealed that the point mutations increased the mobility of Septin4 in SDS-gel 
electrophoresis compared to Sept4-wt (figure 32B). 
 
Figure 32: Ser107 is the major DYRK1A phosphorylation site in Septin4. 
(A) Potential DYRK1A phosphorylation sites in murine Septin4. The Septin4_v1 amino acid 
sequence from position 60-110 is shown. Potential DYRK1A consensus motifs and serine positions 
are printed in bold. The general DYRK1A consensus phosphorylation sequence is illustrated below 
(Himpel et al., 2000). (B) HeLa cells were cotransfected with GFP-DYRK1A (GFP-D1A) and Flag-
Septin4-wt or different phosphorylation resistant serine (S) to alanine (A) point mutants as 
indicated. Untransfected cells were used as negative control (-). Total protein was extracted, 
subjected to SDS-PAGE, and analyzed by western blotting. GFP-DYRK1A overexpression was 
detected with an anti-GFP, and Septin-4 with an anti-Flag antibody. A customized antibody 
detecting phosphorylated Ser107 in Septin4 was tested. Migration of mass standards is indicated in 
kDa (left). 
Of all three mutated putative phosphorylation sites, Ser107 mutation to alanine showed 
the largest effect on Septin4 electrophoretic mobility, which was not enhanced by 
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additional mutations of Ser68 and Ser100. This result strongly suggested Ser107 as the 
major DYRK1A phosphorylation site in murine Septin4. Furthermore, to analyze Septin4 
Ser107 phosphorylation, a specific antibody was raised against phosphorylated Ser107. 
The custom-made antibody detected Septin4-wt and the S68A mutant but not Septin4-
S107A (figure 32B), indicating functionality and specificity. 
To evaluate DYRK1A dependent Septin4 Ser107 phosphorylation, Septin4-wt was 
cotransfected with GFP, GFP-DYRK1A or GFP-DYRK1A-K188R into HeLa cells. 
Additionally, endogenous or overexpressed DYRK1A activity was inhibited with harmine 
for 24 h (figure 33A).  
 
Figure 33: Analysis of DYRK1A dependent Septin4 Ser107 phosphorylation in HeLa cells. 
(A) HeLa cells were cotransfected with Flag-Septin4-wt (Flag-S4-wt) and GFP, GFP-DYRK1A 
(GFP-D1A) or GFP-DYRK1A-K188R (GFP-KR) and treated with harmine for 24 h, if indicated, 
starting at the day after transfection. (B) Septin4-wt was cotransfected with GFP or GFP-D1A into 
HeLa cells and treated with 1 µM of the DYRK1A inhibitors AnnH31 (AH31), harmine (Har) or 
iodotubercidin (Iodo) for 5 h starting the day after transfection. Untreated cells served as control (-). 
Densitometric evaluation of relative Ser107 phosphorylation is indicated below. Tubulin served as 
loading control. Migration of mass standards is indicated in kDa (left). Symbols (*, #, ▪) indicate 
band patterns and are defined in the text. 
Analysis with the phosphospecific antibody revealed that GFP-DYRK1A overexpression 
increases phosphorylation of Ser107. In contrast, inhibition of endogenous as well as 
overexpressed DYRK1A with harmine resulted in a slight decrease of Ser107 
phosphorylation. Notably, when Septin4 was cotransfected with GFP, detection of 
pSer107 immunoreactivity already revealed a high basal phosphorylation. In contrast to 
DYRK1A-wt, the kinase deficient mutant DYRK1A-K188R did not increase Septin4 
Ser107 phosphorylation. Immunodetection with a Septin4 antibody showed a double band 
at approximately 63 kDa when Septin4 was cotransfected with GFP or GFP- DYRK1A-
K188R, whereof the lower band (marked with #) showed less immunoreactivity if Septin4 
was coexpressed with GFP-DYRK1A. Obviously, the upper band (marked with *) 
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correlated in shape and migration pattern with the signal gained by the anti-pSer107 
antibody. These results indicate that overexpressed Septin4 occurs at least in two 
different phosphorylated states in HeLa cells, as reflected by the band-shift after GFP-
DYRK1A cotransfection in comparison to GFP transfection control. Ser107 
phosphorylation seemed to contribute to the phosphorylation dependent shift, as the 
phosphospecific antibody did not detect the lower band. Furthermore, potential 
fragmentation of overexpressed Septin4 is observed, supported by the observation that 
both antibodies independently showed similar immunoreactivity at a molecular weight of 
approximately 48 kDa (marked with ▪) which correlated in its signal intensity with total 
Septin4 levels.  
As basal Ser107 phosphorylation was already high when Septin4 was overexpressed in 
HeLa cells, the effect of pharmacological inhibition of endogenous and overexpressed 
DYRK1A on Ser107 phosphorylation was verified. Therefore, Septin4 was coexpressed 
with GFP or GFP-DYRK1A in HeLa cells and kinase activity of endogenous as well as of 
overexpressed DYRK1A was reduced with three different inhibitors for 5 h (figure 33B). 
Densitometric evaluation revealed a reduced Ser107 phosphorylation after inhibition of 
endogenous DYRK1A, although a residual phosphorylation of 30% remained if compared 
to control. Consistent with the former results, coexpression of GFP-DYRK1A increased 
Ser107 phosphorylation and generated the characteristic band shift described above 
(indicated by * and #). Inhibition of exogenous DYRK1A activity decreased Ser107 
phosphorylation and increased the intensity of the faster migrating band (#) if detected 
with the total Septin4 antibody. Nonetheless, Ser107 phosphorylation was not reduced 
like in the GFP cotransfection control, probably because of residual DYRK1A activity due 
to the strong overexpression. Anyway, the results indicate that DYRK1A contributes to 
Septin4 Ser107 phosphorylation in a cellular environment. However, the observation that 
inhibition of endogenous DYRK1A could not totally abolish Ser107 phosphorylation raised 
the question if other kinases GMGC group might contribute to Septin4 phosphorylation at 
this residue. 
4.2.2 Other GMGC-group kinases do not phosphorylate Septin4 at Ser107 
To test this hypothesis, HeLa cells overexpressing Septin4 were treated for 24 h with 
different kinase inhibitors as shown in figure 34A. Compared to the control, DYRK1A 
inhibition with harmine only slightly decreased Ser107 phosphorylation but reduced the 
intensity of the upper band (*) as revealed by detection of total Septin4. Inhibition of 
ERK1/2 activation (PD98659) or specific inhibition of p38 MAPK (doramapimod) revealed 
no obvious changes in Ser107 phosphorylation. Inhibition of GSK3 with LiCl affected 
pSer107 immunoreactivity but also reduced total Septin4 protein levels. Moreover, 
Results 
 72
inhibition of CDKs with 10 µM purvalanol or roscovitine not only reduced pSer107 
immunoreactivity but also remarkably decreased Septin4 total protein. To exclude that the 
effect on pSer107 and total Septin4 protein abundance was due to the high CDK inhibitor 
concentrations of 10 µM, HeLa cells transfected with Septin4 were treated with harmine or 
purvalanol at concentrations in a range from 1 µM to 10 µM (figure 34B and C).  
 
Figure 34: Analysis of Septin4 Ser107 phosphorylation by different GMGC protein kinases. 
HeLa cells were transfected with Flag-Septin4-wt and treated with different kinase inhibitors for 
24 h, starting the day after transfection. Total protein was extracted, subjected to SDS-PAGE, and 
analyzed by western blotting with the indicated antibodies. Migration of mass standards are 
indicated in kDa (left). (A) Kinase inhibitors were used as follows: DYRK1A, harmine (1 µM); GSK3, 
LiCl (10 mM); CDKs, purvalanol (10 µM) and roscovitine (20 µM); MAPK, PD98659 (10 µM); p38 
MAPK, doramapimod/BIRB 796 (10 µM). Control cells were left untreated (-) and DMSO was used 
as solvent control. Additionally, cells were treated with increasing harmine (B) or purvalanol 
concentrations (C). Representative blot from three different experiments (A) and of two 
representative experiments (C). Tubulin served as loading control. Symbols (*, #) indicate band 
patterns and are defined in the text. 
1 µM harmine led to a decreased Ser107 phosphorylation, an effect that was intensified at 
a concentration of 2.5 µM. As expected, intensity of the slower migrating total Septin4 
band (*) representing Ser107 phosphorylated protein reduced, indicating faster Septin4 
electrophoretic migration due to reduced Ser107 phosphorylation. Harmine concentrations 
higher than 2.5 µM likewise reduced Ser107 phosphorylation but also reduced total 
Septin4 protein. Purvalanol decreased Ser107 phosphorylation at a concentration range 
of 5 to 10 µM but simultaneously affected total Septin4 protein abundance. Notably, 
purvalanol concentrations of 1 µM and 2.5 µM neither inhibited Ser107 phosphorylation 
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potently, nor affected appearance of the characteristic Septin4 double band (*, #). Thus, in 
contrast to harmine, purvalanol did not cause a Septin4 band shift due to reduced Ser107 
phosphorylation. In summary, these results support the assumption that CDKs, MAP-
kinases or GSK3 do not phosphorylate Septin4 at Ser107 in HeLa cells. Anyway, it has to 
be taken into account that purvalanol and roscovitine are known to inhibit DYRK1A at high 
concentrations of 10 µM (Bain et al., 2003). It also must be noted that both CDK inhibitors, 
as well as harmine inhibit a panel of other kinases if applied in high concentrations like 
10 µM, and similar inhibitory side effects are known for 10 mM LiCl (Bain et al., 2007). 
Therefore, it is likely that the decrease of total Septin4 protein that occurs at high inhibitor 
concentrations is due do inhibitory effects on other cellular kinases and a disturbance of 
cellular signal transduction. 
4.2.3 Septin4 Ser107 phosphorylation regulates protein turnover 
The previously shown results indicate a high basal Ser107 phosphorylation when Septin4 
was overexpressed in HeLa cells. Septins are involved in cell division and phosphorylation 
seems to play an important role in their regulation (Dobbelaere et al., 2003; Versele and 
Thorner, 2004). Because Ser107 is phosphorylated by DYRK1A, a kinase involved in cell 
cycle control (section 1.3.3), the question raised if Ser107 phosphorylation or Septin4 
protein stability might be regulated during cell cycle progression. Therefore, Septin4 or the 
phosphorylation resistant mutant S107A were transfected into HeLa cells and cell cycle 
progression was arrested in S-phase with a thymidine block or in M-phase with a 
nocodazole block, which results in a high CDK activity (figure 35A). Western blot analysis 
showed slightly increased total Septin4-wt immunoreactivity in cells synchronized with 
thymidine or nocodazole. This effect was concomitant with an increased Ser107 
phosphorylation after S-phase synchronization if compared to asynchronous cells. 
Moreover, cells synchronized with thymidine and nocodazole showed higher levels of total 
Septin4-S107A than unsynchronized control cells. Remarkably, if compared to Septin4-wt, 
overexpressed Septin4-S107A in general showed a higher immunoreactivity, which 
indicates higher protein abundance. To test the hypothesis that Ser107 phosphorylation is 
regulated from S- to M-phase transition, HeLa cells transfected with Septin4-wt or 
Septin4-S107A were synchronized in S-phase. After release from S-phase arrest, total 
cell extracts were collected at different points of time and Ser107 phosphorylation, as well 
as Septin4 total protein levels analyzed (figure 35B). In line with the previous result, 
overexpressed Septin4-S107A showed higher protein level than Septin4-wt. Nonetheless, 
in this experiment, no considerable deviations of Septin4-wt or Septin4-S107A total 
protein abundance could be observed in relation to the release from S-phase block. 
Additionally, if compared to the results shown in figure 35A, Ser107 phosphorylation was 
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not remarkably increased after S-phase synchronization. 
 
Figure 35: Septin4 expression and Ser107 phosphorylation in S- and M-Phase in HeLa cells. 
HeLa cells were transfected with Flag-Septin4 constructs as indicated. (A) 24 h after transfection, 
cells were synchronized in S-phase with 2 mM thymidine or in M-phase with 75 ng/ml nocodazole. 
Non-synchronized cells (async) served as control. After 24 h of treatment total protein was 
extracted, subjected to SDS-PAGE, and analyzed by western blotting using the indicated 
antibodies. (B) The day after transfection cells were synchronized in S-phase for 24 h. Afterwards, 
thymidine was washed out and total protein extracted at the indicated points of time, subjected to 
SDS-PAGE, and analyzed by western blotting. GAPDH served as loading control. Migration of 
mass standards is indicated in kDa (left). 
Subsequently, analysis of Septin4 protein stability was performed. HeLa cells were 
transfected with Septin4-wt or Septin4-S107A and treated with cycloheximide to interrupt 
protein translation (figure 36). Immunodetection revealed that total Septin4-wt protein was 
decreased after 30 minutes of cycloheximide treatment, whereas Septin4-S107A total 
protein remained unchanged. In consideration, that overexpression of Septin4-S107A 
resulted in higher protein abundance than overexpression of Septin4-wt (figure 35), it 
seems to be likely that Ser107 phosphorylation may decrease Septin4 protein stability. 
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Figure 36: Ser107 phosphorylation regulates Septin4 protein turnover. 
HeLa cells were transfected with Flag-Septin4-wt or the S107A mutant and were treated with 
90 µM cycloheximide (CHX) 24 h after transfection to inhibit translation. After 0.5 h of treatment, 
total protein was extracted, subjected to SDS-PAGE, and analyzed by western blotting with the 
indicated antibodies. Migration of mass standards is indicated in kDa (left). 
4.2.4 Construction and validation of Septin4 HaloTag- and RFP-fusion proteins 
Since Ser107 phosphorylation apparently regulated Septin4 protein stability, a different 
experimental approach was developed to investigate consequences of increased or 
abolished Ser107 phosphorylation. Furthermore, Septins form cellular homo- and 
heterooligomeric complexes and filaments. Because of an altered Septin4 stability due to 
Ser107 phosphorylation, complex formation and cellular mobility might be also affected. 
For this reason, a possibility should be found to analyze effects of Ser107 phosphorylation 
on Septin4 subcellular localization and mobility. 
Therefore, on the one hand a HaloTag® (Promega) was subcloned into Flag-Septin4, 
located in between the Flag-tag and the Septin4 N-terminus as illustrated in figure 37A. 
Furthermore, a phosphorylation resistant (S107A) and a phosphorylation mimicking 
(S107E) mutant were constructed. The HaloTag allows pulse labeling with different 
ligands which are cell permeable and covalently bind to the HaloTag domain (Los and 
Wood, 2007; Los et al., 2008). After washing out the ligand, labeled Septin4 can be 
traced, compared to unlabeled Septin4, and the protein turnover determined. Additionally, 
to allow cellular tracking of Septin4 by live cell imaging, Flag-Septin4 was subcloned into 
the pTag-RFP expression vector (Evrogen, Merzlyak et al., 2007), resulting in a 
C-terminal fusion of tagRFP to Septin4 as illustrated in figure 37B. To investigate 
consequences of Ser107 phosphorylation on Septin4 cellular mobility, Ser107 point 
mutants were constructed as described for Flag-HaloTag-Septin4. In both constructs, the 
Flag-tag was preserved to facilitate immunodetection or immunoprecipitation. For 
convenience, Flag-HaloTag-Septin4 and Flag-Septin4-RFP will be hereafter referred to as 
HaloTag-Septin4 and Septin4-RFP. 
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Figure 37: Structure of Flag-HaloTag-Septin4 and Flag-Septin4-RFP. 
To analyze the consequences of Ser107 phosphorylation on Septin4 protein stability and 
subcellular localization, two different Septin4 fusion proteins were generated. (A) The HaloTag 
(Promega) allows irreversible pulse labeling with different available ligands and subsequent cellular 
tracking of the labeled protein. (B) To follow Septin4 subcellular localization tagRFP (Evrogen) was 
fused to the Septin4 C-terminus. Additionally, a phosphorylation resistant (S107A) and a 
phosphomimetic (S107E) point mutant were generated. The epitope positions of available 
antibodies for immunodetection are indicated: 1anti-Flag antibody, 2anti-Septin4 antibody (AA 33-
44), 3anti-pSer107 Septin4 antibody, and 4anti-RFP antibody. 
To analyze a heterologous full-length expression of the constructed fusion proteins, 
HaloTag-Septin4-wt and HaloTag-Septin4-S107A were transfected into HeLa cells with a 
doxycycline inducible overexpression of DYRK1A, and compared to overexpressed Flag-
tagged Septin4-wt and Septin4-S107A (figure 38). Compared to Septin4, overexpressed 
HaloTag-Septin4 showed equal total protein levels at the expected molecular weight of 
approximately 90 kDa what indicates a full-length translation. Induction of DYRK1A 
overexpression resulted in an increased Ser107 phosphorylation of Septin4 as well as of 
HaloTag-Septin4, whereas the respective S107A mutants showed no pSer107 
immunoreactivity. Interestingly, DYRK1A dependent Ser107 phosphorylation reduced total 
protein levels of both, Septin4 and HaloTag-Septin4 if compared to the controls. 
Additionally, HaloTag-Septin4 and the S107A mutant showed multiple bands below 
90 kDa in similar patterns that were detected by the phosphospecific, as well as the total 
Septin4 antibody. These results indicate that the HaloTag integration does not interfere 
with Septin4 protein expression, protein fragmentation or Ser107 phosphorylation. 
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Figure 38: Flag-Septin4 and Flag-HaloTag-Septin4 expression and Ser107 phosphorylation 
in DYRK1A overexpressing HeLa cells. 
HeLa cells with a stable and doxycycline (dox) inducible GFP-DYRK1A overexpression were 
transfected with Flag-Sept4-wt, HaloTag-S4-wt, or the respective S107A point mutants. DYRK1A 
overexpression was induced with dox as indicated 24 h after transfection. After further 24 h, total 
protein was extracted, subjected to SDS-PAGE, and analyzed by western blotting. Untreated cells 
served as control (-). Migration of mass standards is indicated in kDa (left). 
Next, it was tested whether HaloTag-Septin4 is suitable for cellular pulse labeling and 
subsequent detection by western blot analysis. Therefore, HaloTag-Septin4 or the 
respective point mutants S107A and S107E were transfected into HeLa cells and the 
HaloTag was covalently labeled with a cell permeable biotin ligand (Promega), whereas 
control cells were left untreated. After washing out the ligand, total protein extracts were 
analyzed by western blotting using HRP coupled streptavidin to detect biotin labeled 
HaloTag-Septin4 (figure 39). Biotin labeling was detected at the expected molecular 
weight of HaloTag-Septin4 (asterisk), whereas unlabeled Septin4 showed no background 
signals. Notably, endogenous biotinylated proteins were detected at a molecular weight of 
approximately 90 and 110 kDa. As expected, HaloTag-Septin4-wt showed the 
characteristic double band, whereas the S107A mutant showed faster gel migration 
according to the lower band oft HaloTag-Septin4-wt. The S107E mutant showed slightly 
reduced gel migration, comparable to the upper band of HaloTag-Septin4-wt. Besides, it 
was confirmed that the phosphospecific antibody does not detect the S107E mutation. 
The results indicate that the HaloTag-Septin4 fusion protein is functional in living cells. 
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Figure 39: Biotin pulse labeling of Flag-HaloTag-Septin4. 
HeLa cells were transfected with different HaloTag-Septin4 constructs as indicated. (A) 24 h after 
transfection, biotin labeling was performed. Total protein was extracted 1 h after labeling, subjected 
to SDS-PAGE, and analyzed by western blotting. Signals of biotin labeled Septin4 are indicated 
with an asterisk. Migration of mass standards is indicated in kDa (left). 
To verify expression of Septin4-RFP, all constructs were transfected into HeLa cells and 
Flag-tagged Septin4-wt, S107A, and S107E served as controls (figure 40). 
 
Figure 40: Expression profile of Flag-Septin4- and Flag-Septin4-RFP-wt, S107A and S107E. 
Flag-Septin4 (left panel) or Flag-Septin4-RFP (right panel) as well as all point mutants were 
transfected into HeLa cells as indicated. 24 h after transfection total protein was extracted, 
subjected to SDS-PAGE, and analyzed by western blotting with the indicated antibodies. Migration 
of mass standards is indicated in kDa (left). Symbols (*, #) indicate band patterns and are defined 
in the text. 
As expected, immunodetection of Septin4-wt revealed the characteristic double band 
(indicated as * and #), whereas Septin4-S107A generated a single band at the same 
molecular weight as the faster migrating band (#) of Septin4-wt, again illustrating the 
Ser107 phosphorylation dependent gel shift. Septin4-S107E showed a slower gel 
migration but did not reach total uniformity with the upper band of Septin4-wt (*). Septin4-
RFP showed similar gel migration at the calculated molecular weight of approximately 
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85 kDa, indicating a full length translation of all constructs. In contrast to Septin4-S107E, 
Septin4-RFP-S107E showed a band migration pattern similar to the upper and Ser107 
phosphorylated band of Septin4-wt-RFP (*). Additionally, expression of Septin4-RFP as 
well as the S107A and S107E point mutants exhibited bands below 85 kDa that show 
similar electrophoretic patterns (*, #) as previously described for Flag-tagged Septin4. 
This result indicates that protein fragmentation is not dependent on Ser107 
phosphorylation. Nonetheless, it must be considered that this effect also could be an 
artifact due to the strong overexpression of Septin4 in HeLa cells. 
To verify functional imaging of Septin4-RFP in living cells, RFP expression was visualized 
by fluorescence microscopy in HeLa cells (figure 41). Septin4-RFP and both point mutants 
showed well detectable RFP signals with an exclusively cytosolic distribution.  
 
Figure 41: Expression of Flag-Septin4-RFP in HeLa cells. 
To verify sufficient RFP fluorescence, Flag-Septin4-RFP and the respective S107A and S107E 
point mutants were transfected into HeLa cells. RFP fluorescence was analyzed 24 h after 
transfection. A higher magnification is shown in the lower panels. Scale bar = 50 µm 
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5 Discussion 
5.1 DYRK1A in neuronal cell cycle regulation 
There is growing evidence that overexpression of DYRK1A in Down syndrome affects 
brain development and neuronal differentiation (Altafaj et al., 2001; Fotaki et al., 2002; 
Ahn et al., 2006; Yabut et al., 2010; Park et al., 2010; Tejedor and Hämmerle, 2011; 
Kurabayashi and Sanada, 2013; Hibaoui et al., 2014). Recently, DYRK1A was identified 
as a negative regulator of G1-S phase transition (Park et al., 2010; Litovchick et al., 2011; 
Chen et al., 2013). Overexpression of the kinase, as present in Down syndrome, therefore 
may deregulate cell cycle exit and thus proper brain development. However, the 
underlying mechanisms how DYRK1A affects cell cycle progression in neurons still 
remains largely unknown. 
In this study, human SH-SY5Y neuroblastoma cells with an inducible overexpression of 
DYRK1A were constructed to study effects of DYRK1A overexpression on neuronal cell 
cycle progression and differentiation. The obtained findings are summarized in figure 42. 
 
Figure 42: DYRK1A overexpression induces G0 cell cycle exit and neuronal differentiation 
and alters p27Kip1 and Cyclin D1 protein stability by phosphorylation. 
Overexpression of DYRK1A in SH-SY5Y cells resulted in a reduced proliferation that was identified 
as caused by a G1-cell cycle arrest. Long-term overexpression of DYRK1A induced G0 cell cycle 
exit and subsequent neuronal differentiation. The effects on cell cycle progression and neuronal 
differentiation strictly depended on DYRK1A expression level and its kinase activity. Moreover, 
DYRK1A stabilized p27Kip1
 
by phosphorylation at Ser10 and destabilized Cyclin D1 by 
phosphorylation at Thr286. Furthermore, DYRK1A remarkably contributed to p27Kip1 Ser10 
phosphorylation in differentiating mouse neurons and developing mouse telencephalon. 
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5.1.1 SH-SY5Y cells as a model to study DYRK1A overexpression 
In conclusion, the used tet-ON-expression system allows fast expression of GFP-
DYRK1A, concomitant with a sensitive doxycycline response, and no basal expression 
(figure 9 - figure 11). Analysis of GFP-DYRK1A expression kinetics by live cell imaging 
revealed that the onset of GFP fluorescence could be seen 4 h after doxycycline addition, 
reaching maximal intensities after 12 h. The duration of a neuronal progenitor cell cycle is 
estimated to 20-24 h (Calegari et al., 2005). Although not reflecting a neuronal progenitor 
cell, it can be assumed that the fast doxycycline response allows DYRK1A overexpression 
within the current cell cycle of a SH-SY5Y cell. 
SH-SY5Y cells are the first reported human neuronal cell line with a stable and 
controllable overexpression of GFP-DYRK1A or GFP-DYRK1A-KR. Using a pool of 
transduced cells instead of a single selected cell clone reduces the likeliness of position 
effects due to lentiviral integration. Therefore, the cells will also be useful for further 
studies of DYRK1A functions in a neuronal context. Moreover, the established lentiviral 
vector system can be used to transduce other cellular systems, especially poorly 
transfectable primary cells. 
Increasing interest in DYRK1A overexpression and the neurodevelopmental alterations 
that occur in Down syndrome stimulated further studies in mouse models, in Drosophila 
and in chicken. Moreover, neuropathological analyzes were performed in human brains 
(Tejedor and Hämmerle, 2011; Wegiel et al., 2011a). Investigation of DYRK1A 
overexpression in animal models mainly focused on behavioral and developmental 
neurobiology, but not on signal transduction. DYRK1A overexpression studies in mice 
require an elaborative generation of transgenic animals and the so far generated mice 
overexpressing DYRK1A do not allow an inducible overexpression of the transgene 
(Altafaj et al., 2001; Ahn et al., 2006). Moreover, a transgenic mouse overexpressing 
kinase deficient DYRK1A does not exist. Therefore, observed effects of DYRK1A 
overexpression have to be compared to wild type mice, what limits conclusions that the 
effects are intrinsically due do the elevated DYRK1A kinase activity but not to protein 
overexpression. To achieve single cell overexpression of DYRK1A in CNS neurons, 
complex methods as in utero electroporation of mice (Yabut et al., 2010) or ex vivo 
electroporation of the mouse embryo telencephalon or the chick spinal cord (Hämmerle et 
al., 2011) are required. Nonetheless, also these approaches only allow basic studies of 
protein or transcript expression, cell cycle progression or signal transduction. Until now, 
detailed studies of DYRK1A intracellular signal transduction in neurons are therefore 
lacking. 
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Analysis of cultured primary mouse or rat brain neurons requires elaborate animal 
preparation (Kaech and Banker, 2006), ethical approvals and provides limited cellular 
material for biochemical and cell biological studies. Because of a short lifespan and poor 
transfection properties, primary cells are rarely susceptible to integration of cDNA 
elements with an inducible expression. Moreover, for biochemical studies, extensive 
animal preparation is required, what is in conflict with the 3R guidelines to reduce the 
number of laboratory animals (Russell and Burch, 1959). Therefore, primary neurons were 
in particular used to study effects of DYRK1A on proliferation of neuronal precursors or on 
neuronal differentiation of hippocampal neurons as shown in Park et al. (2010) or Göckler 
et al. (2009).  
As a consequence, established model cell lines as HeLa-, COS- or HEK cells were 
formerly used to identify unknown DYRK1A target proteins and to analyze potential 
cellular effects of DYRK1A overexpression (Aranda et al., 2011). However, these cellular 
systems lack a neuronal character, and transient overexpression of DYRK1A and its 
potential target proteins might not reflect physiologic conditions. 
For that reason, the human SH-SY5Y neuroblastoma cell line was employed as a model 
system to investigate the effect of controlled DYRK1A overexpression (chapter 4.1.1). 
After differentiation with RA and BDNF, SH-SY5Y cells exit the cell cycle and achieve 
proper neuronal characteristics (Encinas et al., 2000). Therefore, they are a well 
established cell line for molecular and biochemical investigations of multiple 
neurobiological questions (Constantinescu et al., 2007; Cuende et al., 2008; Agholme et 
al., 2010). Nonetheless, it has to be concerned that SH-SY5Y cells are tumor cells that 
might show altered cell cycle properties. In this study is reported that DYRK1A 
overexpression induced cell cycle exit and neuronal differentiation of SH-SY5Y cells 
(figure 14 - figure 21). Moreover, DYRK1A phosphorylated Cyclin D1 at Thr286 in 
SH-SY5Y cells (figure 25, figure 26 and figure 28). Since the obtained results are in line 
with other findings in animal models, primary neurons or human fibroblasts (Park et al., 
2010; Yabut et al., 2010; Hämmerle et al., 2011; Chen et al., 2013), the tumorigenic 
properties of SH-SY5Y cells can be assumed to play a subordinated role regarding cell 
cycle progression and neuronal differentiation. Furthermore, due to their human origin, 
SH-SY5Y cells may rather allow conclusions to human neurons than immortalized rodent 
cell lines as PC12- (rat), H19-7- (rat), or Neuro-2a cells (mouse) that were used in 
previous studies (Yang et al., 2001; Kelly and Rahmani, 2005; Park et al., 2010; Yabut et 
al., 2010). Therefore, the constructed tet-ON-GFP-DYRK1A SH-SY5Y cells were 
considered as a suitable model to study consequences of DYRK1A overexpression on cell 
cycle regulation and neuronal differentiation.  
Discussion 
 83
5.1.2 DYRK1A regulates G1-phase cell cycle transition 
DYRK1A suppressed proliferation of SH-SY5Y cells in an expression and kinase activity 
dependent manner (figure 12). This finding supports the validity of the generated cell 
model, since DYRK1A overexpression has previously been reported to attenuate the 
proliferation of neural progenitors in the developing mouse cerebral cortex and in neural 
precursor cells derived from human embryonic stem cells (Park et al., 2010; Yabut et al., 
2010). DYRK1A overexpression did not cause reduced cell proliferation by a loss of cells 
due to induced cell death in SH-SY5Y cells (figure 13). This finding is consistent with 
previous reports that DYRK1A acts as a negative regulator of apoptosis and a positive 
regulator of cell survival (Seifert et al., 2008; Guo et al., 2010; Laguna et al., 2013). 
The majority of SH-SY5Y cells ceased proliferation and arrested in G1-phase after 24 h of 
DYRK1A overexpression (figure 12), whereas RA-induced cell cycle arrest of SH-SY5Y 
cells is characterized by a slow onset after at least 2-3 days (Cuende et al., 2008). Since 
DYRK1A-KR overexpression neither showed influences on cell proliferation nor on cell 
cycle phase distribution, it can be concluded that DYRK1A kinase activity is required for 
its functions in cell cycle control. Moreover, it can be assumed that effects due to cellular 
scaffolding and interaction properties of DYRK1A play a minor, if any role. Therefore, 
DYRK1A directly affects the current G1-phase, once expression levels and activity exceed 
a certain threshold. Additionally, enhanced DYRK1A activity is required to maintain cell 
cycle arrest, since pharmacological inhibition of DYRK1A after 24 h partially restored cell 
proliferation. 
5.1.3 DYRK1A promotes cell cycle exit and neuronal differentiation 
Long-term overexpression of DYRK1A increased a population of SH-SY5Y cells with 
reduced cellular DNA and RNA contents (figure 16), what is characteristic for cells that 
have entered a permanently non-proliferative G0-state (quiescence/differentiation) 
(Shapiro, 1981). Accordingly, the largest fraction of quiescent SH-SY5Y cells was 
observed after induction of full differentiation with RA and BDNF (Encinas et al., 2000). 
DYRK1A overexpressing SH-SY5Y cells not only exited cell cycle into G0 but also 
developed morphological and molecular hallmarks of neuronal differentiation, including 
enhanced neurite outgrowth and expression of the neuronal markers MAPT (Tau) and 
MAP2 (figure 17 - figure 20). In line with the findings shown before, DYRK1A kinase 
activity was also required to induce cell cycle exit and differentiation of SH-SY5Y cells. 
Elongation of G1-phase increases the probability of neuronal progenitors to differentiate 
(Calegari and Huttner, 2003; Calegari et al., 2005). Therefore, the results from SH-SY5Y 
cells strongly indicate that the elevated DYRK1A activity delays G1-S-phase transition and 
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thereby elicits neuronal differentiation. 
In contrast to RA (Kaplan et al., 1993), DYRK1A overexpression only slightly increased 
mRNA levels of the neurotrophin receptor TrkB, and neither was expression of DYRK1A 
affected by RA treatment (figure 21 and figure 9). Considering the fast effect on G1 arrest, 
it can be concluded that DYRK1A mediates cell cycle exit of SH-SY5Y directly by 
phosphorylation of cell cycle proteins, rather than by inducing changes of their gene 
expression like RA (Maden and Hind, 2003; Korecka et al., 2013). Moreover, an elevated 
DYRK1A activity also rapidly influenced the expression of neuronal markers, what is 
consistent with findings that DYRK1A stabilizes the mRNA of overexpressed Tau in cell 
culture (Qian et al., 2011, 2013). Besides that, it was shown that DYRK1A phosphorylates 
Tau at Thr212 in SH-SY5Y cells (figure 20), what was reported to promote microtubule 
disassembly (Ryoo et al., 2007; Wegiel et al., 2011b). Anyway, it seems to be likely that 
the transiently elevated expression of Tau and MAP2 in SH-SY5Y cells is due to the 
DYRK1A-induced differentiation process, because their mRNA levels do not remain 
elevated when DYRK1A overexpression is maintained. Therefore, DYRK1A may indirectly 
affect MAP2 and MAPT (Tau) gene transcription, given that DYRK1A was reported to 
phosphorylate transcription factors and to interact with the REST/NRSF transcriptional 
repressor (RE1-Silencing Transcription factor/Neuron-Restrictive Silencer Factor) (Woods 
et al., 2001; von Groote-Bidlingmaier et al., 2003; Canzonetta et al., 2008; Lepagnol-
Bestel et al., 2009). However, this hypothesis and the signaling pathways by which 
DYRK1A regulates expression of pro-neural genes remain to be investigated. 
Previously, it was reported that DYRK1A overexpression enhances neurite outgrowth in 
rat PC12 cells (Kelly and Rahmani, 2005; Stefos et al., 2013), and that DYRK1A inhibition 
interferes with neurite formation of mouse hippocampal neurons (Göckler et al., 2009). 
Consistent with other previous findings (Hämmerle et al., 2011), the present results 
provide evidence that DYRK1A regulates G1-S transition of neuronal cells and that an 
elevated activity of DYRK1A promotes proliferation arrest, cell cycle exit and premature 
differentiation. 
5.1.4 DYRK1A stabilizes p27Kip1 by Ser10 phosphorylation 
Cell cycle exit and differentiation of neural precursors are regulated by p27Kip1 and 
Cyclin D/CDK complexes (Calegari and Huttner, 2003; Molenaar et al., 2008; Frank and 
Tsai, 2009; Hindley and Philpott, 2012). Interestingly, the phosphorylation of p27Kip1 at 
Ser10 in neural stem cells correlates with cell cycle exit and transition to neuronal 
differentiation and neurite outgrowth (Zheng et al., 2010). In addition, phosphorylation of 
p27Kip1 at Ser10 by an unidentified protein kinase accounts for increased half-life and 
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accumulation of p27Kip1 during RA-induced differentiation of neuroblastoma cells (Borriello 
et al., 2006). 
Ser10 phosphorylation is proposed to fulfil two functions. On the one hand, Ser10 
phosphorylation during early G1-phase triggers p27Kip1 export to the cytosol and leads to 
its ubiquitination. On the other hand, in G0 p27Kip1 is mainly retained in the nucleus and 
stabilized by Ser10 phosphorylation (Ishida et al., 2000; Vervoorts and Lüscher, 2008). 
That DYRK1A overexpression induces G0 cell cycle exit of SH-SY5Y cells (figure 16) 
leads to the assumption that DYRK1A phosphorylates Ser10 and thereby stabilizes 
p27Kip1 in G1-G0 transition of neuronal cells. In this study is shown that DYRK1A increased 
p27Kip1 protein levels in SH-SY5Y cells by phosphorylation at Ser10 (figure 25). In 
SH-SY5Y cells, phosphorylation and stabilization of p27Kip1 were well correlated with the 
levels of DYRK1A overexpression (figure 26) what confirms the importance of balanced 
DYRK1A expression levels in development (Dierssen and de Lagrán, 2006). 
To validate the contribution of DYRK1A to p27Kip1 phosphorylation in vivo, Ser10 
phosphorylation was analyzed in early differentiating mouse hippocampal neurons and in 
developing brain of mouse embryos. Pharmacological inhibition of DYRK1A kinase activity 
with different validated inhibitors reduced p27Kip1 Ser10 phosphorylation in differentiating 
primary hippocampal neurons, as well as in developing mouse telencephalon (figure 30 
and figure 31). Overexpression of p27Kip1 lengthens G1 phase of neural progenitor cells in 
the mouse embryo (Mitsuhashi et al., 2001). However, p27Kip1 Ser10 phosphorylation was 
primarily detected in early differentiating neurons but not in the ventricular zone of mouse 
telencephalon where neural progenitors and newborn neuronal precursors are located 
(figure 30). Thus, our results identify DYRK1A as the predominant kinase that 
phosphorylates and stabilizes p27Kip1 during neuronal differentiation. Beyond its function 
as an inhibitor of CDK activity in the nucleus, p27Kip1 is assumed to be a cytosolic 
mediator of neuronal differentiation, microtubule polymerization and migration (Godin et 
al., 2012; Nguyen et al., 2006a, 2006b). In conclusion, also the shown in vivo data 
strongly indicate that DYRK1A overexpression promotes cell cycle exit and neuronal 
differentiation by increasing p27Kip1 levels through phosphorylation at Ser10. 
DYRK1A directly phosphorylated GST-p27Kip1 at Ser10 in vitro and overexpressed p27Kip1 
in a cellular environment (figure 22 - figure 24). Overexpression of DYRK1A or the kinase 
deficient mutant K188R, as well as inhibition of endogenous DYRK1A kinase activity 
clearly demonstrated a considerable contribution of both, cellular and overexpressed 
DYRK1A to Ser10 phosphorylation. Furthermore, DYRK1A phosphorylated p27Kip at 
Ser10 with at least the same efficiency as HIPK2 and DYRK1B, which both have been 
reported to phosphorylate Ser10 (Deng et al., 2004; Pierantoni et al., 2011). Therefore, it 
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can be concluded that p27Kip1 Ser10 is a bona fide proline directed DYRK1A 
phosphorylation site, although it does not perfectly match the DYRK1A consensus motif. 
Several other DYRK1A substrates have been described that do not contain the complete 
DYRK1A consensus motif reported by Himpel et al. (2000). Nonetheless, the majority of 
these substrates harbor a serine or threonine phosphorylation motif with a proline residue 
at the +1 position (Papadopoulos et al., 2011; Soundararajan et al., 2013), like present in 
p27Kip1 at Ser10 (S N G S P). 
In contrast to previous observations in neuronal precursors of developing chicken spinal 
cord and mouse telencephalon (Hämmerle et al., 2011), p27Kip1 mRNA levels were not 
significantly changed. However, DYRK1A was reported to phosphorylate the transcription 
factor FKHR (FOXO1a) at Ser329 in vitro, thereby facilitating its nuclear export and 
reducing its activity (Woods et al., 2001). On the contrary, reporter assays showed that 
DYRK1A overexpression co-activated FKHR dependent expression of glucose-6-
phosphatase, remarkably independent of its kinase activity (von Groote-Bidlingmaier et 
al., 2003). Even though a functional relation of DYRK1A and FKHR is not finally clarified, it 
is worth to note that p27Kip expression is regulated by the FKHR family of transcription 
factors (Dijkers et al., 2000; Medema et al., 2000). This might explain the observed 
increase in p27Kip mRNA after DYRK1A overexpression in neuronal precursors as 
reported in Hämmerle et al. (2011). Notably, in this study negative controls were carried 
out with empty expression vectors instead with DYRK1A-KR, thereby hindering a 
conclusion if DYRK1A kinase activity is required for this effect. Nonetheless, SH-SY5Y 
cells already show slight neurite extensions when they are not differentiated (figure 17). 
Therefore, they may not be equated with neuronal precursor cells in the developing brain, 
for which reason a comparison of both results is difficult. However, the results shown in 
this study provide clear evidence that DYRK1A stabilizes p27Kip1 in SH-SY5Y cells by 
phosphorylation at Ser10 and not by elevating transcript levels (figure 27). 
5.1.5 DYRK1A destabilizes Cyclin D1 by Thr286 phosphorylation 
The DYRK1A related family member DYRK1B phosphorylates and destabilizes Cyclin D1 
by Thr288 phosphorylation (Zou et al., 2004). Interestingly, analysis of the sequence motif 
flanking Thr288, led to the hypothesis that DYRK1A may also phosphorylate Cyclin D1, 
but rather at Thr286 than at Thr288. Thr286, but not Thr288 provides a proline directed 
sequence motif, usually facilitating phosphorylation by proline directed kinases like 
DYRKs (de Graaf et al., 2006; Papadopoulos et al., 2011; Soundararajan et al., 2013). 
The current study provides evidence that DYRK1A reduces Cyclin D1 protein levels in 
SH-SY5Y cells by phosphorylation of Thr286. Phosphorylation of Cyclin D1 at Thr286 
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induces ubiquitination by the Skp1-Cul1-F box (SCF) ubiquitin ligase and subsequent 
proteasomal degradation (Lin et al., 2006). Although GSK3β was initially reported to 
phosphorylate Cyclin D1 on Thr286 (Diehl et al., 1998), DYRK1B was later proposed to 
promote Cyclin D1 degradation by phosphorylation at Thr288 (Zou et al., 2004). DYRK1A 
overexpression has been shown to induce nuclear export of heterologously expressed 
Cyclin D1 in neuronal cells (Yabut et al., 2010), which is considered as an S-phase 
specific regulatory mechanism (Diehl et al., 1998; Alt et al., 2000). Two recent reports 
have now revealed that either DYRK1A or DYRK1B can promote Cyclin D1 degradation 
via phosphorylation of Thr286, but do not target Thr288 (Chen et al., 2013; Ashford et al., 
2014). The result that DYRK1A mediated Cyclin D1 phosphorylation at Thr286 in 
SH-SY5Y cells is not reduced by GSK3β inhibition conforms the reports that DYRK1A 
phosphorylates Thr286 independently of GSK3β. Therefore, the demonstrated findings 
indicate that DYRK1A induces degradation of Cyclin D1 in SH-SY5Y cells due to 
enhanced phosphorylation of Thr286. This effect occurred within 24 h after induction of 
DYRK1A overexpression in SH-SY5Y cells and thus may account for the rapid G1-phase 
arrest and the initiation of subsequent G0 coupled neuronal differentiation. In fact, a 
previous study has confirmed that silencing of Cyclin D1 expression is sufficient to induce 
cell cycle exit and subsequent differentiation of neuroblastoma cells (Molenaar et al., 
2008).  
In contrast to Chen et al. (2013), who showed a stable interaction of overexpressed 
Cyclin D1 with DYRK1A in cotransfected HEK293T cells, endogenous Cyclin D1 or p27Kip1 
could not be detected in co-immunoprecipitates of GFP-DYRK1A in SH-SY5Y cells. It 
remains to be clarified whether this discrepancy reflects different experimental conditions 
or differences in protein interactions between the HEK293 cell line and neuronal cells. 
5.1.6 DYRK1A in regulation of neuronal G1-phase  
The observation that DYRK1A regulates protein turnover of p27Kip1 and Cyclin D1 in 
neuronal cells is in line with numerous previous reports that kinases of the DYRK family 
function as regulators of protein stability in cell cycle control (Becker, 2012). However, it 
cannot be excluded that further downstream targets of DYRK1A contribute to its 
differentiation-inducing effect. DYRK1A has been proposed to promote cell cycle exit and 
quiescence by phosphorylation of LIN52 on Ser28, which is required for the assembly of 
the DREAM complex (Litovchick et al., 2011). However, Chen et al. (2013) have recently 
provided convincing evidence that stabilization of the DREAM complex may be a long-
term effect of DYRK1A in the maintenance of quiescence rather than a direct regulatory 
mechanism of G1 cell cycle exit. For example, it is conceivable that DYRK1A-induced 
depletion of nuclear Cyclin D1 promotes DREAM complex formation by reducing 
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Cyclin D1/CDK4-dependent phosphorylation of p130/RBL2 (Sandoval et al., 2009; 
Sadasivam and DeCaprio, 2013). Another substrate of DYRK1A that may contribute to 
neuronal cell cycle regulation and differentiation is p53 (Tedeschi and Di Giovanni, 2009; 
Park et al., 2010). Phosphorylation at Ser15 by DYRK1A enhances the expression of p53 
target genes such as the CDK inhibitor p21CIP1 and thereby attenuates G1-S phase 
transition. An integration of the findings obtained in this study to the so far assumed 
DYRK1A functions in G1-phase cell cycle regulation (figure 4) is shown in figure 43. 
 
Figure 43: Functions of DYRK1A in G1-phase cell cycle regulation. 
It was reported that DYRK1A phosphorylates p53 at Ser15 and thereby induces p21Cip1 expression 
and proliferation arrest (Park et al., 2010). In neuronal precursors, a transient expression of 
DYRK1A upregulates p27Kip1 gene expression and promotes cell cycle exit and differentiation 
(Hämmerle et al., 2011). Moreover, DYRK1A phosphorylates the LIN52 component of the DREAM 
complex and thereby promotes cellular quiescence (Litovchick et al., 2011). The present study 
provides evidence that DYRK1A overexpression inhibits proliferation of SH-SY5Y neuroblastoma 
cells by arresting cells in G1-phase and subsequently inducing G0 cell cycle exit and neuronal 
differentiation. These effects are dependent on DYRK1A kinase activity and correlate with its 
expression. Furthermore, cell cycle exit is paralleled by Cyclin D1 degradation after DYRK1A 
mediated Thr286 phosphorylation and p27Kip1 stabilization after DYRK1A mediated Ser10 
phosphorylation. 
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5.1.7 Conclusion 
The findings obtained in the present study indicate an important influence of DYRK1A 
overexpression on the control of neuronal cell cycle progression and differentiation. In 
conclusion, overexpression of DYRK1A arrests proliferating neuronal SH-SY5Y cells in 
G1-phase within 24 h, which can be explained by the rapid degradation of Cyclin D1 (Chen 
et al., 2013). Thereafter, DYRK1A phosphorylation dependent stabilization of p27Kip1, 
complemented by further Cyclin D1 depletion, may promote cell cycle exit into G0 and 
subsequent neuronal differentiation (Nguyen et al., 2006b; Godin et al., 2012). Because of 
its well documented overexpression in trisomy 21 (Guimera et al., 1996, 1999; Ferrer et 
al., 2005; Dowjat et al., 2007), DYRK1A may affect brain development in Down syndrome 
by deregulating G1-phase of proliferating neuronal precursors, thereby inducing premature 
differentiation. This would result in a depletion of the neural progenitor pool in brain 
development and eventually in an inappropriate number of neurons (Tejedor and 
Hämmerle, 2011; Dierssen, 2012).  
Although to date numerous studies were performed to understand the consequences of 
DYRK1A overexpression in Down syndrome, it is still poorly understood if non-
overexpressed DYRK1A is involved in neuronal cell cycle regulation and differentiation. 
The lethality of DYRK1A knockout mice during gestation, and the reduced viability and 
developmental delay of mice heterozygous for DYRK1A (Fotaki et al., 2002, 2004) 
strongly suggest that the dosage sensitive cellular functions of DYRK1A cannot be 
compensated by another kinase.  
Investigation of brain development in mouse and chicken showed that DYRK1A is 
transiently expressed and asymmetrically segregated in neuronal progenitors prior to their 
neurogenic division. Subsequently, one of the two post mitotic neuronal precursor cells 
maintains high DYRK1A expression levels until terminal differentiation, whereupon 
DYRK1A expression is down regulated (Hämmerle et al., 2002, 2003, 2008, 2011). 
Although these assumptions are quite adoptable, they also implicate the question how 
DYRK1A activity is regulated in physiological conditions.  
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5.1.8 Outlook - Regulation of DYRK1A in neuronal differentiation 
After translation DYRK1A is known to be constitutively activated by autophosphorylation 
(Becker and Sippl, 2011; Walte et al., 2013). So far, several potential regulative 
mechanisms have been suggested. Among those are transcriptional regulation, changes 
of mRNA and protein stability, interaction with 14-3-3β, RanBPM or WDR68, altered 
subcellular localization and conformational changes (Becker and Sippl, 2011). 
Furthermore, DYRK1A was reported to be phosphorylated by LATS2 as an upstream 
kinase, and to be differentially phosphorylated due to its cellular localization in neurons 
(Tschöp et al., 2011; Kaczmarski et al., 2014). Because none of the suggested 
mechanisms is finally validated, it still remains unclear which upstream stimulus regulates 
DYRK1A activity and is critical in neuronal development. Interestingly, RNAi induced 
DYRK1A silencing revealed a reduced differentiation response due to NGF-TrkA signaling 
in PC12 cells (Chen et al., 2012). Because TrkA activation induces MAPK signaling, it is 
worth to note that DYRK1A was also reported to enhance the MAPK cascade in PC12 
cells (Kelly and Rahmani, 2005). Further identification of the mechanisms that regulate 
DYRK1A in the context of neuronal differentiation is of tremendous future interest. 
To solve this question, the SH-SY5Y model system introduced in this study might be a 
versatile tool for studies of differentiation induced signal transduction. For instance, 
DYRK1A properties like subcellular localization, expression patterns, interaction partners 
or posttranslational modifications could be studied upon induced differentiation. 
In addition to the findings reported in this thesis, analysis of DYRK1A subcellular 
localization in SH-SY5Y cells was started using cell compartment fractioning. Moreover, 
expression of GFP-DYRK1A could be used for cellular tracking by live cell imaging using 
the established SH-SY5Y-tet-ON cell line. 
Endogenous or overexpressed DYRK1A from SH-SY5Y cells could be used for 
phosphoproteomic screenings upon induced neuronal differentiation to identify potential 
upstream phosphorylation sites or other posttranslational modifications that may regulate 
its kinase activity. 
Moreover, pharmacological inhibition or RNAi could be useful to study neuronal 
differentiation and cell cycle regulation if endogenous DYRK1A is down regulated or 
inhibited. Beyond the results shown in this study, lentiviral transduction of shRNAs 
targeting endogenous DYRK1A mRNA was established. Unfortunately, the shRNAs did 
not down regulate DYRK1A expression, probably due to a low expression efficiency of the 
used pLV-THM lentiviral vector system (Wiznerowicz and Trono, 2003). To further follow 
this approach, a different vector system like pLKO could be used (Stewart et al., 2003). 
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5.2 Septin4 regulation by phosphorylation 
Although posttranslational modifications of septins including acetylation, SUMOylation and 
phosphorylation have been reported in different organisms (Hernández-Rodríguez and 
Momany, 2012), especially in mammals, mechanistic details and physiological relevance 
of those modifications remain to be elucidated. Mammalian Septin4 was identified as a 
binding partner and phosphorylation substrate of DYRK1A (Sitz et al., 2008). 
This study identified Ser107 as the major DYRK1A phosphorylation site in Septin4 and a 
specific antibody against phosphorylated Ser107 was generated. Other GMGC-group 
kinases were excluded to contribute to Septin4 Ser107 phosphorylation. Furthermore, 
Ser107 phosphorylation was identified to regulate Septin4 protein turnover. Therefore, 
Septin4 fusion proteins for future analysis of Ser107 phosphorylation in regulation of 
Septin4 protein stability and filament assembly were constructed. 
5.2.1 DYRK1A phosphorylates Septin4 at Ser107 
Analysis of the mouse Septin4 amino acid sequence revealed Ser68, Ser100 and 
Serin107 as possible proline directed DYRK1A phosphorylation motifs. Immunoblotting 
showed a DYRK1A phosphorylation dependent electrophoretic shift of Septin4 as 
previously reported by Sitz et al. (2008). Co-expression of DYRK1A with phosphorylation 
resistant Septin4 mutants showed increased gel mobility due to reduced phosphorylation. 
Of all mutated potential DYRK1A phosphorylation sites, serine 107 to alanine mutation 
induced the largest effect on Septin4 electrophoretic mobility (figure 32). Given that Ser68 
is not conserved between mouse and human, Ser107 was considered as the more 
important DYRK1A phosphorylation site in human Septin4 and served as template for 
generation of a specific antibody detecting phosphorylated Ser107 in Septin4. 
Interestingly, a mouse phosphoproteomic screen identified Septin4 as phosphorylated at 
Ser68 and Ser107, but not at Ser100 (Huttlin et al., 2010). In this study, Ser68 was found 
to be phosphorylated in different tissues like brain, spleen and kidney, whereas Ser107 
phosphorylation was solely detected in brain tissue. Additionally, a screening for 
phosphorylated proteins in postsynaptic density (PSD) preparations from mouse brain 
revealed Ser68 as phosphorylated, indicating functions of Septin4 in synaptic 
transmission (Trinidad et al., 2006). The finding that DYRK1A phosphorylates Septin4 at 
Ser107 and that DYRK1A is co-expressed and co-localizes with Septin4 in mouse brain 
neurons (Sitz et al., 2008), therefore supports the hypothesis that DYRK1A may regulate 
Septin4 function by phosphorylation in neurons. 
Notably, transient expression of wt-Septin4 in HeLa cells resulted in inconsistent total 
Septin4 protein levels in different experiments under similar conditions, indicating a high 
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variability of Septin4 expression in this cell line that remains unexplained. Compared to 
co-transfection with GFP or the kinase deficient mutant DYRK1A-K188R, co-expression of 
Septin4 and DYRK1A remarkably increased pSer107 immunoreactivity and reduced 
Septin4 electrophoretic gel mobility due to a higher phosphorylation level. These effects 
could be reduced by application of DYRK1A kinase inhibitors (figure 33). Interestingly, 
inhibition of endogenous DYRK1A in HeLa cells led to similar observations, indicating that 
increased Ser107 phosphorylation is not only an artifact of DYRK1A overexpression.  
This study shows that DYRK1A phosphorylates Septin4 at Ser107 but presumably also on 
other residues. This assumption is supported since inhibition of DYRK1A activity led to an 
increased appearance of the lower Septin4 band, although pSer107 immunoreactivity of 
the upper band remained just slightly inhibited. Neither S68A, nor S100A mutation of 
Septin4 induced a band shift comparable to S107A mutated Septin4 (figure 32). The fact 
that additional S68A and S100A mutations did not increase the electrophoretic shift of 
S107A mutated Septin4, reduces the likeliness that DYRK1A mediated Ser68 or Ser100 
phosphorylation contribute to the observed effect. These findings indicate that besides 
Ser107, DYRK1A may also phosphorylate additional sites in Septin4 that contribute to the 
observed band shift. Given that murine Septin4 does not contain further typical DYRK1A 
consensus motifs besides Ser68, 100 and 107, DYRK1A may additionally phosphorylate 
atypical phosphorylation motifs. DYRK1A phosphorylates sequence motifs that lack an 
arginine at the -3 position in relation to the respective phosphorylated serine or threonine 
residue, but a proline residue at the +1 position still remains a prerequisite (Papadopoulos 
et al., 2011; Soundararajan et al., 2013). Therefore, in Septin4, Thr209, Ser261, or Thr295 
could represent potential sites for proline directed DYRK1A phosphorylation. Moreover, in 
the case of muscle glycogen synthase (Ser640) and histone H3 (Thr45), DYRK1A was 
reported to phosphorylate non-proline directed serine or threonine residues with a valine 
at the +1 position. Nonetheless, in these cases a proline residue is present at -2 and an 
arginine residue at -3, thereby reflecting characteristics of the DYRK1A consensus motif 
(Skurat and Dietrich, 2004; Soundararajan et al., 2013; Jang et al., 2014). Anyway, 
although similar valine directed Ser/Thr sequence motifs are not present in Septin4, it 
cannot be finally excluded that other atypical Ser/Thr motifs might be phosphorylated by 
DYRK1A. 
Given that basal Ser107 phosphorylation was high in HeLa cells when endogenous 
DYRK1A activity was inhibited, other kinases might also phosphorylate Ser107 due to 
similar proline directed phosphorylation consensus motifs. However, the obtained results 
suggest that CDKs, as well as GSK3 and MAP kinases do not significantly contribute to 
Septin4 Ser107 phosphorylation in HeLa cells (figure 34). Nonetheless, it can not be 
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finally excluded that these kinases contribute to phosphorylation of other Septin4 amino 
acid residues, especially because CDKs phosphorylate Septins during cell cycle 
progression in various other organisms (Hernández-Rodríguez and Momany, 2012).  
Due to a balance between newly synthesized and rapidly degraded phosphorylated 
Septin4 one would expect a decline of total Ser107 phosphorylation under constant 
DYRK1A inhibition. The fact that this is not the case in HeLa cells, suggests that other 
kinases besides the tested ones may phosphorylate Ser107. Additionally it has to be kept 
in mind that Septin4 was found to be predominantly expressed in neuronal tissue and that 
Ser107 phosphorylation was identified as tissue specific (Xie et al., 1999; Zieger et al., 
2000; Huttlin et al., 2010). Therefore, the residual Ser107 phosphorylation by another 
kinase can be an artifact due to Septin4 overexpression in HeLa cells. Because Septin4 is 
associated to neurons, also neuronal cell lines were tested for endogenous Septin4 
expression and Ser107 phosphorylation (data not shown). Unfortunately, it was neither 
possible to detect endogenous Septin4 or phosphorylated Ser107 in human SH-SY5Y 
neuroblastoma cells or mouse Neuro2A neuroblastoma cells, nor in mouse hippocampal 
or cortex neurons. Therefore, and due to low transfection properties of neuronal cell lines, 
further experiments to characterize the biochemical consequences of DYRK1A dependent 
Septin4 Ser107 phosphorylation were carried out using transient transfection of HeLa 
cells. Nonetheless, it has to be elucidated why Septin4 remains phosphorylated at Ser107 
after its overexpression in HeLa cells and subsequent DYRK1A inhibition. 
5.2.2 Ser107, a phosphorylation site for regulation of Septin4 protein stability 
An evolutionary conserved function of DYRK protein kinases is phosphorylation 
dependent regulation of protein stability in cell cycle (Becker, 2012). As reported in this 
thesis, DYRK1A phosphorylates and thereby regulates protein stability of the G1-phase 
proteins p27Kip1 and Cyclin D1 in neuronal cells (section 4.1.7). Furthermore, septin 
functions are regulated by phosphorylation during the cell cycle of lower eukaryotes like 
yeast (Hernández-Rodríguez and Momany, 2012). In particular, septin mobility and 
reorganization are associated with altered phosphorylation in different cell cycle phases to 
ensure a functional septin ring formation for cytokinesis (Tang and Reed, 2002; 
Dobbelaere et al., 2003; Li et al., 2012). 
The presented results support evidence that Ser107 phosphorylation regulates Septin4 
protein turnover. Firstly, cell cycle synchronization experiments showed higher Septin4 
total protein levels in S- or M-phase arrest if compared to unsynchronized control cells 
(figure 35). Secondly, detectable total protein of Septin4-S107A was remarkably higher 
than that of Septin4-wt. Septins are regulated by phosphorylation during the cell cycle of 
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lower eukaryotes (Dobbelaere et al., 2003; Hernández-Rodríguez and Momany, 2012) 
what suggests similar functions in mammals. Nonetheless, it has to be concerned that 
Septin4 was heterologously overexpressed in HeLa cells. It might be possible that 
excessive overexpression of Septin4 counteracts a possible Septin4 degradation during 
cell cycle progression. Therefore, for future characterization of Septin4 phosphorylation or 
protein stability in cell cycle, a cellular system with detectable endogenous Septin4 would 
be more appropriate. As mentioned above, Septin4-S107A showed remarkably higher 
total protein levels than Septin4-wt (figure 35). Given that both expression vectors are 
identical (chapter 7.3, table 19), led to the assumption that higher Septin4-S107A 
expression may result from reduced protein turnover. After inhibition of translation with 
cycloheximide, wild type Septin4 showed lower protein levels than the S107A mutant, 
indicating a faster protein turnover (figure 36). Although overexpression Septin4 in HeLa 
cells may not reflect the optimal experimental system, the results give a strong hint that 
Ser107 phosphorylation is involved in regulation of Septin4 protein stability. This result is 
in line with the findings that septins are reorganized by phosphorylation in lower 
eukaryotes (Dobbelaere et al., 2003; Hernández-Rodríguez and Momany, 2012). 
Constitutive overexpression of DYRK1A in Down syndrome causes an altered brain 
development due to impaired neuron differentiation and migration (Tejedor and 
Hämmerle, 2011). DYRK1A and Septin4 co-localize in mouse neurons (Sitz et al., 2008) 
and a Septin4 down regulation impairs formation of neuronal extensions and cell migration 
to the cortical plate (Shinoda et al., 2010). These findings strengthen the hypothesis that 
DYRK1A overexpression dependent Ser107 hyperphosphorylation could be a mechanism 
to destabilize Septin4, leading to impaired neuron development.  
5.2.3 Fusion proteins for the analysis if Septin4 stability and cellular mobility 
Transient transfection of Flag-tagged Septin4 hampers the analysis of protein turnover 
due to required inhibition of cellular protein synthesis or degradation. 
To address the analysis of Ser107 phosphorylation dependent Septin4 protein turnover, 
the HaloTag®-technique (Promega) was used. All generated HaloTag-Septin4 fusion 
constructs (figure 37) could be expressed in HeLa cells and immunodetection revealed 
signals at the expected molecular weight (figure 38). Moreover, the expressed HaloTag-
Septin4 constructs could be successfully pulse labeled in living HeLa cells using the 
HaloTag biotin ligand as shown by detection with HRP coupled streptavidin after western 
blotting (figure 39). According to the results shown previously (figure 35), streptavidin-
HRP signals were of higher intensity for HaloTag-Septin4-S107A than for HaloTag-
Septin4-wt. The results illustrate that HaloTag-Septin4 shows similar protein expression 
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and stability patterns as Flag-Septin4, thereby demonstrating that integration of the 
HaloTag does not interfere with the basic biochemical properties. Moreover, this result 
supports the previous finding that Septin4-wt has a higher protein turnover than Septin4-
S107A. Therefore, all HaloTag-Septin4 fusion constructs can be used to further analyze 
the influence of Ser107 phosphorylation on Septin4 protein stability by pulse labeling in 
living cellular systems. The HaloTag is a genetically modified bacterial haloalkane 
dehalogenase of 35 kDa that can form a covalent bond with a synthetic ligand by 
removing halides from hydrocarbons by a nucleophilic reaction (Los and Wood, 2007; Los 
et al., 2008). The advantage of a small bacterial protein is its absence in higher eukaryotic 
organisms on the one hand, and that the enzymatic reaction does not require any 
cofactors or cellular modifications on the other hand. Besides that, commercially available 
ligands can permeate through the cell membrane and do not cross-react with other 
eukaryotic cellular proteins. Moreover, the ligands can be linked to different molecules 
such as biotin or fluorescent dyes. This method allows different pulse chase analyses 
after covalently labeling the protein of interest (Yamaguchi et al., 2009). Labeling of 
HaloTag-Septin4 in HeLa cells using the cumarin ligand (Promega) emitting blue light at a 
wavelength of 450 nm revealed only weak signals in live cell imaging (data not shown). 
This finding might be due to the high protein turnover of Septin4 and a loss of 
fluorescence after protein degradation. 
Besides that, fixation of transfected cells is required to visualize Septin4 using dye 
coupled anti-Flag antibodies to follow its localization via fluorescent microscopy. This 
method does not allow live cell imaging to follow a potentially altered Septin4 localization 
or mobility after Ser107 phosphorylation in real time. To follow subcellular Septin4 
localization and mobility upon increased Ser107 phosphorylation by continuous live cell 
imaging, a RFP tag was fused to the Septin4 C-terminus (figure 37). Fluorescence 
microscopic and western blot analyses of Flag-Septin-4-RFP or the respective point 
mutants S107A and S107E transfected into HeLa cells revealed full-length protein 
expression as reflected by well detectable cytosolic RFP fluorescence as well as 
electrophoretic gel migration at the expected molecular weight (figure 40 and figure 41). 
These results suggest the engineered RFP fusion constructs as suitable for future studies 
of Septin4 subcellular mobility dependent on Ser107 phosphorylation. Fusion to RFP to 
Septin4 was chosen to allow co-expression of Septin4 with GFP-DYRK1A without 
interference of the fluorescent tags. To ensure proper red fluorescence in living cells, 
Flag-Septin4 was attached to a 27 kDa monomeric RFP (TagRFP, Evrogen) that provides 
high quantum yield along with prolonged fluorescence and a high stability if compared to 
other red fluorescent proteins like DsRed or mCherry (Merzlyak et al., 2007). TagRFP was
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C-terminally fused to Septin4, because a similar fusion of GFP to septins was reported 
tobe uncritical for septin filament and ring formation (Vrabioiu and Mitchison, 2007), thus 
allowing investigation of Septin4 filament assembly in relation to Ser107 phosphorylation. 
Hence, TagRFP can be used for FRET (Förster resonance energy transfer) experiments, 
allowing studies to analyze potential Septin4-RFP interactions as well as filament 
assembly other GFP tagged Septins or other proteins by high resolution microscopy 
(Shcherbo et al., 2009). 
5.2.4 Conclusion 
Taken together, DYRK1A was identified to phosphorylate Septin4 at position Ser107. In 
lower eukaryotes, septins are regulated by CDKs during the cell cycle (Hernández-
Rodríguez and Momany, 2012; Li et al., 2012). Nonetheless, the findings reported in this 
thesis show that especially CDKs do not contribute to Septin4 Ser107 phosphorylation in 
the used cellular system. Given that DYRK1A was found to interact with Septin4 in mouse 
brain (Sitz et al., 2008), a functional relation between DYRK1A and Septin4 in neurons is 
very likely. Imbalanced DYRK1A expression deregulates neuronal G1-phase transition 
(chapter 4.1) and also endogenous DYRK1A is assumed to be involved in the regulation 
of neuronal differentiation (Tejedor and Hämmerle, 2011). Thus, a cell cycle dependent 
phosphorylation of Ser107 by DYRK1A in differentiating neurons could be possible. As 
Septin4 depletion induces defective neuron migration and development (Shinoda et al., 
2010), a hyperphosphorylation of Septin4 at Ser107 by DYRK1A might deregulate Septin4 
stability and thereby alter its functions as a cytoskeletal component in neuron function. 
The constructed Septin4 fusion proteins will allow future investigation of these 
assumptions. 
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5.2.5 Outlook - DYRK1A and Septin4 
The results obtained in this study suggest a role of DYRK1A mediated Ser107 
phosphorylation in the regulation of Septin4 protein turnover, and thus of its properties in 
filament assembly or rearrangement. 
For future investigations, the constructed HaloTag-Septin4 and Septin4-RFP fusion 
constructs will be valuable tools. Co-transfection of HeLa cells with two different 
constructs like Flag-Septin4 and Flag-Septin4-RFP will provide the possibility to study 
Septin4-Septin4 interactions by immunoprecipitation. Combined transfection of Septin4-wt 
with S107A or S107E mutants may provide insights into a potential role of Ser107 
phosphorylation in Septin4-Septin4 interaction. 
Moreover, immunodetection of Flag-Septin4-RFP overexpressed in HeLa cells with a 
combination of an anti-Flag, an anti-Septin4 and an anti-TagRFP antibody will allow 
detailed studies of potential Septin4 fragmentation upon Ser107 phosphorylation. 
Given that transient overexpression of Septin4 and DYRK1A in HeLa cells does not 
provide the optimal experimental system, a neuronal cell model would be more 
appropriate. In particular, SH-SY5Y cells with an inducible overexpression of DYRK1A or 
DYRK1A-K188R (chapter 4.1) may be suitable to study functional consequences of 
Septin4 Ser107 phosphorylation and could be stably transfected with HaloTag-Septin4 or 
Septin4-RFP, respectively. Due to the low transfection properties of SH-SY5Y-tetON-
DYRK1A/K188R cells, nucleofection with the AMAXA (Lonza) system provides an option 
for transfection. Furthermore, subcloning the Septin4 constructs into lentiviral expression 
vectors like FUW (Addgene 14882, Lois et al., 2002) may be an alternative tool for stable 
integration of Septin4 into primary neurons to follow its pSer107 dependent mobility or 
filament assembly. 
Furthermore, neuronal cells stably transfected with HaloTag-Septin4 could be used to 
identify unknown Septin4 interaction partners by mass spectrometry (MS). With purified 
Septin4 from SH-SY5Y cells overexpressing DYRK1A, MS analysis could also identify 
further DYRK1A phosphorylation sites. 
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7 Supplements 
7.1 qRT-PCR primers and conditions 
Table 16: qRT-PCR primers 
Target transcript 
(NCBI reference) 
forward primer 
(5´-3´ orientation) 
reverse primer 
(5´-3´ orientation) 
human DYRK1A 
(NM_001396) 
[also matching 
rat DYRK1A 
(NM_012791)] 
TCTGGGTATTCCACCTGCTC GTCCTCCTGTTTCCACTCCA 
human p27Kip 
(NM_004064) TCCGGCTAACTCTGAGGACA GAAGAATCGTCGGTTGCAGG 
human TrkB 
(NTKR2) 
(NM_006180) 
GGCCCAGATGCTGTCATTAT TCCTGCTCAGGACAGAGGTT 
human MAP2* 
(NM_002374) CATGGGTCACAGGGCACCTATTC 
GGTGGAGAAGGAGGCAG 
ATTAGCTG 
human Tau 
(MAPT)* 
(NM_016834) 
GCGGCAGTGTGCAAATAG 
TCTACAA 
GGAAGGTCAGCTTGTGG 
GTTTCAAT 
human GAPDH 
(NM_002046) CGGGGCTCTCCAGAACATCATCC CCAGCCCCAGCGTCAAAGGTG 
 
Table 17: qRT-PCR conditions 
Target Denaturation Annealing Elongation Cycles Produc
t 
DYRK1A 10 sec 95°C 10 sec 62°C 15 sec 72°C 45 173 bp 
p27Kip1 10 sec 95°C 10 sec 60°C 10 sec 72°C 45 120 bp 
TrkB (NTKR2) 10 sec 95°C 10 sec 62°C 15 sec 72°C 45 203 bp 
MAP2* 10 sec 95°C 10 sec 60°C 10 sec 72°C 45 233 bp 
Tau (MAPT)* 10 sec 95°C 10 sec 60°C 10 sec 72°C 45 228 bp 
GAPDH 10 sec 95°C 10 sec 66°C 15 sec 72°C 40 300 bp 
 
*Primerdesign and qRT-PCR conditions as stated in (Constantinescu et al., 2007) 
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7.2 PCR primers for recombination cloning 
Table 18: PCR primer sequences for recombination cloning 
Integrated restriction sites are printed in bold. 
Template → 
target vector 
primer sequences (forward / reverse) 
in 5´-3´orientation 
5´-GGACCGATCCAGCCTCCGCGGCCCC 
GAATTCCCCACCATGGTGAGCAAGGGCGAG-3 for pEGFP-DYRK1A  
→ 
FUW-tetON-GFP-DYRK1A 5´-GGTTGATTATCGATAAGCTTGATATC 
GAATTCTCACGAGCTAGCTACAGGACTC-3´ rev 
5´-GGATGACGACGATAAGGCCCGGG 
CGGGAGGGGGATCCGAA ATCGGTACAGGC-3´ for pHT2 (Promega) 
→ 
pCMV-HaloTag-Sept4 5´-CCCAGTGAATGGTCCATGAAGGGC 
GAATTCCTGCCGGCCAGCCCGGGGAGCC-3´ rev 
5´-TCGAGCTCAAGCTTCGAATT 
CTGCAGATGGATTACAAGGA TGACGAC-3´ for pCMV-Flag-Sept4 
→ 
pTag-Flag-Septin4-RFP 5´-ACACCATGGTGGCGACCGGT 
GGATCCCGGTGAGTCTCCTT CATCTGTCT-3´ rev 
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7.3 Expression vectors for transfection 
Table 19: Plasmids used for transfection or lentiviral transduction 
Name cDNA Insert / ORF (NCBI accession) 
Backbone / reference /  
supplier 
pEGFP-C1 eGFP (U55763.1) pEGFP-C1, Clontech 
pEGFP-DYRK1A 
GFP-DYRK1A 
(rattus norvegicus) 
(NM_012791) 
pEGFP-C1, Clontech, 
(Becker et al., 1998) 
pEGFP-DYRK1A K188R GFP-DYRK1A-K188R pEGFP-C1, Clontech, (Becker et al., 1998) 
FUW-tetON-GFP-DYRK1A 
GFP-DYRK1A 
(rattus norvegicus) 
(NM_012791) 
FUW-tetO (Addgene 
20723) 
FUW-tetON-GFP-DYRK1A-K188R GFP-ratDYRK1A-K188R FUW-tetO (Addgene 20723) 
pEGFP-HIPK2 
GFP-HIPK2 
(homo sapiens) 
(NM_022740) 
pEGFP-C1, Clontech, 
(Hofmann et al., 2002) 
pCS2-p27Kip1 hp27Kip1 (hCDKN1B) (NM_004064) 
J. Vervoorts-Weber, Dep. 
of Biochemistry, RWTH 
Aachen University 
pCMV-FLAG-Sept4 
Septin4 
(mus musculus) 
(NM_011129) 
pCMV-Tag2 (A), 
Stratagene,  
(Sitz et al., 2008) 
pCMV-FLAG-Sept4 (S68A) mSeptin4-S68A pCMV-Tag2 (A), Stratagene 
pCMV-FLAG-Sept4 (S100A,S107A) mSeptin4-S100A-S107A  pCMV-Tag2 (A), Stratagene 
pCMV-FLAG-Sept4 (S68A,S100A, 
S107A) 
mSeptin4-S86A-S100A-
S107A 
pCMV-Tag2 (A), 
Stratagene 
pCMV-FLAG-Sept4 (S107A) mSeptin4-S107A pCMV-Tag2 (A), Stratagene 
pCMV-FLAG-Sept4 (S107E) mSeptin4-S107E pCMV-Tag2 (A), Stratagene 
pCMV-Flag-HaloTag-Sept4 HaloTag-mSeptin4 pCMV-Tag2 (A), Stratagene 
pCMV-Flag-HaloTag-Sept4 (S107A) HaloTag-mSeptin4-S107A 
pCMV-Tag2 (A), 
Stratagene 
pCMV-FLAG-HaloTag-Sept4 (S107E) HaloTag-mSeptin4-S107E 
pCMV-Tag2 (A), 
Stratagene 
pTag-Flag-Septin4-RFP mSeptin4-RFP pTagRFP-N (Evrogen) 
pTag-Flag-Septin4-RFP (S107A) mSeptin4-S107A-RFP pTagRFP-N (Evrogen) 
pTag-Flag-Sept4-RFP (S107E) mSeptin4-S107E-RFP pTagRFP-N (Evrogen) 
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